fluorodeoxyglucose f18 has been researched along with Cancer of Esophagus in 711 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 15 (2.11) | 18.2507 |
| 2000's | 225 (31.65) | 29.6817 |
| 2010's | 358 (50.35) | 24.3611 |
| 2020's | 113 (15.89) | 2.80 |
| Authors | Studies |
|---|---|
| Adler, DG | 1 |
| Benbow, JH; Bohl, CE; Donahue, EE; Gower, N; Hill, JS; Prabhu, RS; Salo, JC; Squires, MH | 1 |
| Antonoff, MB; Betancourt Cuellar, SL; Erasmus, JJ; Feldman, HA; Hofstetter, WL; Mehran, RJ; Rajaram, R; Rice, DC; Sepesi, B; Swisher, SG; Vaporciyan, AA; Walsh, GL; Zhou, N | 1 |
| Chen, YH; Chen, YT; Lin, CY; Wang, YK; Wu, IC | 1 |
| Aikou, S; Fukayama, M; Momose, T; Okumura, Y; Seto, Y; Takahashi, M; Takyu, S; Yagi, K; Yamaya, T; Yoshimura, S | 1 |
| Baba, H; Kamei, T; Matsubara, H; Murakami, K; Takahashi, K; Taniyama, Y; Toyozumi, T; Uno, T; Yoshida, N | 1 |
| Dong, A; Li, Z; Yu, Z; Zhang, J; Zhu, Y | 1 |
| Castillo, E; Castillo, R; Goodman, KA; Jones, B; Miften, M; Olsen, J; Schefter, T; Vinogradskiy, Y; Zakem, SJ | 1 |
| Chen, L; Shah, A; Sonbol, M; Yang, M | 1 |
| Brambilla, M; Ferrara, E; Franco, P; Guaschino, R; Krengli, M; Luciani, I; Puta, E; Sacchetti, GM; Turri, L | 1 |
| Chang, JS; Chang, WL; Chiu, NT; Hsu, SW; Lin, FC | 1 |
| Bakker, AS; Haj Mohammad, N; Jairam, J; Kroese, TE; Meijer, GJ; Mook, S; Ruurda, JP; van der Horst, S; van Hillegersberg, R; van Rossum, PSN | 1 |
| Lee, BM; Lee, CG | 1 |
| Bakshi, N; Chand, V; Duggal, R; Sangal, R | 1 |
| Emi, M; Hamai, Y; Hirohata, R; Ibuki, Y; Kitasaki, N; Kurokawa, T; Murakami, Y; Nagata, Y; Nishibuchi, I; Ohsawa, M; Okada, M; Yoshikawa, T | 1 |
| Allen, M; Anconina, R; Chen, EX; Darling, GE; Elimova, E; Jang, RW; Liu, ZA; Metser, U; Ortega, C; Swallow, CJ; Taylor, K; Veit-Haibach, P; Wong, R; Yeung, J | 1 |
| Liu, Y; Mamaliga, T | 1 |
| Foley, KG; Goh, V; Withey, SJ | 1 |
| Aldemir, MN; Aydemir, O; Iliklerden, UH; Kotan, MC; Ozcelik, M; Sahin, S; Sakin, A | 1 |
| Chen, YY; Feng, WH; Huang, HK; Huang, TW; Kuo, YS; Lin, KH; Tsai, YM; Wu, TH | 1 |
| Ai, D; Chen, J; Chen, Y; Deng, J; Ge, X; Hao, S; Liu, Q; Lu, K; Luo, H; Mo, M; Song, S; Tseng, IH; Wang, Z; Xu, H; Ye, J; Zhang, J; Zhao, K; Zheng, X; Zhou, J; Zhu, H | 1 |
| Albertsmeier, M; Angele, M; Bassermann, F; Blankenstein, C; Combs, SE; Feith, M; Friess, H; Haller, B; Kasper, S; Liffers, ST; Lorenzen, S; Quante, M; Rauscher, I; Schmid, RM; Schwaiger, M; Siveke, JT; Slotta-Huspenina, J; Weber, WA; Weichert, W | 1 |
| Chen, Z; Fan, B; Hu, M; Sun, T; Xu, J; Yin, Y; Yu, J; Zhang, Y; Zhu, J | 1 |
| Li, W; Shi, W | 1 |
| Li, XT; Liu, C; Lu, ZH; Shen, L; Shi, YJ; Sun, YS; Wei, YY | 1 |
| Cao, B; Cheng, Z; Diao, W; Jia, H; Kou, Y; Wang, Q; Wang, Y; Zhang, W | 1 |
| Hanaoka, K; Hattori, S; Ishii, K; Kaida, H; Kato, H; Kimura, Y; Kitajima, K; Matsukubo, Y; Shiraishi, O; Tsurusaki, M; Yamada, M; Yasuda, T | 1 |
| Capanu, M; Chou, JF; Janjigian, YY; Lewis, JS; Lumish, MA; Lyashchenko, SK; Maron, SB; O'Donoghue, JA; Pandit-Taskar, N; Paroder, V; Philemond, S; Schöder, H | 1 |
| Catenacci, D; Donnelly, EF; Goldstein, A; Henry, TS; Kamel, IR; Kelly, AM; Kuzniewski, CT; Lai, AR; Lee, E; Long, JM; Martin, MD; Morris, MF; Porter, KK; Raptis, CA; Sandler, KL; Sirajuddin, A; Surasi, DS; Wallace, GW | 1 |
| Emi, M; Hamai, Y; Hirohata, R; Ibuki, Y; Kitasaki, N; Kurokawa, T; Ohsawa, M; Okada, M; Yoshikawa, T | 1 |
| Li, N; Liu, X; Song, S; Ta, D; Yue, Y; Zhang, G; Zhu, Z | 1 |
| Atiyah, A; Benveniste, MF; Betancourt Cuellar, SL; Erasmus, JJ; Hofstetter, WL; Nguyen, QN; Truong, M | 1 |
| Dong, A; Ji, X; Wang, Y; Zhang, J | 1 |
| Chen, Y; Hu, Z; Liu, H; Yang, X; You, Z | 1 |
| Doki, Y; Eguchi, H; Kurokawa, Y; Makino, T; Nakajima, K; Noma, T; Nose, Y; Saito, T; Takahashi, T; Tanaka, K; Tatsumi, M; Yamamoto, K; Yamashita, K | 1 |
| Baker, CR; Chicklore, S; Davies, AR; Deere, H; Gossage, JA; Green, M; Kelly, M; Lagergren, J; Maisey, N; Moore, JL; Santaolalla, A; Subesinghe, M; Van Hemelrijck, M | 1 |
| Akagi, S; Hashimoto, M; Hiraki, T; Ihara, H; Maeda, N; Noma, K; Sugiyama, S; Takao, S; Tanabe, S; Yoshio, K | 1 |
| Baker, C; Davies, A; Dunn, J; Gimson, E; Gossage, J; Hill, M; Kelly, M; Lagergren, J; Maisey, N; Meenan, J; Reyhani, A; Subesinghe, M; Zeki, S | 1 |
| Barron, CC; Elimova, E; Wang, X | 1 |
| Adachi, Y; Baba, H; Eto, K; Hara, Y; Horino, T; Horinouchi, T; Kanemitsu, K; Maeda, Y; Matsumoto, C; Mitsuura, C; Morito, A; Ofuchi, T; Shiraishi, S; Tajiri, T; Yoshida, N | 1 |
| Bennink, RJ; Beukinga, RJ; Chatterjee, A; Doukas, M; Lagarde, SM; Lambin, P; Noordzij, W; Plukker, JTM; Roef, MJ; Schreurs, W; Valkema, MJ; Valkema, R; van Klaveren, D; van Lanschot, JJB; Wijnhoven, BPL; Woodruff, HC | 1 |
| Berkane, I; Deshayes, E; Eberlé, MC; Flori, N; Galvez, T; Guillemard, S; Ilonca, AD; Kotzki, PO; Santoro, L; Senesse, P; Thézenas, S | 1 |
| Einama, T; Ishida, J; Kishi, Y; Kouzu, K; Tamura, K; Tsujimoto, H; Ueno, H | 1 |
| Chen, T; Fan, J; Li, W | 1 |
| Chen, Y; Liu, H; Tang, W; Xie, Y | 1 |
| Chae, KJ; Han, YH; Kim, JH; Kim, M | 1 |
| Li, N; Liu, X; Song, S; Ta, D; Xing, W; Yue, Y; Zhang, G; Zhu, Z | 1 |
| Chan, SC; Chang, CB; Chang, YC; Chao, YK; Chiu, CH; Hsieh, JC; Ng, SH; Wang, JH | 1 |
| Ren, J; Zhao, Y | 1 |
| Becker, AS; Delso, G; Huellner, MW; Leibl, S; Reiner, CS; Sah, BR; Schawkat, K; Schneider, PM; Ter Voert, EE; Veit-Haibach, P; Wurnig, M | 1 |
| Hata, M; Kunisaki, C; Misumi, T; Ogino, I; Watanabe, S | 1 |
| Davies, A; Dellaportas, D; Gossage, JA; Laliotis, A; Zylstra, J | 1 |
| Buxó, E; Casanueva, S; Colletti, PM; Fernández-Esparrach, G; Fuster, D; Ginés, A; Mayoral, M; Pagès, M; Perlaza, P; Rios, J; Rubello, D; Sánchez-Izquierdo, N | 1 |
| Higashi, T; Ishizu, K; Kagawa, S; Kusano, K; Nakamoto, R; Okuyama, C; Saga, T; Takahashi, M; Yamauchi, H | 1 |
| Chen, Y; Fu, W; Xu, T; Zeng, C; Zhang, X | 1 |
| Fujiwara, N; Hirano, Y; Koyama, I; Miyawaki, Y; Okamoto, K; Oya, S; Sakuramoto, S; Sato, H; Sugita, H; Yamaguchi, S; Yamane, T | 1 |
| Abgral, R; Amrane, K; Metges, JP; Querellou, S; Schick, U | 1 |
| Chen, KN | 1 |
| Chen, H; Chen, X; He, H; Hu, H; Li, B; Li, N; Li, Y; Liu, S; Qian, B; Sun, Y; Xiang, J; Zhang, Y | 1 |
| Hofstetter, W | 1 |
| Cho, YS; Choi, JY; Hyun, SH; Lee, KH; Lim, CH; Park, YJ; Shin, M | 1 |
| Ajani, JA; Lu, Y; Wang, L | 1 |
| Amthauer, H; Baumann, M; Baur, ADJ; Beck, M; Bütof, R; Ghadjar, P; Hofheinz, F; Hua, W; Kaul, D; Kotzerke, J; Krause, M; Li, Y; Lili, C; Troost, ECG; Zschaeck, S | 1 |
| Ishibashi, M; Kaida, H; Kitajima, K; Minamimoto, R; Morita, T; Nakajo, M; Nakatani, K; Tamaki, Y | 1 |
| Ishikura, S; Kondo, T; Miyakawa, A; Murai, T; Ozawa, Y; Shibamoto, Y; Sugie, C; Yanagi, T | 1 |
| Bozec, L; Champion, L; Seban, RD | 1 |
| Emi, M; Furukawa, T; Hamai, Y; Ibuki, Y; Kurokawa, T; Murakami, Y; Nagata, Y; Nishibuchi, I; Ohsawa, M; Okada, M; Yoshikawa, T | 1 |
| Hamai, Y | 2 |
| Bohn, P; Damilleville-Martin, M; Decazes, P; Modzelewski, R; Thureau, S; Vera, P | 1 |
| Chang, YC; Chao, YK; Chen, PJ; Ho, AT; Hsieh, JC; Hung, TM; Lee, CH; Pai, PC; Tseng, CK; Yang, CK; Yap, WK | 1 |
| Aleman, BMP; Bartels-Rutten, A; Beets-Tan, RGH; Donswijk, ML; Lambregts, DMJ; Maas, M; Ter Beek, LC; van Dieren, JM; van Sandick, JW; Vegt, E; Vollenbrock, SE; Voncken, FEM | 1 |
| Bradley, KM; Ji-Xu, A; Yang, Y | 1 |
| Baba, H; Baba, Y; Harada, K; Horinouchi, T; Iwagami, S; Iwatsuki, M; Miyamoto, Y; Nagai, Y; Shiraishi, S; Sonoda, A; Tokunaga, R; Yoshida, N | 1 |
| Abgral, R; Bourhis, D; Calais, J; Leclère, JC; Lucia, F; Salaün, PY; Schick, U; Vera, P | 1 |
| Baba, H; Sonoda, A; Yoshida, N | 1 |
| Auerbach, MS; Calais, J; Czernin, J; French, SW; Girgis, MD; Hayrapetian, A; Schelbert, HR; Yanagawa, J | 1 |
| Abe, H; Aikou, S; Fukayama, M; Jinbo, K; Kawasaki, K; Koyama, K; Momose, T; Mori, K; Nishida, M; Nomura, S; Okumura, Y; Onoyama, H; Seto, Y; Takahashi, M; Urabe, M; Ushiku, T; Yagi, K; Yamashita, H; Yoshimura, S | 1 |
| Agarwal, JP; Agrawal, A; C S, P; Pande, SS; Prabhash, K; Purandare, N; Puranik, A; Rangarajan, V; Shah, S | 1 |
| Abbasi, S; Abd El-Wahab, A; Abdallah, M; Abebe, G; Aca-Aca, G; Adama, S; Adefegha, SA; Adidigue-Ndiome, R; Adiseshaiah, P; Adrario, E; Aghajanian, C; Agnese, W; Ahmad, A; Ahmad, I; Ahmed, MFE; Akcay, OF; Akinmoladun, AC; Akutagawa, T; Alakavuklar, MA; Álava-Rabasa, S; Albaladejo-Florín, MJ; Alexandra, AJE; Alfawares, R; Alferiev, IS; Alghamdi, HS; Ali, I; Allard, B; Allen, JD; Almada, E; Alobaid, A; Alonso, GL; Alqahtani, YS; Alqarawi, W; Alsaleh, H; Alyami, BA; Amaral, BPD; Amaro, JT; Amin, SAW; Amodio, E; Amoo, ZA; Andia Biraro, I; Angiolella, L; Anheyer, D; Anlay, DZ; Annex, BH; Antonio-Aguirre, B; Apple, S; Arbuznikov, AV; Arinsoy, T; Armstrong, DK; Ash, S; Aslam, M; Asrie, F; Astur, DC; Atzrodt, J; Au, DW; Aucoin, M; Auerbach, EJ; Azarian, S; Ba, D; Bai, Z; Baisch, PRM; Balkissou, AD; Baltzopoulos, V; Banaszewski, M; Banerjee, S; Bao, Y; Baradwan, A; Barandika, JF; Barger, PM; Barion, MRL; Barrett, CD; Basudan, AM; Baur, LE; Baz-Rodríguez, SA; Beamer, P; Beaulant, A; Becker, DF; Beckers, C; Bedel, J; Bedlack, R; Bermúdez de Castro, JM; Berry, JD; Berthier, C; Bhattacharya, D; Biadgo, B; Bianco, G; Bianco, M; Bibi, S; Bigliardi, AP; Billheimer, D; Birnie, DH; Biswas, K; Blair, HC; Bognetti, P; Bolan, PJ; Bolla, JR; Bolze, A; Bonnaillie, P; Borlimi, R; Bórquez, J; Bottari, NB; Boulleys-Nana, JR; Brighetti, G; Brodeur, GM; Budnyak, T; Budnyk, S; Bukirwa, VD; Bulman, DM; Burm, R; Busman-Sahay, K; Butcher, TW; Cai, C; Cai, H; Cai, L; Cairati, M; Calvano, CD; Camacho-Ordóñez, A; Camela, E; Cameron, T; Campbell, BS; Cansian, RL; Cao, Y; Caporale, AS; Carciofi, AC; Cardozo, V; Carè, J; Carlos, AF; Carozza, R; Carroll, CJW; Carsetti, A; Carubelli, V; Casarotta, E; Casas, M; Caselli, G; Castillo-Lora, J; Cataldi, TRI; Cavalcante, ELB; Cavaleiro, A; Cayci, Z; Cebrián-Tarancón, C; Cedrone, E; Cella, D; Cereda, C; Ceretti, A; Ceroni, M; Cha, YH; Chai, X; Chang, EF; Chang, TS; Chanteux, H; Chao, M; Chaplin, BP; Chaturvedi, S; Chaturvedi, V; Chaudhary, DK; Chen, A; Chen, C; Chen, HY; Chen, J; Chen, JJ; Chen, K; Chen, L; Chen, Q; Chen, R; Chen, SY; Chen, TY; Chen, WM; Chen, X; Chen, Y; Cheng, G; Cheng, GJ; Cheng, J; Cheng, YH; Cheon, HG; Chew, KW; Chhoker, S; Chiu, WN; Choi, ES; Choi, MJ; Choi, SD; Chokshi, S; Chorny, M; Chu, KI; Chu, WJ; Church, AL; Cirrincione, A; Clamp, AR; Cleff, MB; Cohen, M; Coleman, RL; Collins, SL; Colombo, N; Conduit, N; Cong, WL; Connelly, MA; Connor, J; Cooley, K; Correa Ramos Leal, I; Cose, S; Costantino, C; Cottrell, M; Cui, L; Cundall, J; Cutaia, C; Cutler, CW; Cuypers, ML; da Silva Júnior, FMR; Dahal, RH; Damiani, E; Damtie, D; Dan-Li, W; Dang, Z; Dasa, SSK; Davin, A; Davis, DR; de Andrade, CM; de Jong, PL; de Oliveira, D; de Paula Dorigam, JC; Dean, A; Deepa, M; Delatour, C; Dell'Aiera, S; Delley, MF; den Boer, RB; Deng, L; Deng, Q; Depner, RM; Derdau, V; Derici, U; DeSantis, AJ; Desmarini, D; Diffo-Sonkoue, L; Divizia, M; Djenabou, A; Djordjevic, JT; Dobrovolskaia, MA; Domizi, R; Donati, A; Dong, Y; Dos Santos, M; Dos Santos, MP; Douglas, RG; Duarte, PF; Dullaart, RPF; Duscha, BD; Edwards, LA; Edwards, TE; Eichenwald, EC; El-Baba, TJ; Elashiry, M; Elashiry, MM; Elashry, SH; Elliott, A; Elsayed, R; Emerson, MS; Emmanuel, YO; Emory, TH; Endale-Mangamba, LM; Enten, GA; Estefanía-Fernández, K; Estes, JD; Estrada-Mena, FJ; Evans, S; Ezra, L; Faria de, RO; Farraj, AK; Favre, C; Feng, B; Feng, J; Feng, L; Feng, W; Feng, X; Feng, Z; Fernandes, CLF; Fernández-Cuadros, ME; Fernie, AR; Ferrari, D; Florindo, PR; Fong, PC; Fontes, EPB; Fontinha, D; Fornari, VJ; Fox, NP; Fu, Q; Fujitaka, Y; Fukuhara, K; Fumeaux, T; Fuqua, C; Fustinoni, S; Gabbanelli, V; Gaikwad, S; Gall, ET; Galli, A; Gancedo, MA; Gandhi, MM; Gao, D; Gao, K; Gao, M; Gao, Q; Gao, X; Gao, Y; Gaponenko, V; Garber, A; Garcia, EM; García-Campos, C; García-Donas, J; García-Pérez, AL; Gasparri, F; Ge, C; Ge, D; Ge, JB; Ge, X; George, I; George, LA; Germani, G; Ghassemi Tabrizi, S; Gibon, Y; Gillent, E; Gillies, RS; Gilmour, MI; Goble, S; Goh, JC; Goiri, F; Goldfinger, LE; Golian, M; Gómez, MA; Gonçalves, J; Góngora-García, OR; Gonul, I; González, MA; Govers, TM; Grant, PC; Gray, EH; Gray, JE; Green, MS; Greenwald, I; Gregory, MJ; Gretzke, D; Griffin-Nolan, RJ; Griffith, DC; Gruppen, EG; Guaita, A; Guan, P; Guan, X; Guerci, P; Guerrero, DT; Guo, M; Guo, P; Guo, R; Guo, X; Gupta, J; Guz, G; Hajizadeh, N; Hamada, H; Haman-Wabi, AB; Han, TT; Hannan, N; Hao, S; Harjola, VP; Harmon, M; Hartmann, MSM; Hartwig, JF; Hasani, M; Hawthorne, WJ; Haykal-Coates, N; Hazari, MS; He, DL; He, P; He, SG; Héau, C; Hebbar Kannur, K; Helvaci, O; Heuberger, DM; Hidalgo, F; Hilty, MP; Hirata, K; Hirsch, A; Hoffman, AM; Hoffmann, JF; Holloway, RW; Holmes, RK; Hong, S; Hongisto, M; Hopf, NB; Hörlein, R; Hoshino, N; Hou, Y; Hoven, NF; Hsieh, YY; Hsu, CT; Hu, CW; Hu, JH; Hu, MY; Hu, Y; Hu, Z; Huang, C; Huang, D; Huang, DQ; Huang, L; Huang, Q; Huang, R; Huang, S; Huang, SC; Huang, W; Huang, Y; Huffman, KM; Hung, CH; Hung, CT; Huurman, R; Hwang, SM; Hyun, S; Ibrahim, AM; Iddi-Faical, A; Immordino, P; Isla, MI; Jacquemond, V; Jacques, T; Jankowska, E; Jansen, JA; Jäntti, T; Jaque-Fernandez, F; Jarvis, GA; Jatt, LP; Jeon, JW; Jeong, SH; Jhunjhunwala, R; Ji, F; Jia, X; Jia, Y; Jian-Bo, Z; Jiang, GD; Jiang, L; Jiang, W; Jiang, WD; Jiang, Z; Jiménez-Hoyos, CA; Jin, S; Jobling, MG; John, CM; John, T; Johnson, CB; Jones, KI; Jones, WS; Joseph, OO; Ju, C; Judeinstein, P; Junges, A; Junnarkar, M; Jurkko, R; Kaleka, CC; Kamath, AV; Kang, X; Kantsadi, AL; Kapoor, M; Karim, Z; Kashuba, ADM; Kassa, E; Kasztura, M; Kataja, A; Katoh, T; Kaufman, JS; Kaupp, M; Kehinde, O; Kehrenberg, C; Kemper, N; Kerr, CW; Khan, AU; Khan, MF; Khan, ZUH; Khojasteh, SC; Kilburn, S; Kim, CG; Kim, DU; Kim, DY; Kim, HJ; Kim, J; Kim, OH; Kim, YH; King, C; Klein, A; Klingler, L; Knapp, AK; Ko, TK; Kodavanti, UP; Kolla, V; Kong, L; Kong, RY; Kong, X; Kore, S; Kortz, U; Korucu, B; Kovacs, A; Krahnert, I; Kraus, WE; Kuang, SY; Kuehn-Hajder, JE; Kurz, M; Kuśtrowski, P; Kwak, YD; Kyttaris, VC; Laga, SM; Laguerre, A; Laloo, A; Langaro, MC; Langham, MC; Lao, X; Larocca, MC; Lassus, J; Lattimer, TA; Lazar, S; Le, MH; Leal, DB; Leal, M; Leary, A; Ledermann, JA; Lee, JF; Lee, MV; Lee, NH; Leeds, CM; Leeds, JS; Lefrandt, JD; Leicht, AS; Leonard, M; Lev, S; Levy, K; Li, B; Li, C; Li, CM; Li, DH; Li, H; Li, J; Li, L; Li, LJ; Li, N; Li, P; Li, T; Li, X; Li, XH; Li, XQ; Li, XX; Li, Y; Li, Z; Li, ZY; Liao, YF; Lin, CC; Lin, MH; Lin, Y; Ling, Y; Links, TP; Lira-Romero, E; Liu, C; Liu, D; Liu, H; Liu, J; Liu, L; Liu, LP; Liu, M; Liu, T; Liu, W; Liu, X; Liu, XH; Liu, Y; Liuwantara, D; Ljumanovic, N; Lobo, L; Lokhande, K; Lopes, A; Lopes, RMRM; López-Gutiérrez, JC; López-Muñoz, MJ; López-Santamaría, M; Lorenzo, C; Lorusso, D; Losito, I; Lu, C; Lu, H; Lu, HZ; Lu, SH; Lu, SN; Lu, Y; Lu, ZY; Luboga, F; Luo, JJ; Luo, KL; Luo, Y; Lutomski, CA; Lv, W; M Piedade, MF; Ma, J; Ma, JQ; Ma, JX; Ma, N; Ma, P; Ma, S; Maciel, M; Madureira, M; Maganaris, C; Maginn, EJ; Mahnashi, MH; Maierhofer, M; Majetschak, M; Malla, TR; Maloney, L; Mann, DL; Mansuri, A; Marelli, E; Margulis, CJ; Marrella, A; Martin, BL; Martín-Francés, L; Martínez de Pinillos, M; Martínez-Navarro, EM; Martinez-Quintanilla Jimenez, D; Martínez-Velasco, A; Martínez-Villaseñor, L; Martinón-Torres, M; Martins, BA; Massongo, M; Mathew, AP; Mathews, D; Matsui, J; Matsumoto, KI; Mau, T; Maves, RC; Mayclin, SJ; Mayer, JM; Maynard, ND; Mayr, T; Mboowa, MG; McEvoy, MP; McIntyre, RC; McKay, JA; McPhail, MJW; McVeigh, AL; Mebazaa, A; Medici, V; Medina, DN; Mehmood, T; Mei-Li, C; Melku, M; Meloncelli, S; Mendes, GC; Mendoza-Velásquez, C; Mercadante, R; Mercado, MI; Merenda, MEZ; Meunier, J; Mi, SL; Michels, M; Mijatovic, V; Mikhailov, V; Milheiro, SA; Miller, DC; Ming, F; Mitsuishi, M; Miyashita, T; Mo, J; Mo, S; Modesto-Mata, M; Moeller, S; Monte, A; Monteiro, L; Montomoli, J; Moore, EE; Moore, HB; Moore, PK; Mor, MK; Moratalla-López, N; Moratilla Lapeña, L; Moreira, R; Moreno, MA; Mörk, AC; Morton, M; Mosier, JM; Mou, LH; Mougharbel, AS; Muccillo-Baisch, AL; Muñoz-Serrano, AJ; Mustafa, B; Nair, GM; Nakanishi, I; Nakanjako, D; Naraparaju, K; Nawani, N; Neffati, R; Neil, EC; Neilipovitz, D; Neira-Borrajo, I; Nelson, MT; Nery, PB; Nese, M; Nguyen, F; Nguyen, MH; Niazy, AA; Nicolaï, J; Nogueira, F; Norbäck, D; Novaretti, JV; O'Donnell, T; O'Dowd, A; O'Malley, DM; Oaknin, A; Ogata, K; Ohkubo, K; Ojha, M; Olaleye, MT; Olawande, B; Olomo, EJ; Ong, EWY; Ono, A; Onwumere, J; Ortiz Bibriesca, DM; Ou, X; Oza, AM; Ozturk, K; Özütemiz, C; Palacio-Pastrana, C; Palaparthi, A; Palevsky, PM; Pan, K; Pantanetti, S; Papachristou, DJ; Pariani, A; Parikh, CR; Parissis, J; Paroul, N; Parry, S; Patel, N; Patel, SM; Patel, VC; Pawar, S; Pefura-Yone, EW; Peixoto Andrade, BCO; Pelepenko, LE; Peña-Lora, D; Peng, S; Pérez-Moro, OS; Perez-Ortiz, AC; Perry, LM; Peter, CM; Phillips, NJ; Phillips, P; Pia Tek, J; Piner, LW; Pinto, EA; Pinto, SN; Piyachaturawat, P; Poka-Mayap, V; Polledri, E; Poloni, TE; Ponessa, G; Poole, ST; Post, AK; Potter, TM; Pressly, BB; Prouty, MG; Prudêncio, M; Pulkki, K; Pupier, C; Qian, H; Qian, ZP; Qiu, Y; Qu, G; Rahimi, S; Rahman, AU; Ramadan, H; Ramanna, S; Ramirez, I; Randolph, GJ; Rasheed, A; Rault, J; Raviprakash, V; Reale, E; Redpath, C; Rema, V; Remucal, CK; Remy, D; Ren, T; Ribeiro, LB; Riboli, G; Richards, J; Rieger, V; Rieusset, J; Riva, A; Rivabella Maknis, T; Robbins, JL; Robinson, CV; Roche-Campo, F; Rodriguez, R; Rodríguez-de-Cía, J; Rollenhagen, JE; Rosen, EP; Rub, D; Rubin, N; Rubin, NT; Ruurda, JP; Saad, O; Sabell, T; Saber, SE; Sabet, M; Sadek, MM; Saejio, A; Salinas, RM; Saliu, IO; Sande, D; Sang, D; Sangenito, LS; Santos, ALSD; Sarmiento Caldas, MC; Sassaroli, S; Sassi, V; Sato, J; Sauaia, A; Saunders, K; Saunders, PR; Savarino, SJ; Scambia, G; Scanlon, N; Schetinger, MR; Schinkel, AFL; Schladweiler, MC; Schofield, CJ; Schuepbach, RA; Schulz, J; Schwartz, N; Scorcella, C; Seeley, J; Seemann, F; Seinige, D; Sengoku, T; Seravalli, J; Sgromo, B; Shaheen, MY; Shan, L; Shanmugam, S; Shao, H; Sharma, S; Shaw, KJ; Shen, BQ; Shen, CH; Shen, P; Shen, S; Shen, Y; Shen, Z; Shi, J; Shi-Li, L; Shimoda, K; Shoji, Y; Shun, C; Silva, MA; Silva-Cardoso, J; Simas, NK; Simirgiotis, MJ; Sincock, SA; Singh, MP; Sionis, A; Siu, J; Sivieri, EM; Sjerps, MJ; Skoczen, SL; Slabon, A; Slette, IJ; Smith, MD; Smith, S; Smith, TG; Snapp, KS; Snow, SJ; Soares, MCF; Soberman, D; Solares, MD; Soliman, I; Song, J; Sorooshian, A; Sorrell, TC; Spinar, J; Staudt, A; Steinhart, C; Stern, ST; Stevens, DM; Stiers, KM; Stimming, U; Su, YG; Subbian, V; Suga, H; Sukhija-Cohen, A; Suksamrarn, A; Suksen, K; Sun, J; Sun, M; Sun, P; Sun, W; Sun, XF; Sun, Y; Sundell, J; Susan, LF; Sutjarit, N; Swamy, KV; Swisher, EM; Sykes, C; Takahashi, JA; Talmor, DS; Tan, B; Tan, ZK; Tang, L; Tang, S; Tanner, JJ; Tanwar, M; Tarazi, Z; Tarvasmäki, T; Tay, FR; Teketel, A; Temitayo, GI; Thersleff, T; Thiessen Philbrook, H; Thompson, LC; Thongon, N; Tian, B; Tian, F; Tian, Q; Timothy, AT; Tingle, MD; Titze, IR; Tolppanen, H; Tong, W; Toyoda, H; Tronconi, L; Tseng, CH; Tu, H; Tu, YJ; Tung, SY; Turpault, S; Tuynman, JB; Uemoto, AT; Ugurlu, M; Ullah, S; Underwood, RS; Ungell, AL; Usandizaga-Elio, I; Vakonakis, I; van Boxel, GI; van den Beucken, JJJP; van der Boom, T; van Slegtenhorst, MA; Vanni, JR; Vaquera, A; Vasconcellos, RS; Velayos, M; Vena, R; Ventura, G; Verso, MG; Vincent, RP; Vitale, F; Vitali, S; Vlek, SL; Vleugels, MPH; Volkmann, N; Vukelic, M; Wagner Mackenzie, B; Wairagala, P; Waller, SB; Wan, J; Wan, MT; Wan, Y; Wang, CC; Wang, H; Wang, J; Wang, JF; Wang, K; Wang, L; Wang, M; Wang, S; Wang, WM; Wang, X; Wang, Y; Wang, YD; Wang, YF; Wang, Z; Wang, ZG; Warriner, K; Weberpals, JI; Weerachayaphorn, J; Wehrli, FW; Wei, J; Wei, KL; Weinheimer, CJ; Weisbord, SD; Wen, S; Wendel Garcia, PD; Williams, JW; Williams, R; Winkler, C; Wirman, AP; Wong, S; Woods, CM; Wu, B; Wu, C; Wu, F; Wu, P; Wu, S; Wu, Y; Wu, YN; Wu, ZH; Wurtzel, JGT; Xia, L; Xia, Z; Xia, ZZ; Xiao, H; Xie, C; Xin, ZM; Xing, Y; Xing, Z; Xu, S; Xu, SB; Xu, T; Xu, X; Xu, Y; Xue, L; Xun, J; Yaffe, MB; Yalew, A; Yamamoto, S; Yan, D; Yan, H; Yan, S; Yan, X; Yang, AD; Yang, E; Yang, H; Yang, J; Yang, JL; Yang, K; Yang, M; Yang, P; Yang, Q; Yang, S; Yang, W; Yang, X; Yang, Y; Yao, JC; Yao, WL; Yao, Y; Yaqub, TB; Ye, J; Ye, W; Yen, CW; Yeter, HH; Yin, C; Yip, V; Yong-Yi, J; Yu, HJ; Yu, MF; Yu, S; Yu, W; Yu, WW; Yu, X; Yuan, P; Yuan, Q; Yue, XY; Zaia, AA; Zakhary, SY; Zalwango, F; Zamalloa, A; Zamparo, P; Zampini, IC; Zani, JL; Zeitoun, R; Zeng, N; Zenteno, JC; Zepeda-Palacio, C; Zhai, C; Zhang, B; Zhang, G; Zhang, J; Zhang, K; Zhang, Q; Zhang, R; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, B; Zhao, D; Zhao, G; Zhao, H; Zhao, Q; Zhao, R; Zhao, S; Zhao, T; Zhao, X; Zhao, XA; Zhao, Y; Zhao, Z; Zheng, Z; Zhi-Min, G; Zhou, CL; Zhou, HD; Zhou, J; Zhou, W; Zhou, XQ; Zhou, Z; Zhu, C; Zhu, H; Zhu, L; Zhu, Y; Zitzmann, N; Zou, L; Zou, Y | 1 |
| Liu, Q; Shi, S; Song, S; Xu, X; Yu, X | 1 |
| Ameye, L; Anciaux, M; Deleporte, A; Demetter, P; Donckier, V; Flamen, P; Guiot, T; Hendlisz, A; Sclafani, F; Van Gossum, A; Vandeputte, C; Wenglinski, C | 1 |
| Aasen, T; Abdul Moin, NI; Abdul Wafi, S; Aboukameel, A; Abu-Bakar, N; Acharya, A; Ackermans, L; Adaramoye, O; Adarsh, KV; Adeosun, WA; Ahmad, NH; Ahmadi, F; Akanni, O; Akbar, M; Akbulak, RO; Akev, N; Akkaya, Ö; Al-Rashed, S; AlAbbad, S; Alabi, O; Alappat, BJ; Alcalá, S; Alcoutlabi, M; Aleppo, G; Alexander Ross, JB; Alexander, JH; Alexander, R; Alias, A; Alimba, C; Alken, FA; Allan, R; Alpers, M; Alsbou, EM; Amarasiri, SS; An, T; Anastasiadis, F; Anastassiadou, M; Anderson, KC; Andronikos, P; Anheyer, D; Annapurna, K; Anorlu, RI; Anten, MM; Anthopoulos, TD; Araujo-Castillo, RV; Aravamudhan, S; Arawwawala, LDAM; Arulsamy, N; Arunamata, A; Asghar, A; Asiri, AM; Aslanidou, T; Astrakhantseva, IV; Astutik, E; Attanayake, AP; Atwater, BD; Audureau, E; Augusto, S; Bakare, A; Banach, M; Bandelier, P; Banerjee, S; Barral, M; Bascuñán, J; Bates, FS; Bauer, NJC; Bayrak, BB; Beck, RW; Beckervordersantforth, J; Beeri, R; Begum, R; Beldi-Ferchiou, A; Bellingham, G; Ben-Tal, N; Bendib, I; Bergenstal, RM; Berger, MF; Bernasconi, G; Berry, S; Beuvon, F; Bi, WJ; Bi, Z; Bianconi, V; Bibi, I; Blank, BR; Bliemeister, E; Bobkowski, W; Bode, AM; Booth, CM; Bose, U; Boyd, K; Brancato, A; Brenmoehl, J; Brogi, E; Bronzo, P; Brooks, T; Brown, D; Brown, DN; Bruce, D; Buan, MEM; Bueno-Hernández, F; Bugielski, B; Bulavaitė, A; Buscagan, TM; Buxton, R; Caffaro, MM; Cai, Q; Cai, X; Cai, Y; Calhoun, P; Callander, N; Cambier, S; Camparo, P; Canales-Vargas, EJ; Canham, K; Cantu, J; Cao, J; Cao, JW; Cao, P; Cao, T; Cao, X; Caravella, BA; Carcadea, E; Carè, J; Carmichael, P; Carrasco Cabrera, L; Carteaux, G; Carvalho, PDS; Casarez, E; Cazorla, M; Celestrin, CP; Chakraborty, NK; Chan, B; Chandarlapaty, S; Chandgude, AL; Chang, CC; Chang, JH; Chang, X; Chang, Y; Chankhanittha, T; Chantanis, S; Chapovetsky, A; Chavan, S; Chen, B; Chen, D; Chen, F; Chen, G; Chen, H; Chen, J; Chen, K; Chen, KJ; Chen, KP; Chen, L; Chen, MA; Chen, Q; Chen, S; Chen, W; Chen, WF; Chen, X; Chen, Y; Cheng, D; Cheng, J; Cheng, Q; Cheon, GJ; Chiu, SC; Cho, CH; Cho, J; Choi, H; Choi, JS; Choi, YH; Christie, P; Chu, CH; Chu, Y; Chung, DH; Chung, F; Cline, JP; Cohen, A; Cohen, AD; Cohen, NJ; Comen, E; Compter, I; Cong, J; Cong, Z; Cooper, A; Cornud, F; Costa, C; Costa, S; Covey, A; Cowan, AM; Cramer, H; Cruz-Rivera, C; Cui, J; Cui, M; Cui, Y; Cui, YH; Culquichicón, C; Cushman, T; D'Auria, SJ; da Silva, J; Dalgediene, I; Danenberg, HD; Das, S; Dasgupta, K; Daubit, IM; de Oliveira, PD; de Prost, N; De Ruysscher, D; Dearman, K; Decato, D; Delfau-Larue, MH; Deng, L; Dhakate, SR; Dharuman, V; Di Costanzo, N; Dickler, MN; Dinehart, EE; Ding, D; Dinh, TK; Divya, KP; Djifack Tadongfack, T; Do, T; Domínguez-Roldan, R; Domínguez-Zambrano, E; Dömling, A; Donato, MD; Dong, JH; Dong, W; Dong, X; Dong, XR; Dong, Y; Dong, Z; Downs, M; Drutskaya, MS; Du, B; Du, F; Du, H; Du, L; Du, X; Duan, Z; Duangthip, D; Dunstand-Guzmán, E; Duong, F; Eckert, DJ; Edelhäuser, BAH; Eekers, DBP; Efendi, F; Efraimidis, P; Ehrenberg, H; Ehsanbakhsh, Z; Eickholt, C; Eksterowicz, J; El Mobadder, M; El-Araby, IE; El-Magd, MA; El-Tarabany, MS; Elgorban, AM; Engelmann, D; English, KL; Esfandiari, H; Eslami, B; Espinosa-Cuevas, A; Eswara, S; Faber, E; Fan, XH; Fan, Y; Fang, J; Fang, Z; Fantin, VR; Fei, P; Feng, G; Feng, H; Feng, J; Feng, X; Feng, XJ; Fennell, TR; Fernández-Moreira, V; Ferraz, ABF; Ferreras, KN; Flores, K; Flores-Pérez, I; Flox, C; Fluharty, FL; Fokouong Tchoffo, E; Folefack, GO; Foroutan, T; Fort, D; Fourati, S; Fousas, S; Frapard, T; Freguia, S; Friedman, DJ; Friedman, LS; Fu, D; Fu, Q; Fu, Y; Fujinami, S; Furihata, K; Gal, RL; Gan, H; Gao, C; Gao, F; Gao, R; Gao, SS; Gao, W; Gao, XC; Gao, Y; Gao, Z; Garozi, L; Ge, J; Georgiopoulos, A; Gerakiou, K; Ghazimirsaeed, SM; Ghazimirsaeed, ST; Gimeno, MC; Gjestad, R; Glurich, I; Goetchius, E; Goland, S; Goldstein, S; Gonçalves, CM; Gonçalves, H; Gong, Q; Gonzalez, D; Goplen, FK; Gorshkova, EN; Gotsman, I; Govindasamy, V; Granger, CB; Greco, L; Grigoriadou-Skouta, E; Grigoropoulos, P; Grivicich, I; Gromov, NV; Gruber, S; Grytczuk, M; Grzech-Leśniak, K; Gu, L; Gu, S; Gu, Z; Guadagnini, D; Guan, H; Guilliams, M; Guo, J; Guo, L; Gupta, A; Gupta, SK; Gurzu, S; Gutleb, AC; Haban, A; Hablitz, JJ; Hadisuyatmana, S; Hahn, S; Haiges, R; Hallal-Calleros, C; Hamed, M; Hammad, N; Hammer, N; Han, C; Hao, Y; Harnett, J; Has, EMM; Hassanpour, K; Hatzopoulos, D; Hawaldar, R; He, X; He, Y; He, YY; He, Z; Heberman, D; Heckl, D; Hegde, H; Henson, MA; Hernández-Velázquez, VM; Herrera, E; Hijazi, Z; Hirayama, K; Hirth, JM; Hoeben, A; Hohnloser, SH; Hong, M; Hood, K; Hoplock, LB; Hopman, WM; Horlbogen, LM; Hossein Rashidi, B; Hou, G; Hou, H; Hou, J; Hou, Y; Hu, J; Hu, W; Hu, X; Hua, W; Huang, G; Huang, H; Huang, J; Huang, T; Huang, W; Huang, Y; Huang, YD; Huang, Z; Hudis, CA; Hue, S; Huo, J; Hussain, M; Hvas, AM; Ichii, T; Ide Zeuna, J; Ilyas, S; Inoue, T; Iranzo, A; Irfan, M; Iwasa, Y; Iwashita, Y; Izgorodina, EI; J R, A; Jaber, WA; Jaborek, JR; Jacobus, SJ; Jadeja, SD; Jafarabadi, M; Jalan, D; Jamil, MI; Jarrah, S; Jarvis, D; Jayatilaka, KAPW; Jemal-Turki, A; Jeon, YK; Jeong, N; Jeong, SH; Jeong, SY; Jermy, M; Jhaveri, K; Ji, H; Ji, K; Ji, RY; Jiang, F; Jiang, J; Jiang, X; Jiang, Y; Jiao, Q; Jilani, K; Jiménez-Guerrero, P; Jin, L; Jo, YH; Johnson, JG; Johnson, ML; Jones, WS; Jose, S; Jularic, M; Jung, I; Jung, YJ; Jungen, C; Junttila, MR; Kache, S; Kahanovitch, U; Kalantzi, KI; Kallio, T; Kamnoedboon, P; Kang, CH; Kang, H; Kang, J; Kang, KW; Kapoor, P; Karmakar, D; Kartalis, A; Kauranen, P; Kazocina, A; Keikha, F; Keltai, M; Kershaw, SV; Kettani, M; Khalvati, S; Khandhar, S; Khosla, N; Kiely, CJ; Kim, CC; Kim, H; Kim, MJ; Kim, Y; Kim, YH; Kim, YT; Kimoto, E; Kiyu, A; Klatt, N; Kobayashi, M; Koh, J; Köhler, R; Kondadasula, SV; Kong, H; Kong, W; Kong, X; Kotidis, A; Kotwal, A; Kouvari, M; Kozhinov, AN; Kruger, D; Kuang, S; Kuang, Y; Kubota, M; Kuklik, P; Kumar, P; Kumar, SK; Kuo, YF; Kurup, SP; Kusuhara, H; Kuswanto, H; Lacouture, ME; Lambin, P; Lang, CC; Langroudi, FH; Lanman, RB; Larsen, OH; Laskin, J; Le, VH; Leach, M; Lee, BG; Lee, DF; Lee, DS; Lee, HJ; Lee, SB; Lee, YA; Lei, Y; Lekashvili, O; Lelj, F; Lemin, AS; Lemoine, J; Leuschner, R; Li, B; Li, BT; Li, C; Li, D; Li, F; Li, G; Li, H; Li, HW; Li, J; Li, M; Li, P; Li, Q; Li, S; Li, W; Li, X; Li, XY; Li, Y; Li, Z; Lian, Y; Liang, C; Liao, J; Liao, W; Liao, Y; Lin, D; Lin, W; Lin, YL; Lindbäck, J; Lindsay, AP; Ling, J; Linser, PJ; Liu, C; Liu, H; Liu, JJ; Liu, L; Liu, Q; Liu, SF; Liu, X; Liu, Y; Liu, Z; Liu, ZM; Lo Sterzo, C; Lo, ECM; Lobchuk, MM; Lodge, TP; Logotheti, S; Lonial, S; Lopes, G; Lopes, RD; Lopez, J; Lopez, SA; López-Santos, AL; López-Sendón, JL; Loring, Z; Louis, C; Lovita, AND; Lu, DZ; Lu, H; Lu, J; Lu, K; Lu, TT; Lu, Y; Luengo, A; Lum, LG; Luna, JM; Luo, L; Luo, R; Luo, T; Luo, X; Luo, Z; Lv, B; Lymperopoulos, N; Lyras, A; Lyu, Y; M Kannan, A; Ma, H; Ma, M; Ma, Q; Ma, S; Ma, WY; Ma, Y; Maalouf, E; Machado, FA; Maeda, K; Magrans, JO; Maharani, A; Maia, G; Mainwaring, RD; Maji, TK; Majumdar, K; Mannarino, MR; Mansuri, MS; Marinescu, SC; Markatos, G; Marquardt, S; Marraiki, N; Martens, C; Martínez, TJ; Marumo, K; Maruyama, H; Marwani, HM; Marzo, I; Masrati, G; Matamba, P; Mathialagan, S; Matys, J; Mayatra, JM; Mboua, PC; McArthur, T; McCrimmon, RJ; McIntosh, S; McSpadden, S; Medina-Campos, ON; Medvedovsky, AT; Mei, Z; Mekontso-Dessap, A; Menezes, AMB; Meng, J; Meng, P; Meng, Y; Menter, A; Mets, MB; Mets-Halgrimson, R; Metzger, T; Metzler-Nolte, N; Meyer, C; Mi, Y; Michailoviene, V; Mikrogeorgiou, A; Militz, H; Miller Iii, TF; Minarowska, A; Mir, S; Miron, I; Miyake, T; Moayer, F; Modi, S; Moeller, SJ; Mohamad, MN; Mohammed, EHM; Mokhonov, VV; Mondal, A; Moore, J; Moravcova, M; Mordi, IR; Mordi, NA; Mortensen, NP; Moscariello, C; Moser, J; Moynahan, ME; Mu, J; Mu, W; Mudduwa, LKB; Mukherjee, S; Mukhtar, A; Mulkey, DK; Murr, N; Mushtaq, Z; Muthuswamy, N; Mutlu, O; Muto, C; Myroforou, I; Na, KJ; Nabi, M; Nagornov, KO; Nagy, RJ; Naik, A; Nakajima, K; Nam, KT; Nam, YW; Namburath, M; Nammour, S; Namour, A; Namour, M; Nanan, S; Natsume, H; Nave, S; Naveed, A; Nazir, H; Ndubaku, C; Nedospasov, SA; Neradilek, MB; Newcomb, C; Nguépy Keubo, FR; Nguyen, M; Ning, J; Ning, Q; Noguchi, S; Nordahl, SHG; Nordfalk, KF; Norton, L; Noupoue, EM; Nouri, SS; Nowak, JK; Núñez, K; Oakes, K; Odegaard, JI; Ogorodnikova, OL; Ogunsuyi, O; Oh, HK; Oh, HR; Oh, KH; Ohgi, K; Okunade, KS; Oliveira, AG; Olorunfemi, G; Olsen, ML; Olson, BA; Omari, KW; Ondruschka, B; Orfali, R; Orkopoulos, A; Orlowski, RZ; Oser, SM; Oser, TK; Özcan, M; Padilla, V; Paeng, JC; Pajuelo-Lozano, N; Pal, SK; Palmieri, S; Palomeque, E; Pan, W; Panagiotakos, DB; Pandey, M; Pang, D; Pang, Q; Pangarah, CA; Panny, A; Paparella, A; Papirio, S; Papouskova, K; Parang, K; Park, HJ; Park, IK; Park, S; Parker, TL; Parkhomenko, A; Parmon, VN; Parsons, B; Parsons, J; Patel, PR; Patil, S; Patsourakos, NG; Patterson, KC; Pavlidis, P; Pedernera, M; Pedersen, R; Pedraza-Chaverri, J; Pellegrini, M; Peña-Chora, G; Pereira, EDM; Pereira, MADS; Peretz, A; Perez-Padilla, R; Perlman, GY; Perona, R; Petras, C; Phuntsho, S; Picada, JN; Pinder, TA; Piper, LFJ; Pirozzi, F; Pirro, M; Pleckaityte, M; Ploutz-Snyder, LL; Ploutz-Snyder, R; Pogorzelski, A; Poles, L; Postma, AA; Prager, A; Prakash, J; Punn, R; Pützer, BM; Qi, J; Qi, MC; Qi, Y; Qian, J; Qian, Y; Qiang, L; Qiu, J; Qu, Y; Rabiu, KA; Rahighi, S; Rahman, MM; Rahmani, B; Rajkumar, SV; Ramanathan, R; Raras, TYM; Rashi, Y; Rasool, G; Rathore, MG; Ratnawati, R; Ratola, N; Raucci, U; Ray, SK; Razavi, P; Razazi, K; Razek, S; Razi, SS; Reback, M; Reddy, K; Rees, DC; Reginatto, FH; Reich, H; Reis-Filho, JS; Ren, X; Ren, Y; Renner, G; Rey, G; Reymen, B; Riaz, M; Ricci, A; Richardson, PG; Richter, C; Riga, M; Ritchie, C; Rivoal, S; Roberts, W; Robson, ME; Rocha, GZ; Rodrigues, AD; Rogach, AL; Rojas, A; Rosenberg, A; Rosenberg, E; Rosenheck, RA; Roslan, K; Rothenberger, C; Rouschop, KMA; Rubagumya, F; Ryan, CM; Ryder, JW; Saad, MJA; Sacan, O; Sacchi, A; Sahebkar, A; Saini, A; Sainz, B; Sajo, EA; Sakizadeh, J; Saleh, AA; Salgado Júnior, IB; Salvi, R; Samoylova, YV; Samuni, A; Sanchez, DM; Sanchez-Perez, I; Santos, M; Sarapulova, A; Sardot, T; Saud, N; Sauerbier, P; Scaltriti, M; Schaeffer, B; Schalk, DL; Scherschel, K; Schijven, MP; Schreuder, HWR; Schuhmacher, M; Schultz-Lebahn, A; Schwarzl, J; Scott, JM; Sebayang, SK; Seeger, ZL; Segabinazi Peserico, C; Selenica, P; Serio, A; Seruga, B; Shah, A; Shah, C; Shah, PD; Shahrokh Tehraninezhad, E; Shan, A; Shao, Z; Sharma, AMR; Sharma, RK; Shen, J; Shen, R; Shi, X; Shi, Y; Shi, ZE; Shih, YC; Shimohata, H; Shimpi, N; Shin, SH; Shon, HK; Shuvy, M; Siddique, AB; Siegbahn, A; Sikandar, M; Silvani, Y; Singh, A; Singh, AK; Singh, D; Singh, JS; Singh, KP; Singh, M; Situ, B; Skipper, MT; Skouloudi, M; Sloane, BF; Smyrnioudis, N; Snyder, MA; Söhnchen, C; Solis Condor, R; Solit, DB; Someya, S; Song, H; Song, J; Song, W; Song, Y; Sorokina, KN; Soshi, S; Soyer, P; Spitschak, A; Sreekrishnan, TR; Srinivasan, M; Staruschenko, A; Steel, A; Stefan-van Staden, RI; Stein, AM; Strayer, H; Struthers, AD; Su, H; Su, Q; Su, X; Sudore, RL; Sugimura, H; Sugiyama, Y; Sujuti, H; Sumner, SJ; Sun, B; Sun, D; Sun, H; Sun, J; Sun, JY; Sun, X; Sun, Y; Sun, Z; Sung, YC; Surenaud, M; Sutimantanapi, D; Suwandaratne, NS; Swaroop, S; Sychrova, H; Syed, A; Szczepanik, M; Szederjesi, J; Szodorai, R; Tacy, TA; Tadelle, RM; Takayasu, M; Tammeveski, K; Tan, H; Tan, M; Tang, HX; Tang, S; Tang, X; Tanokura, M; Tao, F; Tao, H; Tarafdari, A; Tarín-Carrasco, P; Tasson Tatang, C; Teixeira, JP; Thakur, A; Theobald, A; Thevenot, P; Thomaidis, K; Tian, J; Tillib, SV; Toma, C; Tomita, M; Tonchev, I; Tong, F; Toy, W; Trypuć, M; Tselepis, AD; Tsetseris, L; Tsikouri, GE; Tsikouris, EI; Tsoplifack, CB; Tsoumani, ME; Tsujimoto, R; Tsybin, YO; Tu, J; Tu, TM; Turco, M; Turkyilmaz, IB; Uddin, MJ; Ung, J; Unsihuay, D; Utsunomiya, T; Vagenende, B; Vaishnav, J; Valdes, C; Validad, MH; Valle, J; van Ginkel, MPH; van Grevenstein, WMU; Vanderpuye, V; Vasan, N; Vasilenko, EA; Vasques, GJ; Vavoulis, P; Verani, A; Veziroglu, E; Viegas, A; Vitali, MG; Vitsas, G; Voccio, JP; Vogiatzidis, C; Volow, A; Volpin, F; Vourvahis, M; Wagner, LI; Walkowiak, J; Wallace, R; Wallentin, L; Wan, D; Wan, L; Wan, T; Wang, C; Wang, F; Wang, FN; Wang, H; Wang, J; Wang, L; Wang, Q; Wang, S; Wang, T; Wang, W; Wang, X; Wang, XW; Wang, Y; Wang, YS; Wang, Z; Ward, J; Ward, L; Waseem, R; Watson, DF; Weber, P; Wehrmeister, FC; Wei, CH; Wei, H; Wei, L; Wei, Q; Wei, Y; Weinstock, RS; Weiss, M; Welborn, M; Wen, L; Wen, LM; Wen, Q; Wen, Z; Wesseling, P; Westerbergh, J; White, K; Wick, MP; Willems, S; Wiyasa, IWA; Wójciak, R; Wolkenhauer, O; Won, HH; Wong, J; Woo, YC; Wood, LS; Wu, CT; Wu, CY; Wu, D; Wu, G; Wu, J; Wu, K; Wu, M; Wu, Q; Wu, T; Wu, W; Wu, X; Wu, XT; Wu, Y; Xi, D; Xi, J; Xiang, W; Xiang, Y; Xiao, M; Xiao, Z; Xie, H; Xie, Q; Xie, S; Xie, X; Xing, M; Xing, YL; Xu, C; Xu, X; Xu, Y; Xu, Z; Xue, F; Xue, XD; Yaglioglu, HG; Yamada, H; Yamashita, M; Yan, W; Yan, Z; Yanardag, R; Yang, D; Yang, H; Yang, K; Yang, QQ; Yang, R; Yang, S; Yang, T; Yang, X; Yang, Y; Yao, H; Yao, Y; Yari, D; Yassin, MT; Ye, C; Ye, J; Ye, Q; Yildiz, EA; Ying, S; Yoon, H; Yu, D; Yu, K; Yu, N; Yu, PL; Yuan, C; Yuan, D; Yuan, LJ; Yuan, Z; Yuen, N; Zagatto, AM; Zakaria, Y; Zalewski, AM; Zamora, S; Zavorotinskaya, T; Zeid, JL; Zeinoun, T; Zeng, C; Zerby, HN; Zhan, X; Zhang, A; Zhang, D; Zhang, E; Zhang, F; Zhang, H; Zhang, J; Zhang, L; Zhang, M; Zhang, P; Zhang, Q; Zhang, QY; Zhang, RG; Zhang, S; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, CK; Zhao, H; Zhao, J; Zhao, K; Zhao, Q; Zhao, S; Zhao, T; Zhao, XQ; Zhao, Y; Zhao, Z; Zheng, J; Zheng, L; Zheng, Y; Zhou, B; Zhou, G; Zhou, L; Zhou, T; Zhou, X; Zhu, C; Zhu, J; Zhu, Y; Zhu, ZQ; Zhuang, T; Zimmermannova, O; Zin, NNINM; Zisimos, K; Zoghebi, KA; Zonder, JA; Zou, C; Zwirner, J | 1 |
| Ahn, MJ; Choi, JY; Lee, J; Lim, SW; Oh, D; Park, K; Shim, YM; Sun, JM; Zo, JI | 1 |
| Wang, L; Zhang, Y | 1 |
| Chicco, A; Cong, E; Ho Shon, I; Lee, MT; Lin, M; Lin, P; Oar, AJ; Yap, J | 1 |
| Amthauer, H; Beck, M; Berger, J; Biebl, M; Budach, V; Hofheinz, F; Hua, W; Kruppa, J; Li, Y; Lili, C; Lin, Q; Mai, HD; Päßler, T; Stromberger, C; Thuss-Patience, PC; Tinhofer, I; Zschaeck, S | 1 |
| Aggarwal, A; Durga, G; Goel, S; Gupta, M; Gupta, N; Iqbal, SA; Singh, S; Talwar, V | 1 |
| Beukinga, RJ; Burgerhof, JGM; Coppes, RP; Dijksterhuis, WPM; Faber, H; Karrenbeld, A; Mul, VEM; Plukker, JTM; Slart, RHJA; Wang, D | 1 |
| Abecasis, N; Brandão, F; Cabral, F; Casaca, R; Cruz, A; Fonseca, R; Monteiro, C; Pedro, C; Pinto, I; Ramos, P; Ratão, P; Salgado, L | 1 |
| Agarwal, JP; Ghosh-Laskar, S; Karmakar, S; Kumar, R; Mehta, S; Mummudi, N; Noronha, V; Pathuthara, S; Patil, P; Prabhash, K; Purandare, N; Tibdewal, A | 1 |
| Fontaine, JP; Frakes, JM; Harrison, LB; Hoffe, SE; Latifi, K; Mehta, R; Moros, EG; Pimiento, JM; Rishi, A; Sim, AJ; Song, EY; Tomaszewski, MR; Yuan, Z; Zhang, GG | 1 |
| Albenda, DG; Buchpiguel, CA; Cecconello, I; Duarte, PS; Junior, UR; Sallum, RAA; Takeda, FR; Tustumi, F | 1 |
| Gani, C; Gatidis, S; la Fougère, C; Nikolaou, K; Pfannenberg, C; Reinert, CP; Sekler, J | 1 |
| Hotta, M; Minamimoto, R; Nakajima, K; Nohara, K; Takase, K; Toyohara, J; Yamada, K | 1 |
| Han, S; Kim, TH; Kim, YI; Ryu, JS; Woo, S | 1 |
| Chen, J; He, Y; Li, C; Tian, Y; Wen, B | 1 |
| Baues, C; Bruns, CJ; Celik, E; Drzezga, A; Fischer, T; Kobe, C; Linde, P; Marnitz, S; Quaas, A; Rosenbrock, J; Schomaecker, K; Trommer, M; van Heek, L; Wegen, S; Wester, HJ | 1 |
| Bansal, H; Lukose, TT; Mishra, AK; Moideen, A; Ravina, M | 1 |
| Bjerring, OS; Fristrup, CW; Hess, S; Lundell, L; Mortensen, MB; Petersen, H | 1 |
| Gopal, A; Pinho, DF; Subramaniam, RM; Xi, Y | 1 |
| Aleman, BMP; Bartels-Rutten, A; Grootscholten, C; Sonke, JJ; Takken, SL; van de Kamer, JB; van Dieren, JM; van Sandick, JW; Vegt, E; Voncken, FEM | 1 |
| Haruštiak, T; Obermannová, R; Zemanová, M | 1 |
| Hattori, S; Hirata, K; Hung, A; Ishibashi, M; Ishii, K; Kaida, H; Kitajima, K; Matsunaga, T; Minamimoto, R; Nakajo, M; Nakatani, K; Yasuda, T | 1 |
| Chen, C; Hu, X; Huang, Q; Jiang, M; Tang, Y | 1 |
| Chiu, NC; Lu, HH; Tsai, MH | 1 |
| Bekaii-Saab, T; Boffa, DJ; Frankel, WL; Fruth, B; Goodman, KA; Hall, NC; Ilson, DH; Janjigian, YY; Meyerhardt, JA; Meyers, MO; Mitchell, K; Niedzwiecki, D; Noonan, A; O'Reilly, EM; Ou, FS; Thurmes, PJ; Twohy, E; Venook, AP | 1 |
| Chen, CC; Chuang, CY; Li, C; Lin, JW; Yeh, HL | 1 |
| Chung, H; Kim, HJ; Lee, R; Lee, TH; Paeng, JC; Ryoo, HG | 1 |
| Hecht, M; Semrau, S | 1 |
| Kuriyama, K; Nakazawa, N; Ogawa, H; Saeki, H; Saito, H; Sakai, M; Sano, A; Shirabe, K; Sohda, M; Ubukata, Y; Uchida, S; Watanabe, T; Yamaguchi, A; Yokobori, T | 1 |
| Fujita, H; Imai, K; Kemuriyama, K; Maeda, E; Minamiya, Y; Motoyama, S; Nagaki, Y; Sasaki, Y; Sato, Y; Wakita, A | 1 |
| Choi, JY; Choi, Y; Choi, YL; Hong, TH; Kim, HK; Lee, KS; Oh, D; Shim, YM; Woo, SY; Zo, JI | 1 |
| Fang, N; Liu, LL; Wang, YL; Wu, ZJ; Zeng, L | 1 |
| Fan, B; Fan, P; Fu, Z; Hu, M; Kong, L; Ma, L; Sun, X; Wang, S; Yu, J; Zhao, S; Zheng, J | 1 |
| Abe, O; Nakagawa, K; Yamashita, H | 1 |
| Kakugawa, Y; Matsuda, T; Saito, Y; Sekiguchi, M; Shimada, N; Terauchi, T | 1 |
| Abgral, R; Bourhis, D; Caradec, P; El Kabbaj, O; Encaoua, J; Leleu, C; Pradier, O; Schick, U | 1 |
| Ho, L; Hofstetter, WL; Komaki, R; Liao, Z; Lin, SH; Xi, M | 1 |
| Alchawaf, A; Germetaki, T; Khoja, L; Kordatou, Z; Mansoor, W; Owen-Holt, V; Papaxoinis, G; Patrao, A; Stamatopoulou, S; Weaver, JMJ | 1 |
| Chang, YC; Chao, YK; Hou, MM; Hsieh, CE; Hsieh, CH; Hung, TM; Lin, CR; Pai, PC; Su, PJ; Tseng, CK; Wu, YY; Yang, CK; Yap, WK | 1 |
| Ho, MJ; Kobayashi, S; Miyata, H; Ohue, M; Omori, T; Sakon, M; Sugimura, K; Takahashi, H; Yanagimoto, Y; Yano, M | 1 |
| Baretton, G; Baumann, M; Bütof, R; Hofheinz, F; Jentsch, C; Kotzerke, J; Krause, M; Löck, S; Schmollack, J; Weitz, J; Zöphel, K; Zschaeck, S | 1 |
| Choi, W; D'Souza, WD; Kang, MK; Li, L; Lu, W; Tan, S | 1 |
| Doki, Y; Hatazawa, J; Makino, T; Mori, M; Takiguchi, S; Tanaka, K; Tatsumi, M; Yamasaki, M | 1 |
| Hiasa, G; Hosokawa, S; Kawada, Y; Kawaguchi, N; Kawamura, G; Kazatani, Y; Kosaki, T; Matsuoka, H; Okayama, H; Shigematsu, T; Takahashi, T; Yamada, T | 1 |
| Goel, R; Subramaniam, RM; Wachsmann, JW | 1 |
| Dong, A; Wang, Y; Yang, B; Zhao, Q; Zuo, C | 1 |
| Alessi, A; Battiston, C; Berenato, R; Caporale, M; Coppa, J; Cotsoglou, C; de Braud, F; Delconte, G; Di Bartolomeo, M; Fucà, G; Greco, G; Infante, G; Lazzati, S; Mazzaferro, V; Mennitto, A; Morano, F; Niger, M; Padovano, B; Pellegrinelli, A; Pietrantonio, F | 1 |
| Goody, R; Marshall, K; McDermott, G; Murray, P; Prestwich, R; Radhakrishna, G; Scarsbrook, A; Ward, G | 1 |
| Imai, K; Kawakita, Y; Konno, H; Liu, J; Minamiya, Y; Mizusawa, KT; Motoyama, S; Nagaki, Y; Saito, H; Sasaki, T; Sato, Y; Wakita, A | 1 |
| Goense, L; Heethuis, SE; Lagendijk, JJW; Lam, MGEH; Lin, SH; Meijer, GJ; Mook, S; Ruurda, JP; Terhaard, CH; van Hillegersberg, R; van Lier, ALHMW; van Rossum, PSN; Voncken, FEM | 1 |
| Aleman, BMP; Grootscholten, C; Lalezari, F; Steinberg, JD; van Dieren, JM; van Sandick, JW; Vegt, E; Voncken, FEM | 1 |
| Ishikawa, Y; Jingu, K; Kadoya, N; Kozumi, M; Takahashi, N; Takanami, K; Takeda, K; Umezawa, R; Yamamoto, T | 1 |
| Betancourt Cuellar, SL; Carter, BW; Correa, AM; Hofstetter, WL; Marom, EM; Palacio, DP; Wu, CC | 1 |
| Hara, K; Higuchi, T; Honjyo, H; Kuwano, H; Miyazaki, T; Ozawa, D; Sakai, M; Sohda, M; Tsushima, Y; Yokobori, T | 1 |
| Dunphy, MP; Haque, S; Mahajan, S; Pandit-Taskar, N | 1 |
| Chang, YC; Chao, YK; Chen, CC; Hsieh, CH; Hung, TM; Shih, MC; Yap, WK | 1 |
| Hiraoka, M; Ishida, Y; Itasaka, S; Mizowaki, T; Nakamoto, Y; Sakanaka, K; Togashi, K | 1 |
| Enzinger, PC; Gerbaudo, VH; Hornick, JL; Killoran, JH; Kim, CK; Mamon, HJ; Nowak, JA | 1 |
| Angele, MK; Belka, C; Boeck, S; Boeckle, D; Fendler, WP; Hegemann, NS; Koepple, R; Roeder, F; Walter, F | 1 |
| Fencl, P; Harustiak, T; Hornofova, L; Lischke, R; Pazdro, A; Salkova, E; Snajdauf, M; Stolz, A; Zemanova, M | 1 |
| Fukuda, A; Kimura, T; Matsumura, T; Nagao, M; Seno, H | 1 |
| Matsushima, S; Nishimura, M; Okuyama, C; Sasaki, N; Yoshimatsu, R | 1 |
| Ahmed, HS; Farwell, MD; Metz, JM; Pantel, AR; Plastaras, JP | 1 |
| Carter, BW; Goense, L; Ho, L; Hofstetter, WL; Lin, SH; Maru, DM; Meijer, GJ; van Hillegersberg, R; van Rossum, PSN; Xi, M | 1 |
| Katsuura, T; Kitajima, K; Kurahashi, Y; Odawara, S; Shinohara, H; Yamakado, K | 1 |
| Hamerla, G; Meyer, HJ; Purz, S; Surov, A | 1 |
| Goense, L; Lam, MGEH; Meijer, GJ; Meziani, J; Ruurda, JP; van Hillegersberg, R; van Rossum, PSN; Wessels, FJ | 1 |
| Ahmed, N; Borakati, A; Cawthorne, C; Razack, A; Roy, R; Usmani, S | 1 |
| Carter, BW; Fang, P; Fellman, BM; Hobbs, BP; Lin, SH; Ma, J; Mawlawi, O; Moreno, AC; Musall, BC; Son, JB | 1 |
| Cho, YS; Choi, JY; Hyun, SH; Kim, BT; Kim, SJ; Lee, KH; Moon, SH; Shim, YM; Yi, HK | 1 |
| Aymar, N; Gimenez, M; Jimenez-Jimenez, E; Mateos, P; Ortiz, I; Pardo, J; Roncero, R; Sabater, S; Salinas, J | 1 |
| Doki, Y; Hatazawa, J; Kimura, Y; Makino, T; Masuike, Y; Mori, M; Motoori, M; Tanaka, K; Tatsumi, M; Yamasaki, M | 1 |
| de Keizer, B; Goense, L; Kroese, TE; Mook, S; Ruurda, JP; van Hillegersberg, R; van Rossum, PSN | 1 |
| Kato, H; Kikuchi, M; Muroi, H; Nakajima, M; Sasaki, K; Yamaguchi, S; Yokoyama, H | 1 |
| Fu, X; Ma, J; Ren, Y; Xiong, J; Yu, W; Zhao, J | 1 |
| Barbour, AP; Burmeister, BH; Burmeister, E; Effeney, R; Harvey, J; Mai, GT; Pryor, DI; Shaw, T; Smithers, BM; Thomas, J | 1 |
| Ackerson, BG; Cui, Y; Czito, BG; Hong, JC; Marin, D; Palta, M; Rushing, CN; Tandberg, DJ; Willett, CW; Zhang, X | 1 |
| Albert Tsai, J; Axelsson, R; Gabrielson, S; Johansson, O; Klevebro, F; Nilsson, M; Sanchez-Crespo, A | 1 |
| Chan, D; Fielding, P; Foley, KG; Lewis, WG; Patel, N; Powell, AG; Roberts, SA; Wheat, JR | 1 |
| Itoh, S; Miyake, H; Miyata, K; Shimizu, D; Takeuchi, E; Yuasa, N | 1 |
| Chen, C; Cui, F; Su, M; Tian, R | 1 |
| Jun, S; Park, JG; Seo, Y | 1 |
| Brismar, TB; Herlin, G; Lundell, L; Nilsson, M; Rouvelas, I; Zhang, YH | 1 |
| Han, S; Kim, YJ; Lee, JJ; Suh, CH; Woo, S | 1 |
| Kong, MC; Nadel, HR | 1 |
| Bains, MS; Chou, JF; Goodman, KA; Greally, M; Ilson, DH; Janjigian, YY; Kelsen, DP; Ku, GY; Molena, D; Park, BJ; Rusch, VW; Wu, AJ | 1 |
| Gao, R; Gao, S; Jia, X; Wang, H; Zhang, G | 1 |
| Ba-Ssalamah, A; Fueger, B; Haug, A; Ilhan-Mutlu, A; Schmid, R; Schoppmann, SF; Stift, J; Tamandl, D | 1 |
| Beer, DG; Brown, RKJ; Carrott, PW; Chang, AC; Heiden, BT; Hermann, M; Lin, J; Lynch, WR; Nancarrow, DJ; Orringer, MB; Patel, N; Reddy, RM; Zhao, L | 1 |
| Bernstine, H; Brenner, B; Domachevsky, L; Groshar, D; Kashtan, H; Kundel, Y; Morgenstern, S; Nidam, M | 1 |
| Hu, J; Yang, Y; Zhu, D | 1 |
| Chen, CJ; Chiu, NT; Ho, KW; Hsu, CC; Huang, YC; Li, SH; Lin, WC; Lu, HI; Wang, YM | 1 |
| Cattan, P; Costantini, A; Hammoudi, N; Hennequin, C; Quéro, L; Valverde, A; Vercellino, L | 1 |
| Janjigian, YY; Mondaca, S | 1 |
| Aoki, Y; Emi, M; Furukawa, T; Hamai, Y; Hihara, J; Ibuki, Y; Murakami, Y; Nagata, Y; Nishibuchi, I; Okada, M | 1 |
| Chen, L; Chen, S; Li, Y; Lin, Q; Wu, H; Zschaeck, S | 1 |
| Ålgars, A; Kemppainen, J; Ristamäki, R; Salminen, P; Sundström, J; Vihervaara, H | 1 |
| Ishikawa, Y; Jingu, K; Kadoya, N; Matsushita, H; Takahashi, N; Takeda, K; Umezawa, R; Yamamoto, T | 1 |
| Fukugawa, Y; Imuta, M; Iyama, A; Kai, Y; Matsuyama, T; Murakami, R; Oya, N; Saito, T; Sakamoto, F; Shimohigashi, Y; Shiraishi, S; Toya, R; Tsuda, N; Watakabe, T; Yamashita, Y | 1 |
| Apolle, R; Aust, DE; Babatz, J; Brückner, S; Frosch, S; Hampe, J; Lohaus, F; Rehm, M; Thiele, J; Troost, EGC; Valentini, C | 1 |
| Altini, C; Bianco, G; Ferrari, C; Lavelli, V; Merenda, N; Niccoli Asabella, A; Pisani, A; Rubini, G; Ungaro, A | 1 |
| Christian, A; Foley, KG; Kynaston, H; Marshall, C; Peaker, J; Roberts, A; Spezi, E | 1 |
| Bennink, RJ; Bijlsma, MF; Creemers, A; Ebbing, EA; Hulshof, MCCM; Jibodh, RA; Krishnadath, KK; Medema, JP; Meijer, SL; Punt, CJA; Steins, A; van Delden, OM; van der Zalm, AP; van Laarhoven, HWM; Waasdorp, C | 1 |
| Cheng, CT; Chou, TY; Ho, HL; Huang, YY; Lee, MY; Lin, CS; Liu, CC; Pan, SC; Shih, CH; Wei, YH; Yeh, YC | 1 |
| Higashi, T; Ishizu, K; Kagawa, S; Kusano, K; Nakamoto, R; Okuyama, C; Takahashi, M; Yamauchi, H | 1 |
| Eyck, BM; Lagarde, SM; Nieboer, D; Noordman, BJ; Onstenk, BD; Spaander, MCW; Valkema, R; van Lanschot, JJB; Wijnhoven, BPL | 1 |
| Ahn, YC; Choi, JY; Hyun, SH; Kim, SJ; Lee, KS; Moon, SH; Oh, D; Shim, YM; Sun, JM; Zo, JI | 1 |
| Foley, K; Parkinson, C; Spezi, E; Staffurth, J; Whybra, P | 1 |
| Bradley, KM; Dickson, E; Findlay, JM; Fiorani, C; Gillies, RS; Maynard, ND; Middleton, MR; Mukherjee, S | 1 |
| Fatima, N; Tahseen, R; Zaman, A; Zaman, MU; Zaman, S; Zaman, U | 1 |
| Duhamel, A; Huglo, D; Mariette, C; Mirabel, X; Petyt, G; Piessen, G | 1 |
| Cheng, H; Huo, X; Shi, W; Wang, J; Wang, W | 1 |
| Hattori, N; Hirata, K; Hosokawa, M; Itoh, K; Manabe, O; Oyama-Manabe, N; Takahashi, H; Tamaki, N | 1 |
| Abe, K; Asai, K; Atsumi, K; Baba, S; Hirakawa, M; Honda, H; Isoda, T; Nakamura, K; Ohga, S; Sasaki, T; Shinoto, M; Shioyama, Y; Yoshitake, T | 1 |
| Bender, K; Grünberg, K; Haberkorn, U; Kauczor, HU; Ott, K; Stange, A; von Gall, CC; Weber, MA; Zechmann, C | 1 |
| Baumann, M; Bütof, R | 1 |
| Liu, J; Xing, L; Yu, J; Yue, J | 1 |
| Bardet, S; Benyoucef, A; Bridji, B; Di Fiore, F; Diana, C; Faure, G; Houzard, C; Itti, E; Jalali, K; M'vondo, CM; Ménard, JF; Meyer, ME; Michel, P; Mornex, F; Olivier, P; Palie, O; Rio, E; Rousseau, C; Vera, P | 1 |
| Hayashi, T; Ishii, T; Kikuchi, T; Kobayashi, Y; Minami, T; Nishimoto, M; Nozawa, M; Shimizu, N; Tsuji, H; Uemura, H; Yamamoto, Y; Yoshimura, K | 1 |
| Chen, EC; Jiang, W; Li, MH; Liu, P; Ma, JB; Song, YP; Yu, JM | 1 |
| Boellaard, R; Huisman, MC; Kinahan, PE; Lammertsma, AA; Makris, NE | 1 |
| Aparici, CM; Win, AZ | 1 |
| Cheze Le Rest, C; Hatt, M; Pradier, O; Tixier, F; Visvikis, D | 1 |
| Shim, KN; Yun, HW | 1 |
| Blazeby, JM; Blencowe, NS; Callaway, M; Ganesh, S; Hotton, EJ; Roach, H; Strong, S; Whistance, RN | 1 |
| Dubray, B; Lazarescu, I; Nkhali, L; Pradier, O; Thureau, S | 1 |
| Doki, Y; Kurokawa, Y; Miyata, H; Mori, M; Murakami, K; Nakajima, K; Takahashi, T; Takiguchi, S; Yamasaki, M | 1 |
| Hosokawa, M; Itoh, K; Kikkawa, T; Kinoshita, Y; Kusumi, T; Nishida, Y; Sakashita, K; Sasaki, S; Takenouchi, T; Uemura, S; Yamada, H | 1 |
| Chen, W; D'Souza, WD; Lu, W; Tan, S; Zhang, H; Zhang, Y | 1 |
| Azuma, K; Fujimoto, K; Fujita, H; Hattori, S; Hayabuchi, N; Hayakawa, M; Hiromatsu, Y; Hirose, Y; Ishibashi, M; Kage, M; Kaida, H; Kawahara, A; Kurata, S; Nakashima, T; Takamori, S | 1 |
| Chen, W; D'Souza, WD; Kim, G; Kligerman, S; Lu, W; Suntharalingam, M; Tan, S; Zhang, H | 1 |
| Doki, Y; Hatazawa, J; Miyata, H; Mori, M; Morii, E; Murakami, K; Nakajima, K; Takahashi, T; Takiguchi, S; Tanaka, K; Yamasaki, M; Yukinori, K | 1 |
| Almond, LM; Fry, J; Lyburn, ID; Torrance, AD; Wadley, MS | 1 |
| Alfieri, R; Castoro, C; Cervino, AR; Evangelista, L; Galuppo, S; Pomerri, F; Sileni, VC | 1 |
| Chen, SW; Ding, HJ; Hsieh, TC; Kao, CH; Liang, JA; Lin, CY; Yen, KY | 1 |
| Jeong, Y; Jung, HY; Kim, HR; Kim, JH; Kim, SB; Kim, YH; Lee, GH; Park, SI; Ryu, JS; Yoon, DH | 1 |
| Kessing, R | 1 |
| Chan, SC; Chao, YK; Chen, SH; Yen, TC | 1 |
| Darling, G; Evans, WK; Gulenchyn, K; Urbain, JL; Wong, RK; You, JJ | 1 |
| Kaibe, N; Kikuchi, S; Niwa, H; Oshima, T; Sasako, M; Takemura, M; Takii, M; Yamashita, H | 1 |
| Fujishiro, T; Kono, T; Matsubara, H; Ohira, G; Okazumi, S; Shuto, K; Tochigi, T; Tohma, T | 1 |
| Akutsu, Y; Fujishiro, T; Gunji, H; Hanaoka, T; Hoshino, I; Imanishi, S; Kono, T; Matsubara, H; Murakami, K; Narushima, K; Ohira, G; Okazumi, S; Shiratori, T; Shuto, K; Tochigi, T; Tohma, T; Uesato, M | 1 |
| Fukuchi, M; Higuchi, T; Kato, H; Kuwano, H; Miyazaki, T; Nakajima, M; Sakai, M; Sohda, M; Suzuki, S; Tanaka, N; Tsushima, Y; Yokobori, T | 1 |
| Bal, C; Jain, S; Julka, PK; Karunanithi, S; Kumar, R; Malhotra, A; Pal, S; Sharma, P; Thulkar, S | 1 |
| Darling, G; Guindi, M; Knox, J; Metser, U; Moshonov, H; Rashidi, F; Wong, R | 1 |
| Ela Bella, AJ; Fan, W; Fu, JH; Lin, P; Luo, KJ; Rong, TH; Yang, H; Zhang, YR | 1 |
| Dong, A; Wang, Y; Wen, W; Zhai, Z; Zuo, C | 1 |
| Dai, MM; Li, YM; Lin, Q; Luo, ZM; Sun, L; Wang, LC; Wu, H; Zhao, L; Zheng, H | 1 |
| Bertrand, C; Borght, TV; Crott, R; D'Hondt, L; Krug, B; Schollaert, P | 1 |
| Hashimoto, J; Ichikawa, T; Imai, Y; Kikuchi, T; Yabe, M | 1 |
| Choi, JY; Choi, YS; Hyun, SH; Kim, BT; Kim, HS; Lee, KH; Moon, SH; Shim, YM; Zo, JI | 1 |
| Agrawal, A; Jiwnani, S; Karimundackal, G; Kulkarni, M; Laskar, SG; Pramesh, CS; Purandare, NC; Rangarajan, V; Shah, S | 1 |
| Adams, HL; Jaunoo, SS | 1 |
| Blake, P; Chan, D; Fielding, P; Foley, KG; Karran, A; Lewis, WG; Roberts, SA | 1 |
| Herrmann, K; Lordick, F; Ott, K; Schmidt, T | 2 |
| Baba, H; Baba, Y; Ida, S; Ishimoto, T; Iwagami, S; Iwatsuki, M; Miyamoto, Y; Nagai, Y; Sakamoto, Y; Watanabe, M; Yamao, T | 1 |
| Groen, H; Hollema, H; Pavlov, K; Plukker, JT; Pruim, J; Pultrum, BB; Schreurs, LM; Smit, JK | 1 |
| Doki, Y; Fujiwara, Y; Higuchi, I; Miyata, H; Takiguchi, S; Yamasaki, M; Yano, M; Yasuda, T | 1 |
| Baba, H; Baba, Y; Ida, S; Imamura, Y; Iwagami, S; Karashima, R; Miyamoto, Y; Sakamoto, Y; Watanabe, M; Yoshida, N | 1 |
| Di Fiore, F; Dubray, B; Gouel, P; Hapdey, S; Lemarignier, C; Marre, C; Michel, P; Modzelewski, R; Vera, P | 1 |
| Antonescu, C; Bains, MS; Gollub, MJ; Levine, MS; Shia, J; Winant, AJ | 1 |
| Aleman, BM; Boot, H; Sanders, J; Stiekema, J; van Sandick, JW; Vegt, E; Vermeulen, D; Voncken, FE | 1 |
| Ajani, JA; Carter, BW; Correa, AM; Cuellar, SL; Erasmus, JJ; Hofstetter, WL; Komaki, R; Lee, JH; Macapinlac, HA; Swisher, SG; Welsh, JW | 1 |
| An, H; Chen, H; Li, Y; Lin, Q; Sun, L; Wu, H; Zhao, L | 1 |
| Lam, MGEH; Lips, IM; Meijer, GJ; Reerink, O; Ruurda, JP; van Hillegersberg, R; van Lier, ALHMW; van Rossum, PSN; van Vulpen, M | 1 |
| Mortensen, MB | 1 |
| Berry, MF; D'Amico, TA; Englum, BR; Erhunmwunsee, L; Onaitis, MW | 1 |
| Huang, ZQ; Li, J; Li, X; Liu, QW; Tan, HH; Tan, R; Yao, SZ | 1 |
| Elliott, JA; Halpenny, D; Johnston, C; King, S; Malik, V; Muldoon, C; O'Farrell, NJ; Reynolds, JV | 1 |
| Benyoucef, A; Doyeux, K; Dubray, B; Edet-Sanson, A; Gardin, I; Michel, P; Nkhali, L; Thureau, S; Vera, P | 1 |
| Berveling, MJ; Beukema, JC; Groen, H; Hospers, GA; Langendijk, JA; Muijs, CT; Mul, VE; Plukker, JT; Pruim, J; van der Jagt, EJ; Woutersen, D | 1 |
| Bradshaw, L; Farukhi, I; Gould-Simon, A; Kaif, M; Lazaga, F; Schmidt, R; Stagg, J; Thompson, C | 1 |
| Doki, Y; Fujiwara, Y; Miyata, H; Takiguchi, S; Yamasaki, M; Yano, M; Yasuda, T | 1 |
| Bomanji, J; le Grange, F; Tobias, JS; Warrilow, J; Warry, A; Wickers, S | 1 |
| Colletti, PM; Fernández-Esparrach, G; Fuster, D; Mayoral, M; Pagès, M; Pineda, E; Pons, F; Rubello, D | 1 |
| Chang, CF; Chuang, CY; Hsu, CP; Huang, JW; Lin, JC; Lin, JF; Lu, YY; Yeh, HL | 1 |
| Dharmendran, R; Fathinul Fikri, AS; Nordin, AJ; Vikneswaran, P | 1 |
| Ansari, S; Aso-Gonzalez, S; Castillo, E; Castillo, R; Guerrero, TM; Hobbs, B; Palacio, D; Pham, N; Skinner, H | 1 |
| Cai, XW; Feng, W; Fu, XL; Liu, Q; Yao, ZF; Yu, W; Zhang, Q; Zhang, YJ; Zhu, ZF | 1 |
| Fu, XL; Liu, Q; Yu, W; Zhang, YJ; Zhu, ZF | 1 |
| Agrawal, A; Jatale, P; Purandare, NC; Puranik, AD; Rangarajan, V; Sawant, S; Shah, S | 1 |
| Cheng, JC; Cheng, MF; Lee, JM; Liu, CJ; Tzen, KY; Yen, RF | 1 |
| Calais, J; Di Fiore, F; Dubray, B; Gardin, I; Lemarignier, C; Michel, P; Modzelewski, R; Nkhali, L; Thureau, S; Vera, P | 1 |
| Kuyumcu, S; Mudun, A; Şanlı, Y; Yeğen, G | 1 |
| Bal, C; Behera, A; Chakraborty, PS; Kumar, R; Mukherjee, A | 1 |
| Dong, X; Li, W; Sun, X; Wan, H; Wu, P; Xing, L; Yu, J | 1 |
| Akutsu, Y; Hoshino, I; Kono, T; Matsubara, H; Murakami, K; Narushima, K; Okazumi, S; Shutou, K; Tochigi, T; Toma, T; Uesato, M | 1 |
| Hagiwara, N; Matsutani, T; Miyashita, M; Nomura, T; Uchida, E; Wachi, E; Yamashita, N | 1 |
| Hagiwara, N; Hosone, M; Katayama, H; Matsuda, A; Matsutani, T; Nomura, T; Uchida, E; Yokoyama, T; Yoshida, H | 1 |
| Kwee, RM; Marcus, C; Sheikhbahaei, S; Subramaniam, RM | 1 |
| Alnaji, RM; Attwood, K; Ben-David, K; Gannon, J; Hochwald, SN; Jabi, F; Kanehira, K; Kukar, M; Malhotra, U; Mattson, D; Nava, H; Platz, TA; Salerno, K | 1 |
| Fisichella, PM | 1 |
| Eluvathingal Muttikkal, TJ; Jones, DR; Rehm, PK; Shami, VM | 1 |
| Goense, L; Lam, MG; Meijer, GJ; Reitsma, JB; Ruurda, JP; van Hillegersberg, R; van Rossum, PS; van Vulpen, M | 1 |
| Cook, GJ; Doumou, G; Goh, V; Siddique, M; Tsoumpas, C | 1 |
| Ba-Ssalamah, A; Fueger, B; Gore, RM; Haug, A; Hejna, M; Kinsperger, P; Paireder, M; Schoppmann, SF; Tamandl, D | 1 |
| Torigian, DA; Vilstrup, MH | 1 |
| Baumann, M; Bütof, R; Hofheinz, F; Jentsch, C; Kotzerke, J; Löck, S; Schmollack, J; Stadelmann, T; van den Hoff, J; Zöphel, K | 1 |
| Cosman, P; Das, A; Devadas, M; Lin, M; Merrett, N; Mittal, A; Wilson, R; Ziazaris, W | 1 |
| Wang, H; Yang, J; Yin, Y; Zhang, Y | 1 |
| Khong, PL; Tong, DK; Vardhanabhuti, V; Yuan, H | 1 |
| Bednarek, C; Bosset, JF; Cerda, T; Chevalier, C; Crehange, G; Cueff, A; Maingon, P; Mazoyer, F; Petegnief, Y; Quivrin, M; Servagi Vernat, S; Vulquin, N | 1 |
| Demir, Y; Şengöz, T; Sürücü, E | 1 |
| Claxton, Z; Fagan, AJ; Harmon, M; Johnston, C; Keogan, M; Malik, V; Meaney, JF; Muldoon, C; O'Toole, D; Ravi, N; Reynolds, JV | 1 |
| Ajani, JA; Bhutani, MS; Blum, MA; Charalampakis, N; Elimova, E; Etchebehere, E; Hofstetter, W; Lee, JH; Macapinlac, HA; Maru, D; Planjery, V; Rogers, JE; Shimodaira, Y; Shiozaki, H; Skinner, HD; Wadhwa, R; Wang, X; Weston, BR | 1 |
| Jung, HS; Kim, DJ; Lee, JW; Park, CK; Park, SY; Yun, MJ | 1 |
| Cook, G; Davies, A; Goh, V; Montana, G; Siddique, M; Sohn, HM; Ypsilantis, PP | 1 |
| Bundschuh, RA; Guckenberger, M; Lapa, C; Polat, B; Sonke, JJ; Thomas, L | 1 |
| Cao, J; Li, D; Ma, C; Yin, Y | 1 |
| Fujii, H; Harata, N; Isogai, J; Oota, S; Yoshida, K; Yoshimura, R | 1 |
| Acar, T; Ersöz, G; Kocaçelebi, K; Savaş, R | 1 |
| Braden, B; Bradley, KM; Findlay, JM; Gillies, RS; Maile, EJ; Maw, J; Maynard, ND; Middleton, MR; Phillips-Hughes, J | 1 |
| Fuccio, L; Giaccherini, L; Guido, A; Morganti, AG | 1 |
| Kitagawa, Y; Kuroshima, T; Okamoto, S; Sato, J; Satoh, A; Shiga, T; Tamaki, N; Wada, M; Watanabe, S | 1 |
| Lee, SJ; Park, SY; Yoon, JK | 1 |
| Doki, Y; Kurokawa, Y; Makino, T; Miyata, H; Miyazaki, Y; Mori, M; Takahashi, T; Takiguchi, S; Tatsumi, M; Yamasaki, M | 1 |
| Chang, S; Kim, SJ; Pak, K | 1 |
| Baba, H; Baba, Y; Harada, K; Higashi, T; Ida, S; Imamura, Y; Ishimoto, T; Iwagami, S; Izumi, D; Kosumi, K; Miyamoto, Y; Miyata, T; Sakamoto, Y; Shiraishi, S; Taki, K; Tokunaga, R; Watanabe, M; Yamashita, Y; Yoshida, N | 1 |
| Domeki, Y; Ihara, K; Kato, H; Kikuchi, M; Muroi, H; Nakajima, M; Okamoto, K; Sakamoto, S; Sasaki, K; Takahashi, M; Tani, Y; Tsuchioka, T; Yamaguchi, S | 1 |
| Capitain, O; Couturier, O; Gustin, P; Hatt, M; Lacombe, M; Marquis, A; Ménager, É; Paumier, A; Peyraga, G; Rio, E; Septans, AL; Trémolières, P; Vénara, A; Visvikis, D | 1 |
| Byun, JH; Choi, EK; Han, EJ; Hong, JH; Jang, HS; Kang, JH; Kim, HH; Yoo, IeR | 1 |
| Chang, S; Kim, SJ; Koo, PJ; Kwak, JJ | 1 |
| Aydin, Y; Eroğlu, A; Genc, B; Kantarci, M; Karaca, L; Ogul, H; Okur, A; Orsal, E; Sade, R | 1 |
| Court, LE; Fried, DV; Hofstetter, WL; Lin, SH; Meijer, GJ; van Rossum, PS; van Vulpen, M; Zhang, L | 1 |
| Hsieh, TC; Kao, CH; Lin, CY; Sun, SS; Wu, YC | 1 |
| Chen, E; Dong, Y; Jiang, W; Ma, J; Song, Y; Wang, C; Wang, W; Wang, Z; You, D; Zang, R | 1 |
| Chang, S; Kim, SJ | 1 |
| Bradley, KM; di Carlo, S; Findlay, JM; Franklin, JM; Gillies, RS; Gleeson, FV; Jones, GE; Maynard, ND; Middleton, MR; Teoh, EJ | 1 |
| Chang, S; Kim, SJ; Koo, PJ | 1 |
| Hara, K; Honjo, H; Kuwano, H; Miyazaki, T; Ozawa, D; Sakai, M; Sohda, M; Suzuki, S; Tanaka, N; Yokobori, T | 1 |
| Healy, MA; Reddy, RM; Wong, SL; Yin, H | 1 |
| Dong, A; Wang, Y; Zhang, L; Zuo, C | 1 |
| Boellaard, R; Bossuyt, PM; Dekken, HV; Hagen, PV; Heijl, MV; Henegouwen, MI; Hoekstra, OS; Kate, FJ; Lanschot, JJ; Sloof, GW | 1 |
| D'Imporzano, S; Fabrini, MG; Genovesi, D; Giorgetti, A; Lencioni, M; Marzullo, P; Pallabazzer, G; Pieraccini, L; Ripoli, A; Santi, S; Solito, B | 1 |
| Baldari, S; Iatì, G; Minutoli, F; Pergolizzi, S; Pontoriero, A; Sindoni, A | 1 |
| Chiu, KW; Khong, PL; Law, SY; Tong, DK; Vardhanabhuti, V; Yuan, H | 1 |
| Cavedon, C; Ferdeghini, M; Giri, MG; Mazzarotto, R | 1 |
| Liu, DF; Meng, T; Wang, GM; Xu, YP; Zhu, F | 1 |
| Bennink, RJ; Geijsen, ED; Hulshof, MC; Machiels, M; van Laarhoven, HW; van Os, RM; Wouterse, SJ | 1 |
| Abe, T; Hirose, Y; Ishibashi, M; Kage, M; Kaida, H; Kawahara, A; Kurata, S; Matono, S; Tanaka, T | 1 |
| Bongioanni, F; Fazio, V; Giannini, EG; Moscatelli, A; Nero, LD; Pellegatta, G; Sambuceti, G; Savarino, V | 1 |
| Emi, M; Furukawa, T; Hamai, Y; Hihara, J; Kurokawa, T; Okada, M; Yamakita, I | 1 |
| Emi, M; Furukawa, T; Hamai, Y; Hihara, J; Ibuki, Y; Okada, M; Yamakita, I | 1 |
| Belohlavek, O; Fencl, P; Harustiak, T; Zemanova, M | 2 |
| Kato, S; Momose, T; Nakamura, Y; Seto, Y; Shimazoe, K; Takahashi, H; Takahashi, M; Yoshimura, S | 1 |
| Carter, BW; Court, LE; Fried, DV; Ho, L; Hofstetter, WL; Lin, SH; Meijer, GJ; van Rossum, PSN; Zhang, L | 1 |
| Gobara, H; Iguchi, T; Inai, R; Kanazawa, S; Sato, S; Tada, A; Tanaka, T; Yanai, H | 1 |
| Arnett, ALH; Haddock, MG; Hallemeier, CL; James, SE; Macintosh, EM; Merrell, KW; Nathan, MA; Neben Wittich, MA; Ravi, K; Shen, KR | 1 |
| Haam, S; Jung, J; Lee, SJ; Park, SY; Yoon, JK | 1 |
| Allemann, P; Jreige, M; Pomoni, A; Prior, JO; Van Der Gucht, A | 1 |
| Guler, OC; Onal, C; Torun, N; Yildirim, BA | 1 |
| Fukukura, Y; Higashi, R; Jinguji, M; Nakabeppu, Y; Nakajo, M; Natsugoe, S; Sasaki, K; Uchikado, Y; Yoshiura, T | 1 |
| Gautam, S; Rathi, PM; Sharma, S | 1 |
| Abdul-Rahman, H; Bauerfeind, P; Eshmuminov, D; Fischer, M; Gubler, C; Lehmann, K; Reiner, C; Schneider, PM; Veit-Haibach, P; Weber, A | 1 |
| Cong, L; Gao, T; Hu, L; Wang, S | 1 |
| Kudithipudi, V; Maheshwary, R; Nguyen, D; Rajput, A; Tran, C | 1 |
| Coolen, J; Coosemans, W; Demey, K; Deroose, CM; Haustermans, K; Nafteux, P; Van Cutsem, E; Van Veer, H; Vandecaveye, V | 1 |
| Cheng, HY; Lu, J; Qin, Q; Sun, XC; Sun, XD; Tang, XY; Yang, X; Zhu, HC | 1 |
| Claxton, Z; Johnston, C; Lucey, J; Malik, V; O'Farrell, N; O'Toole, D; Reynolds, JV | 1 |
| Cambridge, L; Dunphy, M; Garcia, B; Goodman, KA; Wu, AJ | 1 |
| Jeon, JH; Kim, MS; Lee, GK; Lee, JM; Moon, DH; Yang, HC; Zo, JI | 1 |
| Akutsu, Y; Fujishiro, T; Gunji, H; Hanaoka, T; Hayano, K; Kono, T; Matsubara, H; Narushima, K; Ohira, G; Okazumi, S; Shuto, K; Tochigi, T; Tohma, T | 1 |
| Alnaji, R; Attwood, K; Du, W; Gabriel, E; Hochwald, S; Kukar, M | 1 |
| Guo, Y; Li, J; Li, Y; Shao, Q; Xu, M; Zhang, P | 1 |
| Bradley, KM; Findlay, JM; Franklin, JM; Gillies, RS; Gleeson, FV; Maynard, ND; Middleton, MR; Teoh, EJ; Wang, LM | 1 |
| Dong, X; Huang, Y; Li, W; Sun, L; Sun, X; Wan, H; Xing, L; Yu, J; Zhao, X; Zhu, W | 1 |
| Arigami, T; Kita, Y; Maemura, K; Natsugoe, S; Okumura, H; Omoto, I; Owaki, T; Sasaki, K; Uchikado, Y; Uenosono, Y | 1 |
| Desbordes, P; Di Fiore, F; Gardin, I; Gouel, P; Michel, P; Modzelewski, R; Pineau, P; Ruan, S; Vauclin, S; Vera, P | 1 |
| Chong, S; Coupe, N; Lee, S; Lin, M; Manoharan, V; Merrett, N; Ng, W; Wilson, R; Yap, J | 1 |
| Lenglinger, J; Riegler, M; Ringhofer, C | 1 |
| Cheze-Le Rest, C; Jestin-Le Tallec, V; Lozac'h, P; Metges, JP; Teyton, P; Visvikis, D; Volant, A | 1 |
| Fu, Z; Han, A; Kong, FM; Li, D; Li, H; Mu, D; Song, P; Yang, G; Yu, J; Zhang, B; Zhang, W; Zhong, X | 1 |
| Boellaard, R; Fockens, P; Hoekstra, OS; Jager, PL; Omloo, JM; Plukker, JT; Sloof, GW; van Dullemen, HM; van Lanschot, JJ | 1 |
| Balan, A; Mirsadraee, S; Naik, K; Salahudeen, HM; Scarsbrook, AF | 1 |
| Fu, Z; Guo, H; Hu, Q; Wang, W; Yu, J; Yuan, S; Zhong, X | 1 |
| Doki, Y; Fujiwara, Y; Fukunaga, H; Hatazawa, J; Higuchi, I; Miyata, H; Monden, M; Takiguchi, S; Tatsumi, M; Yano, M; Yasuda, T | 1 |
| Decker, PA; Meyers, BF; Putnam, JB; Veeramachaneni, NK; Zoole, JB | 1 |
| Blake, MA; Colen, RR; Fischman, AJ; King, K; Mueller, PR; Roedl, JB | 1 |
| Ahn, SH; Jeon, SY; Kim, CH; Koh, JS; Lee, JC; Lim, SM | 1 |
| Blake, MA; Colen, RR; Fischman, AJ; Mueller, PR; Roedl, JB; Sahani, DV | 1 |
| Douis, H; Jafri, M | 1 |
| Huguet, F; Talbot, JN; Touboul, E | 1 |
| Blake, MA; Choi, NC; Colen, RR; Fischman, AJ; Holalkere, NS; Roedl, JB | 1 |
| Finestone, H; Geller, MD; Gerard, PS; Lazzaro, R | 1 |
| Breen, S; Brock, K; Cheung, F; Darling, G; Dinniwell, R; Grabarz, D; Haider, M; Kamra, J; Knox, J; Mah, K; Mansouri, A; Pond, G; Ung, Y; Vesprini, D; Wong, RK | 1 |
| Kubo, A; Mitsui, Y; Nakahara, T; Shigematsu, N; Takagi, Y; Takemasa, K; Tsuyuki, A | 1 |
| Chang, JY; Chang, KY; Chao, J; Yen, Y | 1 |
| Baldey, A; Chatterton, BE; Ho Shon, I; Kelley, B; Lenzo, N; Patrikeos, A; Ramshaw, JE; Scott, AM; Wong, D | 1 |
| Bradley, KM; Chowdhury, FU; Gleeson, FV | 1 |
| Azar, RR; Chen, J; Early, DS; Edmundowicz, SA; Govindan, R; Keswani, RN; Kohlmeier, C; Meyers, BF; Sharma, A | 1 |
| Hasegawa, Y; Hyodo, I; Nakashima, T; Nishio, M; Ogawa, T; Suzuki, H; Suzuki, M; Tamaki, T; Terada, A | 1 |
| Atmani, A; Bail, JP; Cheze Le Rest, C; Jestin-Le Tallec, V; Lozac'h, P; Metges, JP; Pradier, O; Teyton, P; Visvikis, D; Volant, A | 1 |
| Doki, Y; Fujiwara, Y; Hatazawa, J; Higuchi, I; Makino, T; Miyata, H; Monden, M; Takiguchi, S; Yamasaki, M; Yasuda, T | 1 |
| Bollschweiler, E; Dietlein, M; Eschner, W; Hölscher, A; Kobe, C; Mönig, SP; Schicha, H; Schmidt, M; Vallboehmer, D; Vallböhmer, D | 1 |
| Berry, H; Gananadha, S; Hazebroek, EJ; Leibman, S; Marx, G; Osgood, L; Pavlakis, N; Shon, IH; Smith, GS | 1 |
| Ajani, JA; Bhutani, MS; Hofstetter, W; Javeri, H; Komaki, R; Lee, JH; Maru, D; Rohren, E; Swisher, SG; Wang, X; Xiao, L | 1 |
| Brix, WK; Jones, DR; Kozower, BD; Smith, PW; Swenson, BR; Taylor, MD; Theodosakis, N; Wick, MR | 1 |
| Alavi, A; Basu, S; Heidari, P; Salavati, A | 1 |
| Hosono, M; Kumano, S; Kuwabara, M; Murakami, T; Okada, M; Shimono, T; Shiozaki, H | 1 |
| Barbour, AP; Gotley, DC; Martin, I; Shenfine, J; Smithers, BM; Thomas, J; Wong, D | 1 |
| Chiti, A | 1 |
| Park, KG; Suttie, SA; Welch, AE | 1 |
| Abood, G; Aranha, GV; Moreira, J; Nagda, S; Shoup, M; Smith, JW; Wagner, RH | 1 |
| Baba, H; Baba, Y; Hayashi, N; Hiyoshi, Y; Imamura, Y; Nagai, Y; Toyama, E; Watanabe, M; Yoshida, N | 1 |
| Aly, A; Azad, A; Chong, G; Tauro, A; Tebbutt, NC | 1 |
| Cassivi, SD; Lowe, VJ; Romero, Y; Yoon, HH | 1 |
| Gu, P; Huang, G; Pan, L; Wu, S; Xue, H | 1 |
| Ahmadzadehfar, H; Biersack, HJ; Ezziddin, S; Hinterthaner, B; Näke, K; Sabet, A | 1 |
| Allen-Auerbach, M; Weber, WA | 1 |
| Guan, YS; Luo, ZM; Pan, WM; Su, XH; Sun, L; Wei, JH; Wu, H; Zhao, L | 1 |
| Hsieh, CC; Hsu, PK; Hsu, WH; Huang, CS; Lin, KH; Wang, SJ; Wu, YC | 1 |
| Herrmann, K; Krause, BJ; Wieder, H; zum Büschenfelde, CM | 1 |
| Endo, K; Fukuchi, M; Inose, T; Kato, H; Kuwano, H; Miyazaki, T; Nakajima, M; Oriuchi, N; Sohda, M; Tanaka, N | 1 |
| Hatakeyama, K; Kanda, T; Komukai, S; Kosugi, S; Mashima, Y; Matsuki, A; Ohashi, M; Suzuki, T; Umezu, H | 1 |
| Adusumilli, PS; Akhurst, TJ; Bains, MS; Goodman, K; Ilson, D; Rizk, NP; Rusch, VW; Tang, L | 1 |
| Das, A; Ngamruengphong, S; Nguyen, B; Sharma, VK | 1 |
| Ajani, J; Baker, J; Ezhil, M; Guerrero, T; Johnson, V; Khan, M; Luo, D; McAleer, MF; McCurdy, M; Wei, W | 1 |
| Casneuf, V; Dierckx, R; Fonteyne, P; Pauwels, P; Peeters, M; Van Damme, N; Van de Wiele, C | 1 |
| Akazawa, K; Kubota, T; Matsushima, S; Nishida, K; Nishimura, T; Oda, M; Okuyama, C | 1 |
| Fan, W; Hu, YY; Liang, PY; Lin, XP; Zhang, WG; Zhang, X | 1 |
| Cook, GJ; Llamas Elvira, JM; Ramos-Font, C; Rebollo Aguirre, AC; Tabares, AR; Villegas Portero, R | 1 |
| Abe, T; Fujita, H; Hayabuchi, N; Ishibashi, M; Kaibara, H; Kaida, H; Kobayashi, M; Kurata, S; Nakashima, T; Tanaka, N; Uchida, M; Uchiyama, Y | 1 |
| Chang, JY; Fu, XL; Jiang, GL; Shen, L; Xiang, JQ; Yu, W; Zhang, YJ | 1 |
| Beukema, JC; Busz, DM; Langendijk, JA; Muijs, CT; Plukker, JT; Pruim, J; Schreurs, LM; van der Borden, AJ; Van der Jagt, EJ | 1 |
| Doki, Y; Fujiwara, Y; Kawabata, R; Makino, T; Miyata, H; Mori, M; Nakajima, K; Nishida, T; Nushijima, Y; Takeno, A; Takiguchi, S; Yamasaki, M | 1 |
| Cho, YS; Choi, JY; Hyun, SH; Kim, BT; Kim, K; Lee, JY; Lee, KH; Lee, SJ; Shim, YM | 1 |
| Fujita, M; Hosokawa, M; Itoh, K; Shimizu, S; Shirato, H; Takahashi, H | 1 |
| Feith, M; Siewert, JR; Stein, HJ | 1 |
| Hato, S; Ino, H; Miyoshi, K; Naito, M; Ueno, T | 1 |
| Fu, Z; Han, D; He, W; Huo, Z; Kong, L; Liu, X; Lu, J; Mu, D; Sun, X; Yin, Y; Yu, J; Yu, Y; Zhang, B; Zhang, G; Zhao, S; Zhong, X | 1 |
| Feng, R; Kong, L; Li, MH; Shi, F; Yang, GR; Yu, JM | 1 |
| Baldus, SE; Bollschweiler, E; Dietlein, M; Hölscher, AH; Metzger, R; Mönig, SP; Schicha, H; Schmidt, M; Vallböhmer, D | 1 |
| Albrecht, S; Balmer-Majno, S; Brauchli, P; Caspar, C; Cescato-Wenger, C; Hany, T; Klaeser, B; Köberle, D; Nitzsche, E; Pestalozzi, BC; Ruhstaller, T; Schuller, JC; von Moos, R; Widmer, L; Zünd, M | 1 |
| Beukema, JC; Busz, DM; Groen, H; Jager, PL; Langendijk, JA; Paardekooper, GM; Plukker, JT; Schreurs, LM; van Dam, GM; Van der Jagt, EJ | 1 |
| Kwee, RM | 1 |
| Büchler, P; Friess, H; Kranzfelder, M; Lange, K | 1 |
| Emami, B; Gao, M; Hall, W; Hong, R; Lee, SH; Nagda, S; Shoup, M; Sinacore, J; Vali, FS | 1 |
| Ariga, H; Jingu, K; Kaneta, T; Koto, M; Nemoto, K; Ogawa, Y; Sakayauchi, T; Takahashi, S; Takai, Y; Takeda, K; Yamada, S | 1 |
| Schauer, M; Theisen, J | 1 |
| Cabrera, AR; Chen, L; Han, A; Han, D; Li, Y; Ma, L; Ma, Y; Mu, D; Sun, X; Teng, X; Yu, J; Yue, J; Zhao, S; Zhao, X; Zheng, F; Zheng, J | 1 |
| Doki, Y; Fujiwara, Y; Hatazawa, J; Higuchi, I; Makino, T; Miyata, H; Mori, M; Nakajima, K; Takiguchi, S; Yamasaki, M | 1 |
| Moinuddin, A; Nguyen, NC; Osman, MM | 1 |
| Becker, K; Herrmann, K; Keller, G; Langer, R; Lordick, F; Lorenzen, S; Ott, K; Panzram, B; Schwaiger, M; Siewert, JR | 1 |
| Brown, RK; Frey, KA; Hansen, N; Khan, A; Orringer, M | 1 |
| Beukema, JC; Groen, H; Langendijk, JA; Muijs, CT; Mul, VE; Plukker, JT; Pruim, J | 1 |
| Boellaard, R; Omloo, JM; Sloof, GW; van Berge Henegouwen, MI; van Heijl, M; van Lanschot, JJ | 1 |
| Arikawa, S; Fujita, H; Hayabuchi, N; Hirose, Y; Ishibashi, M; Kage, M; Kaida, H; Kawahara, A; Kobayashi, M; Kurata, S; Uchida, M; Uozumi, J; Yuzuriha, M | 1 |
| Endo, K; Fukuchi, M; Inose, T; Kato, H; Kuwano, H; Miyazaki, T; Nakajima, M; Oriuchi, N; Sakai, M; Sano, A; Sohda, M; Suzuki, S; Tanaka, N | 1 |
| Ajani, JA; Bhutani, MS; Hofstetter, WL; Lee, JH; Liao, Z; Macapinlac, HA; Murthy, SB; Patnana, SV; Rohren, E; Swisher, SG; Wang, X; Xiao, L | 2 |
| Bettenworth, D; Domagk, D; Domschke, W; Fuchs, M; Reuter, S; Schnöckel, U; Weckesser, M; Wessling, J | 1 |
| Bollschweiler, E; Hölscher, A; Schmidt, M | 1 |
| Sendler, A | 1 |
| Aboagye, EO; Albarghach, NM; Cheze-Le Rest, C; Hatt, M; Kenny, LM; Metges, JP; Pradier, O; Rosso, L; Turkheimer, FE; Visvikis, D | 1 |
| Bradley, KM; Gillies, RS; Gleeson, FV; Maynard, ND; Middleton, MR | 1 |
| Aklilu, M; Blackstock, AW; Clark, P; Geisinger, KR; Isom, S; Levine, EA; Mishra, G; Monjazeb, AM; Riedlinger, G | 1 |
| Krause, BJ; Lordick, F; Ott, K | 2 |
| Al-Nahhas, A; Alavi, A; Cordiano, C; De Manzoni, G; Grassetto, G; Marzola, MC; Rubello, D | 1 |
| Duffy, GJ; Gillham, C; Keogan, M; Lucey, JA; Malik, V; McNamara, L; Reynolds, JV; Wilson, L | 1 |
| Abdelsalam, M; Abouzied, M; Amin, T; Bazarbashi, S; Darwish, A; Rahal, M; Soudy, H | 1 |
| Hsieh, TC; Kao, CH; Sun, SS; Wu, YC; Yen, KY | 1 |
| Campbell, F; Jeganathan, R; Lynch, T; McGuigan, J | 1 |
| Fukuda, H; Hiraide, T; Kaneta, T; Mitamura, A; Miyata, G; Satomi, S; Takahashi, S; Takanami, K | 1 |
| Akutsu, Y; Kono, T; Matsubara, H; Natsume, T; Ohira, G; Ota, T; Saito, H; Shuto, K; Toma, T; Uesato, M | 1 |
| Bergman, JJ; Boellaard, R; Bonenkamp, HJ; Bossuyt, PM; Busch, OR; Cuesta, MA; Hoekstra, OS; Hulshof, MC; Nieuwenhuijzen, GA; Omloo, JM; Plukker, JT; Pruim, J; Sloof, GW; Ten Kate, FJ; Tilanus, HW; van Berge Henegouwen, MI; van Dekken, H; van der Gaast, A; van Heijl, M; van Lanschot, JJ | 1 |
| Li, G; Ma, W; Wang, J; Wang, S; Yang, W | 1 |
| Hong, SH; Kang, EJ; Kim, DW; Kim, SH; Lee, KN | 1 |
| Albarghach, N; Corcos, L; Hatt, M; Le Rest, CC; Metges, JP; Pradier, O; Tixier, F; Visvikis, D | 1 |
| Herrmann, K; Krause, BJ; Wieder, HA | 1 |
| Albarghach, NM; Cheze-le Rest, C; Hatt, M; Pradier, O; Tixier, F; Visvikis, D | 1 |
| Chen, JH; Hsieh, TC; Kao, CH; Liang, JA; Shum, WY; Su, CC; Yeh, JJ | 1 |
| Chang, JY; Fu, XL; Shen, L; Xiang, JQ; Yu, W; Zhang, YJ | 1 |
| Hoekstra, OS; Omloo, JM; Sloof, GW; van Berge Henegouwen, MI; van Heijl, M; van Lanschot, JJ | 1 |
| Doki, Y; Fujiwara, Y; Kurokawa, Y; Makino, T; Miyata, H; Mori, M; Nakajima, K; Takeno, A; Takiguchi, S; Yamasaki, M | 1 |
| Fockens, P; Groen, H; Janssens, AC; Plukker, JT; Pruim, J; Schreurs, LM; Sloof, GW; Steyerberg, EW; van Berge Henegouwen, MI; van Dullemen, HM; van Lanschot, JJ | 1 |
| Cheze-le Rest, C; Hatt, M; Pradier, O; Visvikis, D | 1 |
| Chua, S; Dickson, J; Groves, AM | 1 |
| Abel, U; Debus, J; Haag, GM; Haberkorn, U; Jäger, D; Lordick, F; Lorenzen, S; Münter, MW; Stange, A; von Gall, C; Weichert, W; Weitz, J | 1 |
| Cheng, EC; Ma, JB; Song, YP; Yu, JM; Zhang, XQ; Zhou, W | 1 |
| Belgers, HJ; Blom, RL; Oostenbrug, LE; Schreurs, WM; Sosef, MN; Vliegen, RF | 1 |
| Lindner, A; Manger, B; Manger, K; Schett, G; Wacker, J | 1 |
| Higashi, M; Kajiya, Y; Koriyama, C; Matsuda, A; Nakajo, M; Nihara, T; Nioh, T; Shimaoka, S; Shirahama, H; Suenaga, T; Tanaka, S; Tani, A | 1 |
| Becker, K; Ebert, M; Friess, H; Geinitz, H; Herrmann, K; Krause, BJ; Langer, R; Lordick, F; Ott, K; Peschel, C; Schuster, T; Schwaiger, M; Zimmermann, F; zum Büschenfelde, CM | 1 |
| Doki, Y; Fujiwara, Y; Hatazawa, J; Higuchi, I; Miyata, H; Takiguchi, S; Yamasaki, M; Yano, M; Yasuda, T | 1 |
| Ahmed, K; Hanna, GB; Kayani, B; Zacharakis, E | 1 |
| Falk, S | 1 |
| Chen, T; Chen, YM; Pan, XF; Shi, YP; Tong, LJ | 1 |
| Fujiwara, T; Fujiwara, Y; Hiraki, T; Kaji, M; Kanazawa, S; Mitani, M; Naomoto, Y; Noma, K; Okumura, Y; Sakurama, K; Shirakawa, Y; Takaoka, M; Tanabe, S; Yamatsuji, T | 1 |
| Feng, R; Han, A; Kong, L; Ma, Y; Sun, X; Yang, Y; Yang, Z; Yu, J; Zheng, J | 1 |
| Bergman, JJ; Bossuyt, PM; Hulshof, MC; Mearadji, BM; Omloo, JM; Phoa, SS; Richel, DJ; Sloof, GW; Stoker, J; Ten Kate, FJ; van Berge Henegouwen, MI; van Heijl, M; van Lanschot, JJ | 1 |
| Fu, Z; Han, D; Mu, D; Xu, G; Yang, W; Yu, J; Zhang, B; Zhao, S; Zhong, X | 1 |
| Raifu, A; Walker-Dilks, C; Wong, R | 1 |
| Bomanji, J; Hashemi, M; Iordanidou, L; Markar, SR; Mitchell, I; Read, S; Stoker, D; Vyas, S; Winslet, M | 1 |
| Büchler, M; Ott, K; Sisic, L | 1 |
| Belgers, HJ; Blom, RL; Oostenbrug, LE; Schreurs, WM; Sosef, MN; Stohr, I; Vliegen, RF | 1 |
| Coosemans, W; Depypere, L; Nafteux, P | 1 |
| Shah, MA; Smyth, EC | 1 |
| Rankin, S | 1 |
| Helin, H; Karhumäki, L; Kauppi, JT; Kemppainen, J; Oksala, N; Räsänen, JV; Salo, JA; Sihvo, EI | 1 |
| Cheze Le Rest, C; Hatt, M; Le Pogam, A; Pradier, O; Visvikis, D | 1 |
| Kawano, T; Kishimoto, S; Makino, T; Nakaminato, S; Shibuya, H; Toriihara, A | 1 |
| Bomanji, JB; Lu, SJ; Read, S; Rodriguez-Justo, M | 1 |
| Bradley, KM; Gillies, RS; Gleeson, FV; Han, C; Marshall, RE; Maynard, ND; Middleton, MR | 1 |
| Chang, DT; Graves, E; Jayachandran, P; Koong, AC; Krakow, TE; La, T; Loo, BW; Pai, RK; Quon, A | 1 |
| Bansal, S; Daniel, VC; Hitchcock, C; Kassis, ES; Perrino, C; Ross, P; Walker, JP | 1 |
| Corcos, L; Hatt, M; Le Pogam, A; Le Rest, CC; Tixier, F; Visvikis, D | 1 |
| I, HS; Kim, IJ; Kim, K; Kim, SJ | 1 |
| Fujita, H; Hattori, S; Hayabuchi, N; Hayakawa, M; Hirose, Y; Ishibashi, M; Kage, M; Kaida, H; Kawahara, A; Kobayashi, M; Kurata, S; Uchida, M | 1 |
| Butrynski, J; Hornick, JL; Jagannathan, JP; Krajewski, KM; Ramaiya, NH; Shinagare, AB; Zukotynski, KA | 1 |
| Capanu, M; Coit, DG; Kelsen, DP; Schöder, H; Shah, MA; Smyth, E; Strong, VE | 1 |
| Blesing, C; Bradley, KM; Gillies, RS; Gleeson, FV; Marshall, RE; Maynard, ND; Middleton, MR; Patel, K; Warner, N | 1 |
| Moriyama, M; Nagata, T; Okumura, T; Sawada, S; Shimada, Y; Tsukada, K; Yoshida, T; Yoshioka, I | 1 |
| Barber, TW; Bressel, M; Drummond, EG; Duong, CP; Hicks, RJ; Leong, T | 1 |
| Cincibuch, J; Formanek, R; Koranda, P; Myslivecek, M; Neoral, C; Vomackova, K; Vrba, R; Zapletalova, J | 1 |
| Cheng, JD; Christensen, M; Cohen, SJ; Crawford, K; Freedman, GM; Haluszka, O; Konski, A; Li, T; Maurer, A; Meropol, NJ; Scott, W; Tokar, J; Yu, JQ | 1 |
| Anthony, MP; Lan Khong, P; Wong, JJ | 1 |
| Cheng, J; Cohen, SJ; Keller, L; Klayton, T; Konski, A; Li, T; Meropol, NJ; Scott, W; Xu-Welliver, M; Yu, JQ | 1 |
| Kato, H; Nakajima, M | 1 |
| Furukita, Y; Goto, M; Morimoto, M; Tangoku, A; Yamamoto, Y | 1 |
| Kong, L; Li, M; Qu, W; Sun, X; Xing, L; Yu, J; Yue, J; Zhu, WQ | 1 |
| Chen, SW; Chien, CR; Hsieh, TC; Hsu, SM; Kao, CH; Liang, JA; Pan, T; Wang, YC; Yang, SN; Yen, KY; Yu, CY | 1 |
| Benyoucef, A; Blondin, V; Di Fiore, F; Edet-Sanson, A; Hitzel, A; Huet, E; Michel, P; Vera, P | 1 |
| Dong, W; Du, J; Li, X; Meng, L; Ni, Y; Shen, H; Wang, G | 1 |
| Hsieh, TC; Kao, CH; Sun, SS; Wu, YC; Yang, CF | 1 |
| Khamwan, K; Krisanachinda, A; Pluempitiwiriyawej, C | 1 |
| Chan, DS; Ellis-Owen, R; Fielding, P; Lewis, WG; Reid, TD; Roberts, SA | 1 |
| Chen, SW; Ding, HJ; Kao, CH; Liang, JA; Shum, WY; Yen, KY | 1 |
| Arens, AI; de Geus-Oei, LF; Hutchings, M; Oyen, WJ; Vriens, D | 1 |
| Thie, JA | 1 |
| Dong, X; Fu, Z; Li, D; Sun, X; Wan, H; Wu, P; Xing, L; Yin, Y; Yu, J | 1 |
| Bernard, V; Buckley, W; Castillo, E; Castillo, R; Echeverria, AE; Guerrero, T; Liu, P; Martinez, J; McCurdy, M; Ramos, NV | 1 |
| Lordick, F | 1 |
| Kruse, V; Maes, A; Sathekge, M; Smeets, P; Van de Wiele, C | 1 |
| Claxton, Z; Donohoe, C; Johnston, C; Lucey, J; Malik, V; Ravi, N; Reynolds, JV | 1 |
| Chowdhury, FU; Godfrey, EM; Radhakrishna, G | 1 |
| Berveling, MJ; Beukema, JC; Langendijk, JA; Muijs, CT; Plukker, JT; Pruim, J | 1 |
| Chen, W; D'Souza, WD; Feigenberg, S; Kim, G; Kligerman, S; Lu, M; Lu, W; Suntharalingam, M; Tan, S | 1 |
| Ishigami, S; Kajiya, Y; Kita, Y; Matsumoto, M; Mori, S; Natsugoe, S; Okumura, H; Omoto, I; Owaki, T; Sasaki, K; Setoyama, T; Tanoue, K; Uchikado, Y; Ueno, S | 1 |
| Capitain, O; Cellier, P; Denis, F; Girault, S; Hamy, A; Mahé, MA; Mesgouez-Nebout, N; Paumier, A; Poirier, AL; Rousseau, D | 1 |
| Jin, S; Li, D; Wang, H; Yin, Y | 1 |
| Cho, KJ; Choi, SH; Kim, JS; Kim, JW; Kim, SY; Lee, JH; Nam, SY; Roh, JL | 1 |
| Bingham, BA; Blackmon, SH; Chevez-Barrios, P; Hatef, DA; Kim, MP | 1 |
| Baruch-Hennequin, V; Cattan, P; Chirica, M; Cuenca, X; Gornet, JM; Hennequin, C; Hindié, E; Quéro, L; Rivera, S; Vercellino, L | 1 |
| Kwee, RM; Vliegen, RF | 1 |
| Higashiyama, S; Kawabe, J; Koyama, K; Ochi, H; Okamura, T; Ozawa, N; Yamada, R | 1 |
| Lowe, VJ; Stack, BC | 1 |
| Bartenstein, P; Junginger, T; Kneist, W; Menzel, C; Oberholzer, K; Schreckenberger, M | 1 |
| Lin, EC | 1 |
| Endo, K; Fukuchi, M; Kato, H; Kuwano, H; Manda, R; Masuda, N; Miyazaki, T; Nakajima, M; Oriuchi, N; Tsukada, K; Yoshikawa, M | 1 |
| Agoston, P; Esik, O; Fekésházy, A; Galuska, L; Kálvin, B; Lengyel, E; Lengyel, Z; Szakáll, S; Székely, J; Trón, L | 1 |
| Bares, R; Bartusek, G; Dittmann, H; Dohmen, BM; Kehlbach, R; Pritzkow, M; Sarbia, M | 1 |
| Himeno, S; Makuuchi, H; Shimada, H; Tajima, T; Yasuda, S | 1 |
| Grünwald, F; Junginger, T; Kneist, W; Menzel, C | 1 |
| Akhurst, T; Bains, MS; Downey, RJ; Ginsberg, R; Gollub, M; Gonen, M; Ilson, D; Koong, H; Larson, SM; Minsky, BD; Rusch, V; Turnbull, A; Zakowski, M | 1 |
| Couper, GW; Park, KG | 1 |
| Flamen, P; Lerut, T | 1 |
| Fink, U; Ott, K; Siewert, JR; Weber, W | 1 |
| Bourguet, P | 2 |
| Chin, BB; Wahl, RL | 1 |
| Kim, BT; Kim, K; Kim, TS; Lee, KS; Shim, YM; Yoon, YC | 1 |
| Bartenstein, P; Böttcher, HD; Döbert, N; Grünwald, F; Junginger, T; Kneist, W; Menzel, Ch; Mose, S; Rieker, O; Teising, A | 1 |
| Hatazawa, J; Higuchi, I; Nakamura, H | 1 |
| Becker, K; Fink, U; Helmberger, H; Müller, J; Ott, K; Schwaiger, M; Siewert, JR; Stein, HJ; Weber, WA | 1 |
| Fukunaga, H; Higuchi, I; Nishimura, T; Paul, AK; Tatsumi, M; Yasuda, T | 1 |
| Groen, H; Heeren, PA; Jager, PL; Plukker, JT; van Dullemen, HM; van Westreenen, HL | 1 |
| Bartenstein, P; Grünwald, F; Junginger, T; Kneist, W; Oberholzer, K; Schreckenberger, M | 1 |
| Gordon, LL; Pope, TL; Ravenel, JG; Reed, CE | 1 |
| Goldsmith, SJ; Kostakoglu, L | 1 |
| Becker, K; Beer, A; Brücher, BL; Fink, U; Lordick, F; Schwaiger, M; Siewert, JR; Stein, HJ; Weber, WA; Wieder, HA; Zimmermann, F | 1 |
| Bley, TA; Brink, I; Hentschel, M; Imdahl, A; Kleimaier, M; Mix, M; Moser, E; Walch, A | 1 |
| Bongaerts, F; Heeren, PA; Jager, PL; Plukker, JT; Sluiter, W; van Dullemen, H | 1 |
| Flamen, P | 1 |
| Brink, I; Hentschel, M; Hopt, UT; Imdahl, A; Kleimaier, M | 1 |
| Dehdashti, F; Siegel, BA | 1 |
| Flamen, P; Haustermans, K; Lerut, T; Mortelmans, L; Van Cutsem, E | 1 |
| Fukuchi, M; Kato, H; Kuwano, H; Manda, R; Miyazaki, T; Nakajima, M | 1 |
| Ichiya, T; Ishibashi, Y; Ito, T; Miyazaki, H; Nishimura, M; Okushiba, S; Tsukidate, N | 1 |
| Bossuyt, PM; Groen, H; Plukker, JT; Pruim, J; Sloof, GW; van Lanschot, JJ; van Westreenen, HL; Westerterp, M | 1 |
| Ajani, JA; Correa, AM; Cox, JD; Erasmus, J; Hong, D; Komaki, RR; Lee, HK; Macapinlac, H; Maish, M; Putnam, JB; Rice, DC; Roth, JA; Smythe, WR; Swisher, SG; Thai, L; Vaporciyan, AA; Walsh, GL; Wu, TT | 1 |
| Ajani, JA; Bresalier, R; Correa, AM; Erasmus, JJ; Komaki, R; Macapinlac, H; Maish, M; Munden, RF; Putnam, JB; Rice, D; Roth, JA; Smythe, WR; Swisher, SG; Vaporciyan, AA; Walsh, GL; Wu, TT | 1 |
| Cham, D; Conti, PS; Henderson, R | 1 |
| Hustinx, R | 1 |
| Coppens, E; El Nakadi, I; Gay, F; Gelin, M; Goldman, S; Liberale, G; Nagy, N; Van Laethem, JL | 1 |
| Choe, YS; Choi, JY; Choi, Y; Jang, HJ; Kim, BT; Kim, K; Lee, KH; Lee, KS; Shim, YM | 1 |
| Endo, K; Faried, A; Fukai, Y; Fukuchi, M; Kato, H; Kimura, H; Kuwano, H; Manda, R; Masuda, N; Miyazaki, T; Nakajima, M; Ojima, H; Oriuchi, N; Sohda, M; Takita, J; Tsukada, K | 1 |
| Fogarty, GB; Peters, LJ; Tartaglia, CJ | 1 |
| Färkkilä, MA; Knuuti, MJ; Luostarinen, ME; Minn, HR; Räsänen, JV; Salo, JA; Sihvo, EI; Viljanen, T | 1 |
| De Wever, W; Ectors, N; Flamen, P; Haustermans, K; Hiele, M; Lerut, T; Van Cutsem, E; Vrieze, O | 1 |
| Groen, H; Heeren, PA; Jager, PL; Plukker, JT; van der Jagt, EJ; van Dullemen, HM; van Westreenen, HL | 1 |
| Hayashi, T; Higashiyama, S; Kawabe, J; Kawamura, E; Kotani, J; Oe, A; Osugi, H; Shiomi, S; Torii, K | 1 |
| Junginger, T; Kneist, W | 1 |
| Alavi, A; Bural, GG; Kumar, R; Mavi, A | 1 |
| Cobben, DC; Elsinga, PH; Jager, PL; Plukker, JT; van Dullemen, HM; van Westreenen, HL; Wesseling, J | 1 |
| Adler, L; Doss, M; Freedman, G; Haluszka, O; Hanlon, A; Konski, A; Milestone, B | 1 |
| Brunken, R; Bybel, B; Lin, H; Neumann, D; Wu, G | 1 |
| Mistry, RC; Pramesh, CS | 1 |
| Bar-Shalom, R; Ben-Nun, A; Frenkel, A; Gaitini, D; Guralnik, L; Israel, O; Keidar, Z; Leiderman, M; Tsalic, M | 1 |
| Fanti, S; Nanni, C; Rampin, L; Rubello, D | 1 |
| Ahn, SD; Cho, KJ; Choi, EK; Kim, JH; Kim, SB; Lee, GH; Lee, SW; Park, SI; Ryu, JS; Shin, SS; Song, HY; Song, SY | 1 |
| Deniaud-Alexandre, E; El Balaa, H; Foulquier, JN; Gendre, JP; Grahek, D; Grange, JD; Grès, B; Hourry, S; Keraudy, K; Kerrou, K; Lerouge, D; Montravers, F; Moureau-Zabotto, L; Petenief, Y; Talbot, JN; Tiret, E; Touboul, E | 1 |
| Cobben, DC; Groen, H; Jager, PL; Plukker, JT; van Westreenen, HL; Verhoogt, CJ | 1 |
| Chang, WC; Cheng, CY; Hsu, HH; Shen, DH; Tzao, C; Yu, CP | 1 |
| Comans, EF; Jager, PL; Plukker, JT; Sloof, GW; van Dullemen, HM; van Lanschot, JJ; van Westreenen, HL; Westerterp, M; Wiggers, T | 1 |
| Fockens, P; Hoekstra, OS; Jager, PL; Plukker, JT; Reitsma, JB; Sloof, GW; Stoker, J; Van Eck-Smit, BL; van Lanschot, JJ; van Westreenen, HL; Westerterp, M | 1 |
| Ichinose, A; Jingu, K; Kaneta, T; Nemoto, K; Ogawa, Y; Takai, Y; Yamada, S | 1 |
| Colle, B; Crevon, L; Debourdeau, P; Mounier, C; Pavic, M; Rabar, D | 1 |
| Alavi, A; Aydin, A; Dhurairaj, T; Shrikanthan, S; Zhuang, H | 1 |
| Deniaud-Alexandre, E; El Balaa, H; Foulquier, JN; Gendre, JP; Grahek, D; Grange, JD; Grès, B; Houry, S; Keraudy, K; Kerrou, K; Lerouge, D; Montravers, F; Moureau-Zabotto, L; Petegnief, Y; Talbot, JN; Tiret, E; Touboul, E | 1 |
| Aklilu, M; Blackstock, AW; Clark, PB; Farmer, MR; Levine, EA; Lovato, J; Melin, SA; Mishra, G; Oaks, T | 1 |
| Hsu, CH; Lee, CM; Lee, TJ; Lou, HY | 1 |
| Castillo, E; Lawler, LP | 1 |
| Beer, AJ; Fischer, M; Lordick, F; Ott, K; Rummeny, EJ; Schwaiger, M; Siewer, JR; Weber, WA; Wieder, HA; Ziegler, S | 1 |
| Forshaw, MJ; Gossage, JA; Mason, RC | 1 |
| Alavi, A; Bhutain, C; Chamroonrat, W; El-Haddad, G; Houseni, M; Mavi, A; Zhuang, H | 1 |
| Fink, U; Ott, K; Schwaiger, M; Stahl, A; Stollfuss, J; Weber, WA; Wieder, H | 1 |
| Chasen, M; Erasmus, JJ; Knight, AE; Macapinlac, HA; Mawlawi, O; Munden, RF; Pan, T; Podoloff, DA | 1 |
| Sarbia, M; Stein, HJ; von Rahden, BH | 1 |
| Demitriou, H; Duong, CP; Hicks, RJ; Thomas, RJ; Thompson, A; Weih, L; Williams, D | 1 |
| Piehler, JM | 1 |
| Akhurst, T; Bains, MS; Downey, RJ; Gonen, M; Larson, S; Rizk, N; Rusch, V | 1 |
| Esteves, FP; Halkar, RK; Schuster, DM | 1 |
| Ackerly, T; Binns, D; Condron, S; Everitt, C; Hicks, RJ; Hui, A; Lau, EW; Leong, T; MacManus, M; Ngan, SY; Pitman, A; Yuen, K | 1 |
| Drummond, E; Duong, CP; Hicks, RJ; Leong, T; Michael, M; Thomas, RJ; Weih, L | 1 |
| Blackstock, AW; Clark, P; Farmer, MR; Geisinger, KR; Ho, C; Levine, EA; Lovato, J; Melin, SA; Mishra, G; Oaks, T | 1 |
| Weber, WA; Wieder, H | 1 |
| Akhurst, T; Meirelles, GS; Ravizzini, G; Yeung, HW | 1 |
| Everitt, C; Leong, T | 1 |
| Bombardieri, E | 1 |
| Boellaard, R; Crezee, H; Hoekstra, OS; Hulshof, MC; Omloo, JM; Sloof, GW; ten Kate, FJ; van Lanschot, JJ; Vervenne, WL; Westerterp, M | 1 |
| Plukker, JT; Sloof, GW; Van Lanschot, JJ; Van Westreenen, HL; Westerterp, M | 1 |
| Chak, A; Das, A | 1 |
| Akamoto, S; Maeta, H; Okano, K; Sugiyama, T; Usuki, H; Wakabayashi, H; Yachida, S | 1 |
| Bryant, AS; Cerfolio, RJ | 1 |
| Chao, KS; Chen, S; Fu, Z; Guo, H; Liu, T; Yang, G; Yang, X; Yin, Y; Yu, J; Yu, Y; Yuan, S | 1 |
| Alexander, M; Brasić, JR | 1 |
| Becker, K; Busch, R; Fink, U; Herrmann, K; Lordick, F; Ott, K; Schwaiger, M; Siewert, JR; Weber, WA; Wieder, H | 1 |
| Ho, L; Jadvar, H; Seto, J | 1 |
| Plukker, JT; van Westreenen, HL | 1 |
| Sloof, GW | 1 |
| Fukuda, H; Ichinose, A; Jingu, K; Kaneta, T; Nakata, E; Narazaki, K; Nemoto, K; Ogawa, Y; Oikawa, M; Sakayauchi, T; Sugawara, T; Takahashi, S; Takai, K; Takai, Y; Yamada, S | 1 |
| Duffy, GJ; Gillham, CM; Hollywood, D; Keogan, M; Lucey, JA; Malik, V; Muldoon, C; O'byrne, K; Raouf, AA; Reynolds, JV | 1 |
| Dam, HQ; Manzone, TM; Sagar, VV | 1 |
| Herts, BR; Remer, EM; Yoon, JK | 1 |
| Quint, LE | 1 |
| Collins, CD; Fennelly, D; Heffernan, E | 1 |
| Bartenstein, P; Brochhausen, C; Buchmann, I; Hansen, T; Junginger, T; Kneist, W; Oberholzer, K; Schreckenberger, M | 1 |
| Chao, KS | 2 |
| Alavi, A; Basu, S | 1 |
| Herrmann, K; Krause, BJ; Ott, K; Wieder, HA | 1 |
| Beer, AJ; Hannig, C; Holzapfel, K; Rummeny, EJ | 1 |
| Balfe, DM; Ballman, KV; Cerfolio, RJ; Decker, PA; Dehdashti, F; Downey, RJ; Keenan, RJ; Landreneau, RJ; Meyers, BF; Putnam, JB; Reed, CE; Rusch, VW; Siegel, BA | 1 |
| Blackstone, EH; Bybel, B; Falk, GW; Little, SG; Mason, DP; Murthy, SC; Rice, TW; Rybicki, LA | 1 |
| Bourguet, P; Metges, JP; Mitry, E; Monteil, J; Planchamp, F; Tubiana-Mathieu, N | 1 |
| Ajani, J; Guerrero, T; Hart, J; Johnson, V; Khan, M; Komaki, R; Liao, Z; Luo, D; Pan, T; Stevens, C | 1 |
| Ajani, JA; Bresalier, R; Bruzzi, JF; Correa, AM; Erasmus, JJ; Fukami, N; Ho, JJ; Hofstetter, WL; Komaki, R; Lee, JH; Liao, Z; Macapinlac, HA; Marom, EM; Munden, RF; Sabloff, BS; Swisher, SG; Truong, MT; Wu, TT | 1 |
| Ahn, JH; Cho, KJ; Choi, KD; Jung, HY; Kim, JH; Kim, MK; Kim, SB; Kim, SY; Kim, YH; Lee, GH; Park, SI; Ryu, JS; Shin, JH; Song, HY | 1 |
| Cheng, JD; Cohen, SJ; Freedman, G; Goldberg, M; Haluszka, O; Konski, AA; Li, T; Maurer, A; Meropol, NJ; Scott, W; Weiner, LM; Yu, JQ | 1 |
| Chen, XX; Fu, Z; Mu, DB; Sun, XR; Wang, SP; Yang, WF; Yu, JM | 1 |
| Hennequin, C; Hindié, E; Moretti, JL | 1 |
| Chambers, J; Damani, N; Katsoulis, IE; Livingstone, JI; Mattheou, AK; Wong, WL | 1 |
| Fu, Z; Guo, H; Huang, Y; Li, L; Xi, Y; Yang, G; Yu, J; Yuan, S; Zhang, B; Zhang, J; Zhu, H | 1 |
| Barberet, M; Fakhry, N; Giovanni, A; Lussato, D; Mundler, O; Zanaret, M | 1 |
| Fu, Z; Guo, HB; Li, WW; Liu, TH; Yang, GR; Yang, XH; Yu, JM; Yu, YH; Yuan, SH | 1 |
| Boellaard, R; Hoekstra, OS; Meijer, GA; Molthoff, CF; Reitsma, JB; Sloof, GW; Ten Kate, FJ; van Lanschot, JJ; Westerterp, M | 1 |
| Mittra, E; Niederkohr, R; Rodriguez, C; Segall, G; Vasanawala, M | 1 |
| Becker, K; Fink, U; Herrmann, K; Lordick, F; Ott, K; Schwaiger, M; Siewert, JR; Stahl, A; Weber, WA; Wieder, HA | 1 |
| Becker, K; Bredenkamp, R; Fink, U; Herrmann, K; Höfler, H; Krause, BJ; Lordick, F; Lorenzen, S; Ott, K; Peschel, C; Schuster, T; Schwaiger, M; Siewert, JR; Stein, HJ; Weber, WA; Wieder, H | 1 |
| Abreu-E-Lima, P; Gerbaudo, VH; Mamede, M; Mamon, H; Nosé, V; Oliva, MR | 1 |
| Downey, RJ; Ilson, DH | 1 |
| Ariga, H; Fujimoto, K; Fukuda, H; Jingu, K; Kaneta, T; Nakata, E; Narazaki, K; Nemoto, K; Ogawa, Y; Oikawa, M; Sakayauchi, T; Takahashi, S; Takai, Y; Takeda, K; Yamada, S | 1 |
| Becker, K; Fink, U; Lordick, F; Ott, K; Peschel, C; Schwaiger, M; Siewert, JR; Stein, HJ; Weber, WA | 1 |
| Bossuyt, PM; Comans, EF; Fockens, P; Groen, H; Jager, PL; Plukker, JT; Sloof, GW; Stoker, J; van der Jagt, EJ; van Dullemen, HM; van Lanschot, JJ; van Westreenen, HL; Westerterp, M | 1 |
| Galysh, RL; Hernandez, A; Jones, DR; Kahaleh, M; McDonough, PB; Northup, PG; Shami, VM; Shen, KR; White, GE | 1 |
| Cho, YS; Choi, JY; Chung, HW; Kim, BT; Kim, K; Lee, EJ; Lee, KH; Lee, SJ; Shim, YM | 1 |
| Lordick, F; Ott, K; Stahl, A; Wieder, HA | 1 |
| Balachandran, A; Bruzzi, JF; Iyer, RB; Johnson, V; Macapinlac, HA; Munden, RF | 1 |
| Bredenkamp, R; Hennig, M; Herrmann, K; Lordick, F; Lorenzen, S; Ott, K; Peschel, C; Schwaiger, M; Weber, WA; Wieder, H | 1 |
| Abreu-e-Lima, P; El Fakhri, G; Gandler, W; Gerbaudo, VH; Mamede, M; Nosé, V | 1 |
| Heijenbrok-Kal, MH; Hunink, MG; Kuipers, EJ; Siersema, PD; van Vliet, EP | 1 |
| Price, P; Rembielak, A | 1 |
| Doki, Y; Fujiwara, Y; Higuchi, I; Hirao, T; Makari, Y; Matsuyama, J; Miyata, H; Monden, M; Takiguchi, S; Yamasaki, M; Yasuda, T | 1 |
| Burmeister, BH; Couper, GC; Gotley, DC; Harvey, JA; Martin, I; Smithers, BM; Thomas, JM; Thomson, DB; Walpole, ET; Watts, N; Wong, D | 1 |
| Cook, G; Harrington, K; John, L; Lee, B; Nutting, C | 1 |
| Fukuda, H; Kaneta, T; Kinomura, S; Takahashi, S; Takanami, K; Yamada, S; Yamada, T | 1 |
| Buchmann, I; Ganten, TM; Haberkorn, U | 1 |
| Bartenstein, P; Brochhausen, C; Buchholz, HG; Buchmann, I; Haberkorn, U; Hansen, T; Schmidtmann, I | 1 |
| Castell, F; Cook, GJ | 1 |
| Bashir, H; Nunan, TO; Shabo, G | 1 |
| Hubner, KF; Raja, S; Yasuda, S | 1 |
| Enomoto, K; Fukunaga, T; Isono, K; Kikuchi, T; Koide, Y; Okazumi, S; Yamamoto, H | 1 |
| Cooper, JD; Dehdashti, F; Flanagan, FL; Patterson, GA; Siegel, BA; Sundaresan, SR; Trask, DD | 1 |
| Cronin, V; Galantowicz, P; Nabi, HA | 1 |
| Belani, CP; Ferson, PF; Keenan, RJ; Landreneau, RJ; Luketich, JD; Meltzer, CC; Schauer, PR; Townsend, DW; Urso, GK | 1 |
| Bailey, MS; Block, MI; Cooper, JD; Dehdashti, F; Flanagan, FL; Patterson, GA; Siegel, BA; Sundaresan, RS | 1 |
| Belani, CP; Cidis Meltzer, C; Ferson, PF; Keenan, RJ; Luketich, JD; Schauer, P; Townsend, DW; Urso, K | 1 |
| Fukunaga, T; Imazeki, K; Isono, K; Koide, Y; Okazumi, S | 1 |
| Cook, GJ; Mason, R; Rankin, SC; Taylor, H | 1 |
| Couper, GW; McAteer, D; Nicolson, M; Norton, M; Park, KG; Wallis, F; Welch, A | 1 |
| Friedman, DM; Keenan, RJ; Luketich, JD; Meehan, MA; Meltzer, CC; Townsend, DW; Weigel, TL | 1 |
| Hara, T; Kirihara, Y; Kobori, O; Kosaka, N | 1 |
| Bruce, D; Couper, G; Gilbert, FJ; McAteer, D; Nicolson, M; Norton, M; Park, K; Sharp, P; Wallis, F; Welch, A | 1 |
| Alia, AG; Amin, T; Bakheet, SM; Kuzo, R; Powe, J | 1 |
| Altehoefer, C; Hoegerle, S; Nitzsche, EU | 1 |
| Choi, JY; Kim, BT; Kim, JJ; Kim, SE; Lee, KH; Lee, KS; Shim, YM | 1 |
| Lightdale, CJ | 1 |
| Bormans, G; Coosemans, W; De Leyn, P; De Wever, W; Dupont, P; Ectors, N; Flamen, P; Haustermans, K; Hiele, M; Lerut, A; Mortelmans, L; Peeters, M; Stroobants, S; Van Cutsem, E; Van Raemdonck, D | 1 |
| Charron, M; Dachille, MA; Friedman, D; Luketich, JD; Meehan, M; Meltzer, CC; Strollo, D; Townsend, DW; Urso, GK | 1 |
| Cambier, JP; De Leyn, P; De Wever, W; Flamen, P; Lerut, A; Maes, A; Mortelmans, L; Peeters, M; Van Cutsem, E; Van Raemdonck, D | 1 |
| Coosemans, W; De Leyn, P; De Wever, W; Decker, G; Deneffe, G; Ectors, N; Flamen, P; Hiele, M; Lerut, T; Mortelmans, L; Peeters, M; Van Cutsem, E; Van Raemdonck, D | 1 |
| Kim, BT; Kim, K; Lee, KS; Park, SJ; Shim, YM | 1 |
| Avril, N; Bauer, M; Brücher, BL; Fink, U; Schwaiger, M; Siewert, JR; Stein, HJ; Weber, W; Werner, M; Zimmerman, F | 1 |
| Lear, J; Lin, EC; Quaife, RA | 1 |
| Avril, NE; Becker, K; Busch, R; Dittler, HJ; Fink, U; Helmberger, H; Meisetschläger, G; Ott, K; Schwaiger, M; Siewert, JR; Weber, WA | 1 |
| Haberkorn, U | 1 |
| Alavi, A; Ghesani, N; Neto, CA; Zhuang, H | 1 |
| Elsinga, P; Jager, PL; Plukker, JT; Pruim, J; Que, TH; Vaalburg, W | 1 |
| Endo, K; Inoue, T; Kato, H; Kuwano, H; Miyazaki, T; Nakajima, M; Ojima, H; Oriuchi, N; Tsukada, K; Yoshikawa, M | 1 |
| Murata, H; Tamura, K; Tsujii, H; Yoshikawa, K | 1 |
| Laking, GR; Price, PM | 1 |
| Bormans, G; Cambier, JP; De Leyn, P; De Wever, W; Ectors, N; Flamen, P; Haustermans, K; Lerut, A; Maes, A; Mortelmans, L; Van Cutsem, E; Van Raemdonck, D | 1 |
| Noboru, O | 1 |
| Agoston, P; Esik, O; Fekésházy, A; Galuska, L; Kálvin, B; Lengyel, E; Lengyel, Z; Szakáll, S; Székely, J; Trón, L; Várady, E | 1 |
| Fukumura, T; Ichiya, Y; Jingu, K; Kuwabara, Y; Masuda, K; Otsuka, M; Tahara, T; Yoshikai, T | 1 |
98 review(s) available for fluorodeoxyglucose f18 and Cancer of Esophagus
| Article | Year |
|---|---|
State-of-the-art imaging in oesophago-gastric cancer.
Topics: Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Stomach Neoplasms | 2022 |
Liver Injury in Patients With Distal Esophageal Carcinoma After Precision Radiation Therapy: Systematic Review of FDG-PET/CT Patterns.
Topics: Carcinoma; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Liver; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies | 2023 |
Neoadjuvant Strategies for Esophageal Cancer: Role of Immunotherapy and Positron emission tomography (PET)-Guided Strategies.
Topics: Chemoradiotherapy; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Immunotherapy; Neoadjuvant Therapy; Positron-Emission Tomography; Radiopharmaceuticals | 2023 |
Benefits of positron emission tomography scans for the evaluation of radiotherapy.
Topics: Chemoradiotherapy; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Neoplasms; Positron Emission Tomography Computed Tomography; Prostatic Neoplasms; Radiopharmaceuticals; Radiotherapy, Adjuvant; Rectal Neoplasms; Treatment Outcome; Uterine Cervical Neoplasms | 2020 |
Correlation between fluorodeoxyglucose hotspots on preradiotherapy PET/CT and areas of cancer local relapse: Systematic review of literature.
Topics: Anatomic Landmarks; Esophageal Neoplasms; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Neoplasms; Patient Positioning; Positron Emission Tomography Computed Tomography; Prospective Studies; Radiopharmaceuticals; Rectal Neoplasms; Retrospective Studies | 2020 |
Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain; Acyclic Monoterpenes; Adenine Nucleotides; Adhesins, Escherichia coli; Adipocytes; Adipocytes, Brown; Adipogenesis; Administration, Inhalation; Administration, Oral; Adrenal Cortex Hormones; Adsorption; Adult; Aeromonas hydrophila; Africa; Aged; Aged, 80 and over; Agrobacterium tumefaciens; Air; Air Pollutants; Air Pollution; Air Pollution, Indoor; Algorithms; Alkaloids; Alkynes; Allosteric Regulation; Amines; Amino Acid Sequence; Amino Acids; Amino Acids, Branched-Chain; Aminoisobutyric Acids; Aminopyridines; Amyotrophic Lateral Sclerosis; Anaerobic Threshold; Angiography; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animal Distribution; Animal Feed; Animal Nutritional Physiological Phenomena; Animals; Ankle Joint; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Inflammatory Agents; Antibodies, Bacterial; Antifungal Agents; Antimalarials; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antioxidants; Antiretroviral Therapy, Highly Active; Antiviral Agents; Aotidae; Apelin; Apoptosis; Arabidopsis Proteins; Argentina; Arginine; Artemisinins; Arthritis, Experimental; Arthritis, Rheumatoid; Arthroscopy; Aspergillus; Aspergillus niger; Asteraceae; Asthma; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; Auditory Cortex; Autoantibodies; Autophagy; Bacteria; Bacterial Infections; Bacterial Proteins; Bacterial Typing Techniques; Base Composition; Base Sequence; Basketball; Beclin-1; Benzhydryl Compounds; Benzimidazoles; Benzo(a)pyrene; Benzofurans; Benzoxazines; Bereavement; beta Catenin; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Betacoronavirus; Betaine; Binding Sites; Biofilms; Biological Assay; Biological Availability; Biological Evolution; Biomarkers; Biomechanical Phenomena; Biopolymers; Biopsy; Bismuth; Blood Glucose; Blood Platelets; Blood Pressure; Body Composition; Body Weight; Bone Marrow; Bone Marrow Cells; Bone Regeneration; Boron; Botrytis; Brain Ischemia; Brain Neoplasms; Brain-Derived Neurotrophic Factor; Brazil; Breast Neoplasms; Breath Tests; Bronchoalveolar Lavage Fluid; Burkholderia; C-Reactive Protein; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Calcification, Physiologic; Calcium; Calcium Signaling; Calorimetry, Differential Scanning; Cameroon; Camptothecin; Candida; Candida albicans; Capillaries; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Carbohydrate Conformation; Carbon; Carbon Dioxide; Carbon Isotopes; Carcinoma, Ovarian Epithelial; Cardiac Output; Cardiomyopathy, Hypertrophic; Cardiotonic Agents; Cardiovascular Diseases; Caregivers; Carps; Case-Control Studies; Catalase; Catalysis; Cats; CD4 Lymphocyte Count; Cell Culture Techniques; Cell Differentiation; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Survival; Cells, Cultured; Cellulose; Centrosome; Ceratopogonidae; Chickens; Child; China; Cholera Toxin; Choline; Cholinesterases; Chromatography, High Pressure Liquid; Chromatography, Liquid; Chromatography, Micellar Electrokinetic Capillary; Chromatography, Reverse-Phase; Chronic Disease; Cinnamates; Cities; Citrates; Climate Change; Clinical Trials, Phase III as Topic; Coal; Coal Mining; Cohort Studies; Coinfection; Colchicine; Colony Count, Microbial; Colorectal Neoplasms; Coloring Agents; Common Cold; Complement Factor H; Computational Biology; Computer Simulation; Continuous Positive Airway Pressure; Contrast Media; Coordination Complexes; Coronary Artery Bypass; Coronavirus 3C Proteases; Coronavirus Infections; Coronavirus Protease Inhibitors; Corynebacterium glutamicum; Cosmetics; COVID-19; Creatinine; Cross-Sectional Studies; Crotonates; Crystallography, X-Ray; Cues; Culicidae; Culture Media; Curcuma; Cyclopentanes; Cyclopropanes; Cymbopogon; Cystine; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inhibitors; Cytokines; Databases, Genetic; Death; Dendritic Cells; Density Functional Theory; Depsides; Diabetes Mellitus, Type 2; Diamond; Diarylheptanoids; Dibenzofurans; Dibenzofurans, Polychlorinated; Diclofenac; Diet; Dietary Carbohydrates; Dietary Supplements; Diffusion Magnetic Resonance Imaging; Dioxins; Diphenylamine; Disease Outbreaks; Disease Susceptibility; Disulfides; Dithiothreitol; Dizocilpine Maleate; DNA Methylation; DNA-Binding Proteins; DNA, Bacterial; Dogs; Dose-Response Relationship, Drug; Double-Blind Method; Doublecortin Protein; Drosophila melanogaster; Droughts; Drug Carriers; Drug Combinations; Drug Delivery Systems; Drug Liberation; Drug Resistance; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Dust; Dynactin Complex; Dysferlin; Echo-Planar Imaging; Echocardiography; Edaravone; Egypt; Elasticity; Electrodes; Electrolytes; Emodin; Emtricitabine; Endometriosis; Endothelium, Vascular; Endotoxins; Energy Metabolism; Energy Transfer; Enterobacteriaceae; Enterococcus faecalis; Enterotoxigenic Escherichia coli; Environmental Monitoring; Enzyme Inhibitors; Epidemiologic Factors; Epigenesis, Genetic; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Vaccines; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Esterases; Esterification; Ethanol; Ethiopia; Ethnicity; Eucalyptus; Evidence-Based Practice; Exercise; Exercise Tolerance; Extracorporeal Membrane Oxygenation; Family; Fatty Acids; Feedback; Female; Ferric Compounds; Fibrin Fibrinogen Degradation Products; Filtration; Fish Diseases; Flavonoids; Flavonols; Fluorodeoxyglucose F18; Follow-Up Studies; Food Microbiology; Food Preservation; Forests; Fossils; Free Radical Scavengers; Freund's Adjuvant; Fruit; Fungi; Gallium; Gender Identity; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Genes, Bacterial; Genes, Plant; Genetic Predisposition to Disease; Genitalia; Genotype; Glomerulonephritis, IGA; Glottis; Glucocorticoids; Glucose; Glucuronides; Glutathione Transferase; Glycogen Synthase Kinase 3 beta; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Grassland; Guinea Pigs; Half-Life; Head Kidney; Heart Atria; Heart Rate; Heart Septum; HEK293 Cells; Hematopoietic Stem Cells; Hemodynamics; Hep G2 Cells; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Hepatocytes; Hesperidin; High-Frequency Ventilation; High-Temperature Requirement A Serine Peptidase 1; Hippocampus; Hirudins; History, 20th Century; History, 21st Century; HIV Infections; Homeostasis; Hominidae; Housing, Animal; Humans; Hydrocarbons, Brominated; Hydrogen Bonding; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydroxybutyrates; Hydroxyl Radical; Hypertension; Hypothyroidism; Image Interpretation, Computer-Assisted; Immunoconjugates; Immunogenic Cell Death; Indoles; Infant, Newborn; Infant, Premature; Infarction, Middle Cerebral Artery; Inflammation; Inflammation Mediators; Infrared Rays; Inhibitory Concentration 50; Injections, Intravenous; Interferon-gamma; Interleukin-23; Interleukin-4; Interleukin-6; Intermediate Filaments; Intermittent Claudication; Intestine, Small; Iridoid Glucosides; Iridoids; Iron; Isomerism; Isotope Labeling; Isoxazoles; Itraconazole; Kelch-Like ECH-Associated Protein 1; Ketoprofen; Kidney Failure, Chronic; Kinetics; Klebsiella pneumoniae; Lactams, Macrocyclic; Lactobacillus; Lactulose; Lakes; Lamivudine; Laparoscopy; Laparotomy; Laryngoscopy; Leucine; Limit of Detection; Linear Models; Lipid A; Lipopolysaccharides; Listeria monocytogenes; Liver; Liver Cirrhosis; Logistic Models; Longitudinal Studies; Losartan; Low Back Pain; Lung; Lupinus; Lupus Erythematosus, Systemic; Machine Learning; Macular Degeneration; Madin Darby Canine Kidney Cells; Magnetic Phenomena; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Magnetics; Malaria, Falciparum; Male; Mannans; MAP Kinase Signaling System; Mass Spectrometry; Melatonin; Membrane Glycoproteins; Membrane Proteins; Meniscectomy; Menisci, Tibial; Mephenytoin; Mesenchymal Stem Cells; Metal Nanoparticles; Metal-Organic Frameworks; Methionine; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Mice, Obese; Mice, Transgenic; Microbial Sensitivity Tests; Microcirculation; MicroRNAs; Microscopy, Video; Microtubules; Microvascular Density; Microwaves; Middle Aged; Minimally Invasive Surgical Procedures; Models, Animal; Models, Biological; Models, Molecular; Models, Theoretical; Molecular Docking Simulation; Molecular Structure; Molecular Weight; Morus; Mouth Floor; Multicenter Studies as Topic; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Muscle, Skeletal; Myocardial Ischemia; Myocardium; NAD; NADP; Nanocomposites; Nanoparticles; Naphthols; Nasal Lavage Fluid; Nasal Mucosa; Neisseria meningitidis; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasms, Experimental; Neural Stem Cells; Neuroblastoma; Neurofilament Proteins; Neurogenesis; Neurons; New York; NF-E2-Related Factor 2; NF-kappa B; Nicotine; Nitriles; Nitrogen; Nitrogen Fixation; North America; Observer Variation; Occupational Exposure; Ochrobactrum; Oils, Volatile; Olea; Oligosaccharides; Omeprazole; Open Field Test; Optimism; Oregon; Oryzias; Osmolar Concentration; Osteoarthritis; Osteoblasts; Osteogenesis; Ovarian Neoplasms; Ovariectomy; Oxadiazoles; Oxidation-Reduction; Oxidative Stress; Oxygen; Ozone; p38 Mitogen-Activated Protein Kinases; Pakistan; Pandemics; Particle Size; Particulate Matter; Patient-Centered Care; Pelargonium; Peptides; Perception; Peripheral Arterial Disease; Peroxides; Pets; Pharmaceutical Preparations; Pharmacogenetics; Phenobarbital; Phenols; Phenotype; Phosphates; Phosphatidylethanolamines; Phosphines; Phospholipids; Phosphorus; Phosphorylation; Photoacoustic Techniques; Photochemotherapy; Photosensitizing Agents; Phylogeny; Phytoestrogens; Pilot Projects; Plant Components, Aerial; Plant Extracts; Plant Immunity; Plant Leaves; Plant Oils; Plants, Medicinal; Plasmodium berghei; Plasmodium falciparum; Platelet Activation; Platelet Function Tests; Pneumonia, Viral; Poaceae; Pogostemon; Poloxamer; Poly I; Poly(ADP-ribose) Polymerase Inhibitors; Polychlorinated Biphenyls; Polychlorinated Dibenzodioxins; Polycyclic Compounds; Polyethylene Glycols; Polylysine; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Population Dynamics; Portasystemic Shunt, Transjugular Intrahepatic; Positron Emission Tomography Computed Tomography; Postoperative Complications; Postprandial Period; Potassium Cyanide; Predictive Value of Tests; Prefrontal Cortex; Pregnancy; Prepulse Inhibition; Prevalence; Procalcitonin; Prodrugs; Prognosis; Progression-Free Survival; Proline; Proof of Concept Study; Prospective Studies; Protein Binding; Protein Conformation; Protein Domains; Protein Folding; Protein Multimerization; Protein Sorting Signals; Protein Structure, Secondary; Proton Pump Inhibitors; Protozoan Proteins; Psychometrics; Pulse Wave Analysis; Pyridines; Pyrrolidines; Quality of Life; Quantum Dots; Quinoxalines; Quorum Sensing; Radiopharmaceuticals; Rain; Random Allocation; Randomized Controlled Trials as Topic; Rats; Rats, Sprague-Dawley; Rats, Wistar; RAW 264.7 Cells; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Receptor, PAR-1; Receptors, CXCR4; Receptors, Estrogen; Receptors, Glucocorticoid; Receptors, Interleukin-1; Receptors, Interleukin-17; Receptors, Notch; Recombinant Fusion Proteins; Recombinant Proteins; Reducing Agents; Reflex, Startle; Regional Blood Flow; Regression Analysis; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Tract Diseases; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Risk Assessment; Risk Factors; Rituximab; RNA, Messenger; RNA, Ribosomal, 16S; ROC Curve; Rosmarinic Acid; Running; Ruthenium; Rutin; Sarcolemma; Sarcoma; Sarcopenia; Sarcoplasmic Reticulum; SARS-CoV-2; Scavenger Receptors, Class A; Schools; Seasons; Seeds; Sequence Analysis, DNA; Severity of Illness Index; Sex Factors; Shock, Cardiogenic; Short Chain Dehydrogenase-Reductases; Signal Transduction; Silver; Singlet Oxygen; Sinusitis; Skin; Skin Absorption; Small Molecule Libraries; Smoke; Socioeconomic Factors; Soil; Soil Microbiology; Solid Phase Extraction; Solubility; Solvents; Spain; Spectrometry, Mass, Electrospray Ionization; Spectroscopy, Fourier Transform Infrared; Speech; Speech Perception; Spindle Poles; Spleen; Sporothrix; Staphylococcal Infections; Staphylococcus aureus; Stereoisomerism; Stomach Neoplasms; Stress, Physiological; Stroke Volume; Structure-Activity Relationship; Substrate Specificity; Sulfonamides; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Rate; T-Lymphocytes, Cytotoxic; Tandem Mass Spectrometry; Temperature; Tenofovir; Terpenes; Tetracycline; Tetrapleura; Textiles; Thermodynamics; Thiobarbituric Acid Reactive Substances; Thrombin; Thyroid Hormones; Thyroid Neoplasms; Tibial Meniscus Injuries; Time Factors; Tissue Distribution; Titanium; Toluidines; Tomography, X-Ray Computed; Tooth; Tramadol; Transcription Factor AP-1; Transcription, Genetic; Transfection; Transgender Persons; Translations; Treatment Outcome; Triglycerides; Ubiquinone; Ubiquitin-Specific Proteases; United Kingdom; United States; Up-Regulation; Vascular Stiffness; Veins; Ventricular Remodeling; Viral Load; Virulence Factors; Virus Replication; Vitis; Voice; Voice Quality; Wastewater; Water; Water Pollutants, Chemical; Water-Electrolyte Balance; Weather; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Young Adult; Zoogloea | 2022 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acrylic Resins; Actinobacillus; Acute Disease; Acute Kidney Injury; Adaptor Proteins, Signal Transducing; Adenosine; Adenosine Triphosphate; Administration, Inhalation; Administration, Oral; Adolescent; Adult; Advance Care Planning; Africa, Northern; Age Factors; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Air Pollution, Indoor; Albendazole; Aluminum Oxide; Anastomosis, Surgical; Ancylostoma; Ancylostomiasis; Androstadienes; Angiogenesis Inhibitors; Angiotensin II; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bispecific; Antibodies, Viral; Anticoagulants; Antihypertensive Agents; Antinematodal Agents; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antiporters; Antiviral Agents; Apoptosis; Aptamers, Nucleotide; Aromatase Inhibitors; Asian People; Astrocytes; Atrial Fibrillation; Auditory Threshold; Aurora Kinase B; Australia; Autophagy; Autophagy-Related Protein 5; Autotrophic Processes; Bacillus cereus; Bacillus thuringiensis; Bacterial Proteins; Beclin-1; Belgium; Benzene; Benzene Derivatives; Benzhydryl Compounds; beta Catenin; beta-Arrestin 2; Biliary Tract Diseases; Biofilms; Biofuels; Biomarkers; Biomarkers, Tumor; Biomass; Biomechanical Phenomena; Bioreactors; Biosensing Techniques; Biosynthetic Pathways; Bismuth; Blood Platelets; Bone and Bones; Bone Regeneration; Bortezomib; Botulinum Toxins, Type A; Brain; Brain Injuries; Brain Ischemia; Brain Neoplasms; Breast Neoplasms; Breath Tests; Bronchodilator Agents; Calcium Phosphates; Cannabis; Carbon Dioxide; Carbon Isotopes; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cardiac Resynchronization Therapy; Cardiac Resynchronization Therapy Devices; Cardiomyopathies; Cardiovascular Diseases; Cariostatic Agents; Case Managers; Case-Control Studies; Catalysis; Cation Transport Proteins; CD8-Positive T-Lymphocytes; Cecropia Plant; Cell Adhesion; Cell Count; Cell Differentiation; Cell Division; Cell Line; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Self Renewal; Cell Survival; Cells, Cultured; Cellular Reprogramming; Cellulose; Charcoal; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemokines; Chemoradiotherapy; Chemoreceptor Cells; Child; Child Abuse; Child, Preschool; China; Chlorogenic Acid; Chloroquine; Chromatography, Gas; Chronic Disease; Clinical Competence; Coated Materials, Biocompatible; Cochlea; Cohort Studies; Color; Comorbidity; Computer Simulation; Computer-Aided Design; Contraception; Contraceptive Agents, Female; Contrast Media; COP-Coated Vesicles; Coronavirus Infections; Cost of Illness; Coturnix; COVID-19; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Culex; Curriculum; Cyclic N-Oxides; Cytokines; Cytoplasm; Cytotoxicity, Immunologic; Cytotoxins; Databases, Factual; Deep Learning; Delivery, Obstetric; Denitrification; Dental Caries; Denture, Complete; Dexamethasone; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dielectric Spectroscopy; Diet, High-Fat; Dietary Fiber; Disease Models, Animal; Disease Progression; DNA; DNA Copy Number Variations; DNA, Mitochondrial; Dog Diseases; Dogs; Dopaminergic Neurons; Double-Blind Method; Down-Regulation; Doxorubicin; Drug Carriers; Drug Design; Drug Interactions; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Dry Powder Inhalers; Dust; E2F1 Transcription Factor; Ecosystem; Education, Nursing; Education, Nursing, Baccalaureate; Electric Impedance; Electricity; Electrocardiography; Electrochemical Techniques; Electrochemistry; Electrodes; Electrophoresis, Polyacrylamide Gel; Endoplasmic Reticulum; Endothelial Cells; Environmental Monitoring; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Estrogen Receptor Modulators; Europe; Evoked Potentials, Auditory, Brain Stem; Exosomes; Feasibility Studies; Female; Ferricyanides; Ferrocyanides; Fibrinogen; Finite Element Analysis; Fistula; Fluorescent Dyes; Fluorides, Topical; Fluorodeoxyglucose F18; Fluticasone; Follow-Up Studies; Food Contamination; Food Microbiology; Foods, Specialized; Forensic Medicine; Frail Elderly; France; Free Radicals; Fresh Water; Fungi; Fungicides, Industrial; Galactosamine; Gastrointestinal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Frequency; Genetic Predisposition to Disease; Genotype; Gingival Hemorrhage; Glioblastoma; Glioma; Glomerular Filtration Rate; Glomerulosclerosis, Focal Segmental; Glucose; Glucose Transport Proteins, Facilitative; Glucosides; Glutamine; Glycolysis; Gold; GPI-Linked Proteins; Gram-Negative Bacteria; Gram-Positive Bacteria; Graphite; Haplotypes; HCT116 Cells; Healthy Volunteers; Hearing Loss; Heart Failure; Hedgehog Proteins; HEK293 Cells; HeLa Cells; Hemodynamics; Hemorrhage; Hepatocytes; Hippo Signaling Pathway; Histone Deacetylases; Homeostasis; Hospital Mortality; Hospitalization; Humans; Hydantoins; Hydrazines; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Hydroxylamines; Hypoglycemic Agents; Immunity, Innate; Immunoglobulin G; Immunohistochemistry; Immunologic Factors; Immunomodulation; Immunophenotyping; Immunotherapy; Incidence; Indazoles; Indonesia; Infant; Infant, Newborn; Infarction, Middle Cerebral Artery; Inflammation; Injections, Intramuscular; Insecticides; Insulin-Like Growth Factor I; Insurance, Health; Intention to Treat Analysis; Interleukin-1 Receptor-Associated Kinases; Interleukin-6; Intrauterine Devices; Intrauterine Devices, Copper; Iron; Ischemia; Jordan; Keratinocytes; Kidney; Kidney Diseases; Kir5.1 Channel; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Laparoscopy; Lasers; Lasers, Semiconductor; Lenalidomide; Leptin; Lethal Dose 50; Levonorgestrel; Limit of Detection; Lipid Metabolism; Lipid Metabolism Disorders; Lipogenesis; Lipopolysaccharides; Liquid Biopsy; Liver; Liver Abscess, Pyogenic; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Longevity; Lung Neoplasms; Luteolin; Lymph Nodes; Lymphocyte Activation; Macaca fascicularis; Macrophages; Mad2 Proteins; Magnetic Resonance Imaging; Male; Mammary Glands, Human; Manganese; Manganese Compounds; MAP Kinase Signaling System; Materials Testing; Maternal Health Services; MCF-7 Cells; Medicaid; Medicine, Chinese Traditional; Melanoma; Membrane Proteins; Mental Health; Mercury; Metal Nanoparticles; Metals, Heavy; Metformin; Methionine Adenosyltransferase; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Mice, Nude; Microalgae; Microbial Sensitivity Tests; Microglia; MicroRNAs; Microscopy, Atomic Force; Microscopy, Electron, Scanning; Middle Aged; Mitochondria; Mitochondrial Proteins; Mitral Valve; Mitral Valve Insufficiency; Models, Anatomic; Molecular Structure; Molybdenum; Monocarboxylic Acid Transporters; Moths; MPTP Poisoning; Multigene Family; Multiparametric Magnetic Resonance Imaging; Multiple Myeloma; Muscle, Skeletal; Mutagens; Mutation; Myeloid Cells; Nanocomposites; Nanofibers; Nanomedicine; Nanoparticles; Nanowires; Neoadjuvant Therapy; Neomycin; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms; Neoplastic Stem Cells; Neostriatum; Neovascularization, Pathologic; Netherlands; Neuromuscular Agents; Neurons; NF-E2-Related Factor 2; NF-kappa B; Nickel; Nitrogen Oxides; Non-alcoholic Fatty Liver Disease; Nucleosides; Nucleotidyltransferases; Nutritional Status; Obesity, Morbid; Ofloxacin; Oils, Volatile; Oligopeptides; Oncogene Protein v-akt; Optical Imaging; Organic Cation Transport Proteins; Organophosphonates; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Osteoblasts; Osteogenesis; Oxidation-Reduction; Oxidative Stress; Oxides; Oxygen Isotopes; Pancreas; Pancreaticoduodenectomy; Pandemics; Particle Size; Particulate Matter; Patient Acceptance of Health Care; Patient Compliance; PC-3 Cells; Peptide Fragments; Peptides; Periodontal Attachment Loss; Periodontal Index; Periodontal Pocket; Periodontitis; Peroxides; Peru; Pest Control, Biological; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phylogeny; Pilot Projects; Piperidines; Plant Bark; Plant Extracts; Plant Leaves; Plasmids; Platelet Function Tests; Pneumonia, Viral; Podocytes; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Terephthalates; Polymers; Polymorphism, Single Nucleotide; Porosity; Portugal; Positron-Emission Tomography; Postoperative Complications; Postural Balance; Potassium Channels, Inwardly Rectifying; Povidone; Powders; Precancerous Conditions; Precision Medicine; Predictive Value of Tests; Pregnancy; Prenatal Care; Prognosis; Promoter Regions, Genetic; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Proteasome Inhibitors; Protective Agents; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Psychiatric Nursing; PTEN Phosphohydrolase; Pulmonary Embolism; Pyrimethamine; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reactive Oxygen Species; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, G-Protein-Coupled; Recombinational DNA Repair; Recovery of Function; Regional Blood Flow; Renal Dialysis; Renin; Renin-Angiotensin System; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Distress Syndrome; Retrospective Studies; Rhodamines; Risk Assessment; Risk Factors; RNA, Long Noncoding; RNA, Messenger; Running; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salinity; Salmeterol Xinafoate; Sarcoma; Seasons; Shoulder Injuries; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Sirtuins; Skull Fractures; Social Determinants of Health; Sodium; Sodium Fluoride; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Soil; Soil Pollutants; Spain; Spectrophotometry; Spectroscopy, Fourier Transform Infrared; Staphylococcal Protein A; Staphylococcus aureus; Stem Cells; Stereoisomerism; Stomach Neoplasms; Streptomyces; Strontium; Structure-Activity Relationship; Students, Nursing; Substance-Related Disorders; Succinic Acid; Sulfur; Surface Properties; Survival Rate; Survivin; Symporters; T-Lymphocytes; Temozolomide; Tensile Strength; Thiazoles; Thiobacillus; Thiohydantoins; Thiourea; Thrombectomy; Time Factors; Titanium; Tobacco Mosaic Virus; Tobacco Use Disorder; Toll-Like Receptor 4; Toluene; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Toxicity Tests, Acute; Toxicity Tests, Subacute; Transcriptional Activation; Treatment Outcome; Troponin I; Tumor Cells, Cultured; Tumor Escape; Tumor Hypoxia; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Tyrosine; Ubiquitin-Protein Ligases; Ubiquitination; Ultrasonic Waves; United Kingdom; United States; United States Department of Veterans Affairs; Up-Regulation; Urea; Uric Acid; Urinary Bladder Neoplasms; Urinary Bladder, Neurogenic; Urine; Urodynamics; User-Computer Interface; Vemurafenib; Verbenaceae; Veterans; Veterans Health; Viral Load; Virtual Reality; Vitiligo; Water Pollutants, Chemical; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Xylenes; Young Adult; Zinc; Zinc Oxide; Zinc Sulfate; Zoonoses | 2021 |
Prognostic and predictive values of interim
Topics: Chemoradiotherapy; Disease Progression; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Middle Aged; Neoadjuvant Therapy; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; ROC Curve; Sensitivity and Specificity; Treatment Outcome | 2021 |
The value of 18F-FDG-PET testing in the management of esophageal and gastroesophageal junction adenocarcinoma - review.
Topics: Adenocarcinoma; Chemoradiotherapy; Esophageal Neoplasms; Esophagogastric Junction; Fluorodeoxyglucose F18; Humans; Positron Emission Tomography Computed Tomography | 2021 |
PET/Computed Tomography Scanning and Precision Medicine: Esophageal Cancer.
Topics: Adenocarcinoma; Carcinoma, Squamous Cell; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Precision Medicine; Radiopharmaceuticals | 2017 |
Limited additional value of cervical ultrasonography over a negative 18F-FDG PET/CT for diagnosing cervical lymph node metastases in patients with esophageal cancer: a systematic review and meta-analysis.
Topics: Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Positron Emission Tomography Computed Tomography; Ultrasonography; Uterine Cervical Neoplasms | 2018 |
Detection of distant interval metastases after neoadjuvant therapy for esophageal cancer with 18F-FDG PET(/CT): a systematic review and meta-analysis.
Topics: Adult; Aged; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Treatment Outcome | 2018 |
Prognostic Value of Volumetric Parameters of Pretreatment 18F-FDG PET/CT in Esophageal Cancer: A Systematic Review and Meta-analysis.
Topics: Esophageal Neoplasms; Fluorodeoxyglucose F18; Glycolysis; Humans; Positron Emission Tomography Computed Tomography; Predictive Value of Tests; Progression-Free Survival; Radiopharmaceuticals | 2018 |
Diagnostic value of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for preoperative lymph node metastasis of esophageal cancer: A meta-analysis.
Topics: Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Neoadjuvant Therapy; Positron Emission Tomography Computed Tomography; Preoperative Care; Prognosis; Radiopharmaceuticals; Retrospective Studies | 2018 |
Accuracy of Detecting Residual Disease After Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Systematic Review and Meta-analysis.
Topics: Adenocarcinoma; Carcinoma, Squamous Cell; Chemoradiotherapy; Endosonography; Esophageal Neoplasms; Esophagoscopy; Fluorodeoxyglucose F18; Humans; Neoadjuvant Therapy; Neoplasm, Residual; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Sensitivity and Specificity | 2020 |
Meta-analysis of 18FDG PET-CT for nodal staging in patients with esophageal cancer.
Topics: Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Meta-Analysis as Topic; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2013 |
Present status and progress of neoadjuvant chemoradiotherapy for esophageal cancer.
Topics: Chemoradiotherapy; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Neoadjuvant Therapy; Positron-Emission Tomography; Radiopharmaceuticals; Treatment Outcome | 2013 |
[Role of ¹⁸F 2-fluoro-2-deoxyglucose positron emission tomography in upper gastrointestinal malignancies].
Topics: Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Neoplasm Metastasis; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Recurrence; Stomach Neoplasms | 2013 |
A systematic review of the predictive value of (18)FDG-PET in esophageal and esophagogastric junction cancer after neoadjuvant chemoradiation on the survival outcome stratification.
Topics: Chemoradiotherapy, Adjuvant; Disease-Free Survival; Esophageal Neoplasms; Esophagogastric Junction; Fluorodeoxyglucose F18; Humans; Neoadjuvant Therapy; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Survival Rate | 2014 |
[Importance of PET in surgery of esophageal cancer].
Topics: Adenocarcinoma; Chemoradiotherapy; Chemoradiotherapy, Adjuvant; Combined Modality Therapy; Esophageal Neoplasms; Esophagogastric Junction; Fluorodeoxyglucose F18; Humans; Molecular Imaging; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Randomized Controlled Trials as Topic; Response Evaluation Criteria in Solid Tumors | 2014 |
Imaging of oesophageal cancer with FDG-PET/CT and MRI.
Topics: Antineoplastic Protocols; Diffusion Magnetic Resonance Imaging; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Magnetic Resonance Imaging; Neoplasm Metastasis; Neoplasm Recurrence, Local; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2015 |
Novel imaging strategies for upper gastrointestinal tract cancers.
Topics: Diagnostic Imaging; Endoscopic Ultrasound-Guided Fine Needle Aspiration; Endosonography; Esophageal Neoplasms; False Negative Reactions; False Positive Reactions; Fluorodeoxyglucose F18; Humans; Inflammation; Magnetic Resonance Imaging; Neoplasm Invasiveness; Neoplasm Staging; Pancreatic Neoplasms; Positron-Emission Tomography; Stomach Neoplasms; Tomography, X-Ray Computed | 2015 |
Is there a role for PET/CT with esophagogastric junction adenocarcinoma?
Topics: Adenocarcinoma; Esophageal Neoplasms; Esophagogastric Junction; Fluorodeoxyglucose F18; Humans; Multimodal Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Stomach Neoplasms; Tomography, X-Ray Computed | 2015 |
Value of functional imaging by PET in esophageal cancer.
Topics: Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Neoplasm Metastasis; Neoplasm Staging; Neoplasms, Multiple Primary; Positron-Emission Tomography; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
PET with Fluorodeoxyglucose F 18/Computed Tomography in the Clinical Management and Patient Outcomes of Esophageal Cancer.
Topics: Aged; Chemoradiotherapy, Adjuvant; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Multimodal Imaging; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Patient Outcome Assessment; Positron-Emission Tomography; Radiography, Interventional; Radiopharmaceuticals; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Diagnostic Performance of ¹⁸F-FDG PET and PET/CT for the Detection of Recurrent Esophageal Cancer After Treatment with Curative Intent: A Systematic Review and Meta-Analysis.
Topics: Biopsy; Esophageal Neoplasms; False Negative Reactions; Fluorodeoxyglucose F18; Humans; Neoplasm Recurrence, Local; Positron-Emission Tomography; Quality Control; Recurrence; Reproducibility of Results; Sensitivity and Specificity; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
[18F]Fluorodeoxyglucose PET in Thoracic Malignancies.
Topics: Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Mesothelioma; Neoplasm Staging; Pleural Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Thoracic Neoplasms; Thymus Neoplasms | 2014 |
Usefulness of four dimensional (4D) PET/CT imaging in the evaluation of thoracic lesions and in radiotherapy planning: Review of the literature.
Topics: Esophageal Neoplasms; Fluorodeoxyglucose F18; Four-Dimensional Computed Tomography; Humans; Lung Neoplasms; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Radiotherapy Planning, Computer-Assisted; Thoracic Neoplasms | 2016 |
The predictive value of 18F-FDG PET for pathological response of primary tumor in patients with esophageal cancer during or after neoadjuvant chemoradiotherapy: a meta-analysis.
Topics: Carcinoma, Squamous Cell; Chemoradiotherapy; Databases, Factual; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorodeoxyglucose F18; Humans; Neoadjuvant Therapy; Odds Ratio; Positron-Emission Tomography; Radiopharmaceuticals; Sensitivity and Specificity; Treatment Outcome | 2016 |
Impact of PET/CT on radiation treatment in patients with esophageal cancer: A systematic review.
Topics: Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Magnetic Resonance Imaging; Neoplasm Staging; Positron Emission Tomography Computed Tomography | 2016 |
[Use of PET for staging, treatment evaluation, and follow-up in esophageal cancers].
Topics: Antineoplastic Agents; Combined Modality Therapy; Esophageal Neoplasms; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radiotherapy, Conformal | 2008 |
Modern staging and utility of PET imaging in esophageal cancer management.
Topics: Combined Modality Therapy; Endosonography; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Neoadjuvant Therapy; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Sensitivity and Specificity | 2008 |
The role of 18F-FDG PET/CT in the evaluation of oesophageal carcinoma.
Topics: Carcinoma; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Neoplasm Invasiveness; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, Emission-Computed; Whole Body Imaging | 2008 |
Impact of fluorodeoxyglucose PET on the management of esophageal cancer.
Topics: Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Treatment Outcome | 2009 |
Positron emission tomography for monitoring response to neoadjuvant therapy in patients with oesophageal and gastro-oesophageal junction carcinoma.
Topics: Esophageal Neoplasms; Esophagogastric Junction; Fluorodeoxyglucose F18; Humans; Neoadjuvant Therapy; Positron-Emission Tomography; Radiopharmaceuticals; Sensitivity and Specificity; Survival Analysis; Treatment Outcome | 2009 |
The role of FDG-PET and staging laparoscopy in the management of patients with cancer of the esophagus or gastroesophageal junction.
Topics: Esophageal Neoplasms; Esophagogastric Junction; Fluorodeoxyglucose F18; Humans; Laparoscopy; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals | 2009 |
Prognostic significance of SUV on PET/CT in patients with esophageal cancer: a systematic review and meta-analysis.
Topics: Disease-Free Survival; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals | 2009 |
Measuring response with FDG-PET: methodological aspects.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Hodgkin Disease; Humans; Lung Neoplasms; Lymphoma, Non-Hodgkin; Neoplasms; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Radiotherapy, Adjuvant; Uterine Cervical Neoplasms | 2009 |
18F-FDG PET and 18F-FDG PET/CT for assessing response to therapy in esophageal cancer.
Topics: Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Subtraction Technique; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
Assessment of response to neoadjuvant therapy in esophageal cancer: an updated systematic review of diagnostic accuracy of endoscopic ultrasonography and fluorodeoxyglucose positron emission tomography.
Topics: Endosonography; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Neoadjuvant Therapy; Outcome Assessment, Health Care; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity | 2010 |
18F-fluorodeoxiglucose positron emission tomography for the evaluation of neoadjuvant therapy response in esophageal cancer: systematic review of the literature.
Topics: Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Neoadjuvant Therapy; Positron-Emission Tomography; Radiopharmaceuticals; Treatment Outcome | 2009 |
[Neoadjuvant therapy in the upper gastro-intestinal tract. Modern strategies for Barrett's cancer].
Topics: Adenocarcinoma; Barrett Esophagus; Blood Glucose; Combined Modality Therapy; Disease-Free Survival; Esophageal Neoplasms; Esophagectomy; Fluorodeoxyglucose F18; Humans; Lymph Node Excision; Lymphatic Metastasis; Neoadjuvant Therapy; Neoplasm Staging; Positron-Emission Tomography; Precancerous Conditions; Prognosis | 2009 |
Prediction of tumor response to neoadjuvant therapy in patients with esophageal cancer with use of 18F FDG PET: a systematic review.
Topics: Chi-Square Distribution; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Neoadjuvant Therapy; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; ROC Curve; Sensitivity and Specificity | 2010 |
Treatment options for squamous cell cancer of the esophagus: a systematic review of the literature.
Topics: Carcinoma, Squamous Cell; Combined Modality Therapy; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Lymph Node Excision; Neoadjuvant Therapy; Outcome and Process Assessment, Health Care; Prognosis; Radiopharmaceuticals; Survival Analysis; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2010 |
A systematic review on the role of FDG-PET/CT in tumour delineation and radiotherapy planning in patients with esophageal cancer.
Topics: Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Neoplasm Staging; Positron-Emission Tomography; Radiotherapy Planning, Computer-Assisted; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Metabolic response evaluation by PET during neoadjuvant treatment for adenocarcinoma of the esophagus and esophagogastric junction.
Topics: Adenocarcinoma; Endosonography; Esophageal Neoplasms; Esophagogastric Junction; Fluorodeoxyglucose F18; Humans; Neoadjuvant Therapy; Positron-Emission Tomography; Stomach Neoplasms; Tomography, X-Ray Computed | 2010 |
New trends for staging and therapy for localized gastroesophageal cancer: the role of PET.
Topics: Adenocarcinoma; Algorithms; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Medical Oncology; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Stomach Neoplasms; Treatment Outcome | 2010 |
Extended staging of oesophageal cancer using FDG-PET - a critical appraisal.
Topics: Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Image Enhancement; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity | 2012 |
[A case of long-term survival after resection for postoperative solitary adrenal metastasis from esophageal adenocarcinoma].
Topics: Adenocarcinoma; Adrenal Gland Neoplasms; Adrenalectomy; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Esophageal Neoplasms; Esophagectomy; Fluorodeoxyglucose F18; Fluorouracil; Humans; Lymph Node Excision; Male; Organoplatinum Compounds; Positron-Emission Tomography | 2010 |
FDG-PET parameters as prognostic factor in esophageal cancer patients: a review.
Topics: Esophageal Neoplasms; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals | 2011 |
[Positron emission tomography - current role in the diagnosis and treatment of upper gastrointestinal carcinomas].
Topics: Adenocarcinoma; Combined Modality Therapy; Dideoxynucleosides; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Sensitivity and Specificity; Stomach Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
[Hypertrophic osteoarthropathy. Bamberger-Marie disease].
Topics: Adult; Cardia; Cooperative Behavior; Diagnosis, Differential; Early Diagnosis; Esophageal Neoplasms; Fluorodeoxyglucose F18; Gastroscopy; Humans; Interdisciplinary Communication; Male; Multimodal Imaging; Neoplasm Invasiveness; Neuroendocrine Tumors; Osteoarthropathy, Secondary Hypertrophic; Paraneoplastic Syndromes; Positron-Emission Tomography; Prognosis; Risk Factors; Stomach Neoplasms; Tomography, X-Ray Computed | 2011 |
Lymph node metastases and prognosis in oesophageal carcinoma--a systematic review.
Topics: Adenocarcinoma; Endosonography; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Tomography, X-Ray Computed | 2011 |
Can ¹⁸F-fluorodeoxyglucose positron emission tomography predict responses to neoadjuvant therapy in oesophageal cancer patients? A meta-analysis.
Topics: Adenocarcinoma; Area Under Curve; Confidence Intervals; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Neoadjuvant Therapy; Odds Ratio; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; ROC Curve; Sensitivity and Specificity | 2011 |
Evidence-based guideline recommendations on the use of positron emission tomography imaging in oesophageal cancer.
Topics: Esophageal Neoplasms; Evidence-Based Medicine; Fluorodeoxyglucose F18; Humans; Positron-Emission Tomography; Practice Guidelines as Topic; Radiopharmaceuticals | 2012 |
[Squamous cell carcinoma of the esophagus].
Topics: Aged; Carcinoma, Squamous Cell; Combined Modality Therapy; Esophageal Neoplasms; Esophagus; Female; Fluorodeoxyglucose F18; Humans; Jejunum; Lymph Node Excision; Male; Microsurgery; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Survival Rate | 2011 |
Role of ¹⁸F 2-fluoro-2-deoxyglucose positron emission tomography in upper gastrointestinal malignancies.
Topics: Drug Therapy; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Peritoneal Neoplasms; Positron-Emission Tomography; Prognosis; Prospective Studies; Radiopharmaceuticals; Recurrence; Sensitivity and Specificity; Stomach Neoplasms | 2011 |
The value of [18F]fluorodeoxyglucose-PET/CT in oesophageal cancer.
Topics: Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Multimodal Imaging; Neoplasm Recurrence, Local; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Tomography, X-Ray Computed | 2011 |
The efficacy of FDG-PET for the management of esophageal cancer: review article.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
The new era of staging as a key for an appropriate treatment for esophageal cancer.
Topics: Decision Support Techniques; Diagnostic Imaging; Endoscopic Ultrasound-Guided Fine Needle Aspiration; Endosonography; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Neoplasm Invasiveness; Neoplasm Staging; Patient Selection; Positron-Emission Tomography; Predictive Value of Tests; Prognosis; Radiopharmaceuticals; Sentinel Lymph Node Biopsy; Tomography, X-Ray Computed | 2012 |
FDG-PET/CT based response-adapted treatment.
Topics: Adenocarcinoma; Esophageal Neoplasms; Esophagogastric Junction; Fluorodeoxyglucose F18; Humans; Lymphoma; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2012 |
Optimizing neoadjuvant chemotherapy through the use of early response evaluation by positron emission tomography.
Topics: Adenocarcinoma; Chemotherapy, Adjuvant; Clinical Trials as Topic; Esophageal Neoplasms; Esophagogastric Junction; Fluorodeoxyglucose F18; Humans; Neoadjuvant Therapy; Positron-Emission Tomography; Radiopharmaceuticals | 2012 |
Esophageal cancer and head and neck cancer.
Topics: Esophageal Neoplasms; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Radiopharmaceuticals; Tomography, Emission-Computed | 2002 |
[Cost-effective PET investigations in oncology].
Topics: Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Cost-Benefit Analysis; Diagnosis, Differential; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Hungary; Lung Neoplasms; Lymphoma; Medicare; Melanoma; Neoplasm Staging; Neoplasms; Predictive Value of Tests; Radiopharmaceuticals; Solitary Pulmonary Nodule; Tomography, Emission-Computed; Tomography, X-Ray Computed; United States | 2002 |
[Standards, Options and Recommendations for the use of PET-FDG in cancerology. Results in digestive system neoplasms].
Topics: Colorectal Neoplasms; Digestive System Neoplasms; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Liver Neoplasms; Neuroendocrine Tumors; Pancreatic Neoplasms; Radiopharmaceuticals; Stomach Neoplasms; Tomography, Emission-Computed | 2003 |
[Standards, Options and Recommendations for the use of PET-FDG in cancerology. Results in cancer of the upper aerodigestive tract].
Topics: Esophageal Neoplasms; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Lymphatic Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Second Primary; Radiopharmaceuticals; Thyroid Neoplasms; Tomography, Emission-Computed | 2003 |
18F-Fluoro-2-deoxyglucose positron emission tomography in the evaluation of gastrointestinal malignancies.
Topics: Adult; Colorectal Neoplasms; Digestive System Neoplasms; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Pancreatic Neoplasms; Radiopharmaceuticals; Stomach Neoplasms; Tomography, Emission-Computed | 2003 |
[Positron emission tomography in oncology].
Topics: Adult; Aged; Brain Neoplasms; Breast Neoplasms; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasms; Radiopharmaceuticals; Tomography, Emission-Computed | 2003 |
PET in the assessment of therapy response in patients with carcinoma of the head and neck and of the esophagus.
Topics: Antineoplastic Agents; Carcinoma; Carcinoma, Squamous Cell; Esophageal Neoplasms; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Practice Patterns, Physicians'; Prognosis; Radiopharmaceuticals; Radiotherapy; Reproducibility of Results; Sensitivity and Specificity; Tomography, Emission-Computed; Treatment Outcome | 2004 |
Positron emission tomography in gastric and esophageal cancer.
Topics: Adenocarcinoma; Carcinoma, Squamous Cell; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Remission Induction; Stomach Neoplasms; Tomography, Emission-Computed | 2004 |
Neoplasms of the esophagus and stomach.
Topics: Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Radiopharmaceuticals; Stomach Neoplasms; Tomography, Emission-Computed; Treatment Outcome; Ultrasonography | 2004 |
Position of positron emission tomography and other imaging diagnostic modalities in esophageal cancer.
Topics: Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Radiopharmaceuticals; Tomography, Emission-Computed | 2004 |
Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer.
Topics: Clinical Trials as Topic; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Neoplasm Staging; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed | 2004 |
Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Docetaxel; Endosonography; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Irinotecan; Life Tables; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Positron-Emission Tomography; Preoperative Care; Prognosis; Proportional Hazards Models; Radiopharmaceuticals; Radiotherapy, Adjuvant; Retrospective Studies; Sensitivity and Specificity; Survival Analysis; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2004 |
PET imaging in assessing gastrointestinal tumors.
Topics: Carcinoma; Colorectal Neoplasms; Esophageal Neoplasms; Fluorodeoxyglucose F18; Gastrointestinal Neoplasms; Humans; Neoplasm Staging; Pancreatic Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals | 2004 |
Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy--systematic review.
Topics: Endosonography; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Neoadjuvant Therapy; Positron-Emission Tomography; Radiopharmaceuticals; ROC Curve; Sensitivity and Specificity; Tomography, Emission-Computed | 2005 |
Diagnostic radiology and nuclear medicine.
Topics: Adenocarcinoma; Aged; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, Emission-Computed; Tomography, Spiral Computed | 2005 |
Neoadjuvant chemotherapy for oesophageal cancer: the need for accurate response prediction and evaluation.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Neoadjuvant Therapy; Neoplasm Staging; Positron-Emission Tomography; Predictive Value of Tests; Prognosis; Radiopharmaceuticals; Treatment Outcome | 2005 |
Gastrointestinal tract malignancies and positron emission tomography: an overview.
Topics: Colorectal Neoplasms; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Neoplasm Recurrence, Local; Positron-Emission Tomography; Radiopharmaceuticals; Stomach Neoplasms; Tomography, X-Ray Computed | 2006 |
Monitoring chemotherapy and radiotherapy of solid tumors.
Topics: Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Lung Neoplasms; Monitoring, Physiologic; Neoplasms; Radionuclide Imaging; Radiopharmaceuticals; Sarcoma; Uterine Cervical Neoplasms | 2006 |
The added value of metabolic imaging with FDG-PET in oesophageal cancer: prognostic role and prediction of response to treatment.
Topics: Adult; Aged; Aged, 80 and over; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Staging; Outcome Assessment, Health Care; Positron-Emission Tomography; Prevalence; Prognosis; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Treatment Outcome | 2006 |
Role of positron emission tomography in the (re-)staging of oesophageal cancer.
Topics: Adenocarcinoma; Carcinoma, Squamous Cell; Clinical Trials as Topic; Endosonography; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Neoadjuvant Therapy; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, X-Ray Computed | 2006 |
Reassessment of patients with esophageal cancer after neoadjuvant therapy.
Topics: Biopsy, Fine-Needle; Chemotherapy, Adjuvant; Endosonography; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Neoadjuvant Therapy; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy, Adjuvant; Sensitivity and Specificity; Tomography, X-Ray Computed; Treatment Outcome | 2006 |
Staging in oesophageal cancer.
Topics: Adenocarcinoma; Bone Neoplasms; Endosonography; Esophageal Neoplasms; Esophagoscopy; Fluorodeoxyglucose F18; Humans; Liver Neoplasms; Lymphatic Metastasis; Neoadjuvant Therapy; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2006 |
Response monitoring of neoadjuvant therapy using CT, EUS, and FDG-PET.
Topics: Adenocarcinoma; Carcinoma, Squamous Cell; Clinical Trials as Topic; Endosonography; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Neoadjuvant Therapy; Positron-Emission Tomography; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, X-Ray Computed | 2006 |
Evolving role of (18)F-fluorodeoxyglucose positron emission tomography in the management of esophageal carcinoma.
Topics: Adenocarcinoma; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals | 2006 |
Functional imaging for early prediction of response to chemoradiotherapy: 3'-deoxy-3'-18F-fluorothymidine positron emission tomography--a clinical application model of esophageal cancer.
Topics: Combined Modality Therapy; Dideoxynucleosides; Esophageal Neoplasms; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Positron-Emission Tomography | 2006 |
[18F-FDG-PET in therapy response of esophageal cancer].
Topics: Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Outcome Assessment, Health Care; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Treatment Outcome | 2007 |
[MSCT for staging and response evaluation of esophageal cancer].
Topics: Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Image Enhancement; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2007 |
[Recommendations for clinical practice: use of TEP-FDG in cancer of the esophagus, stomach, colon and rectum, anal canal, large intestine, pancreas and bile ducts, liver and endocrine tumors (digestive system)].
Topics: Anus Neoplasms; Bile Duct Neoplasms; Colorectal Neoplasms; Digestive System Neoplasms; Endocrine Gland Neoplasms; Esophageal Neoplasms; Fluorodeoxyglucose F18; Gastrointestinal Neoplasms; Humans; Intestine, Large; Liver Neoplasms; Pancreatic Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Stomach Neoplasms | 2007 |
Esophageal cancer.
Topics: Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals | 2008 |
Staging investigations for oesophageal cancer: a meta-analysis.
Topics: Endosonography; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Neoplasm Metastasis; Neoplasm Staging; Positron-Emission Tomography; Sensitivity and Specificity; Tomography, X-Ray Computed | 2008 |
The role of PET in target localization for radiotherapy treatment planning.
Topics: Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Lymphatic Irradiation; Lymphoma; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Radiation Injuries; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
[[18F]-FDG-PET in the diagnostics of gastrointestinal tumors].
Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma, Hepatocellular; Cholangiocarcinoma; Colonic Neoplasms; Esophageal Neoplasms; Fluorodeoxyglucose F18; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Liver Neoplasms; Meta-Analysis as Topic; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, X-Ray Computed | 2008 |
Quantitative techniques in 18FDG PET scanning in oncology.
Topics: Breast Neoplasms; Data Interpretation, Statistical; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Lymphoma; Male; Medical Oncology; Neoplasms; Positron-Emission Tomography; Predictive Value of Tests; Prognosis; Radiopharmaceuticals; Regression Analysis; Solitary Pulmonary Nodule; Stomach Neoplasms | 2008 |
Positron emission tomography scanning is coming to a hospital near you soon!
Topics: Colorectal Neoplasms; Diagnosis, Differential; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphoma; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms; Outcome and Process Assessment, Health Care; Radiopharmaceuticals; Tomography, Emission-Computed; Tomography, X-Ray Computed; United Kingdom | 2008 |
[The role of diagnostic PET in treatment planning before tumor surgery].
Topics: Breast Neoplasms; Carcinoma, Bronchogenic; Clinical Trials as Topic; Colorectal Neoplasms; Combined Modality Therapy; Diagnosis, Differential; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Glucose; Humans; Lung Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Neoplasm Recurrence, Local; Neoplasms; Prognosis; Prospective Studies; Radiopharmaceuticals; Sarcoma; Soft Tissue Neoplasms; Thyroid Neoplasms; Time Factors; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2001 |
[Cost-effective PET scans in oncology].
Topics: Breast Neoplasms; Colorectal Neoplasms; Cost-Benefit Analysis; Diagnosis, Differential; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Hungary; Lung Neoplasms; Lymphoma; Medicare; Melanoma; Neoplasm Staging; Neoplasms; Radiopharmaceuticals; Tomography, Emission-Computed; United States | 2002 |
63 trial(s) available for fluorodeoxyglucose f18 and Cancer of Esophagus
| Article | Year |
|---|---|
Dose escalation based on
Topics: Chemoradiotherapy; China; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorodeoxyglucose F18; Humans; Positron Emission Tomography Computed Tomography; Prospective Studies; Radiopharmaceuticals; Treatment Outcome | 2022 |
Assessment of Response to Neoadjuvant Chemoradiotherapy by 18F-FDG PET/CT in Patients With Locally Advanced Esophagogastric Junction Adenocarcinoma.
Topics: Adenocarcinoma; Chemoradiotherapy; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoadjuvant Therapy; Positron Emission Tomography Computed Tomography; Prognosis; Prospective Studies | 2020 |
Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain; Acyclic Monoterpenes; Adenine Nucleotides; Adhesins, Escherichia coli; Adipocytes; Adipocytes, Brown; Adipogenesis; Administration, Inhalation; Administration, Oral; Adrenal Cortex Hormones; Adsorption; Adult; Aeromonas hydrophila; Africa; Aged; Aged, 80 and over; Agrobacterium tumefaciens; Air; Air Pollutants; Air Pollution; Air Pollution, Indoor; Algorithms; Alkaloids; Alkynes; Allosteric Regulation; Amines; Amino Acid Sequence; Amino Acids; Amino Acids, Branched-Chain; Aminoisobutyric Acids; Aminopyridines; Amyotrophic Lateral Sclerosis; Anaerobic Threshold; Angiography; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animal Distribution; Animal Feed; Animal Nutritional Physiological Phenomena; Animals; Ankle Joint; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Inflammatory Agents; Antibodies, Bacterial; Antifungal Agents; Antimalarials; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antioxidants; Antiretroviral Therapy, Highly Active; Antiviral Agents; Aotidae; Apelin; Apoptosis; Arabidopsis Proteins; Argentina; Arginine; Artemisinins; Arthritis, Experimental; Arthritis, Rheumatoid; Arthroscopy; Aspergillus; Aspergillus niger; Asteraceae; Asthma; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; Auditory Cortex; Autoantibodies; Autophagy; Bacteria; Bacterial Infections; Bacterial Proteins; Bacterial Typing Techniques; Base Composition; Base Sequence; Basketball; Beclin-1; Benzhydryl Compounds; Benzimidazoles; Benzo(a)pyrene; Benzofurans; Benzoxazines; Bereavement; beta Catenin; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Betacoronavirus; Betaine; Binding Sites; Biofilms; Biological Assay; Biological Availability; Biological Evolution; Biomarkers; Biomechanical Phenomena; Biopolymers; Biopsy; Bismuth; Blood Glucose; Blood Platelets; Blood Pressure; Body Composition; Body Weight; Bone Marrow; Bone Marrow Cells; Bone Regeneration; Boron; Botrytis; Brain Ischemia; Brain Neoplasms; Brain-Derived Neurotrophic Factor; Brazil; Breast Neoplasms; Breath Tests; Bronchoalveolar Lavage Fluid; Burkholderia; C-Reactive Protein; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Calcification, Physiologic; Calcium; Calcium Signaling; Calorimetry, Differential Scanning; Cameroon; Camptothecin; Candida; Candida albicans; Capillaries; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Carbohydrate Conformation; Carbon; Carbon Dioxide; Carbon Isotopes; Carcinoma, Ovarian Epithelial; Cardiac Output; Cardiomyopathy, Hypertrophic; Cardiotonic Agents; Cardiovascular Diseases; Caregivers; Carps; Case-Control Studies; Catalase; Catalysis; Cats; CD4 Lymphocyte Count; Cell Culture Techniques; Cell Differentiation; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Survival; Cells, Cultured; Cellulose; Centrosome; Ceratopogonidae; Chickens; Child; China; Cholera Toxin; Choline; Cholinesterases; Chromatography, High Pressure Liquid; Chromatography, Liquid; Chromatography, Micellar Electrokinetic Capillary; Chromatography, Reverse-Phase; Chronic Disease; Cinnamates; Cities; Citrates; Climate Change; Clinical Trials, Phase III as Topic; Coal; Coal Mining; Cohort Studies; Coinfection; Colchicine; Colony Count, Microbial; Colorectal Neoplasms; Coloring Agents; Common Cold; Complement Factor H; Computational Biology; Computer Simulation; Continuous Positive Airway Pressure; Contrast Media; Coordination Complexes; Coronary Artery Bypass; Coronavirus 3C Proteases; Coronavirus Infections; Coronavirus Protease Inhibitors; Corynebacterium glutamicum; Cosmetics; COVID-19; Creatinine; Cross-Sectional Studies; Crotonates; Crystallography, X-Ray; Cues; Culicidae; Culture Media; Curcuma; Cyclopentanes; Cyclopropanes; Cymbopogon; Cystine; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inhibitors; Cytokines; Databases, Genetic; Death; Dendritic Cells; Density Functional Theory; Depsides; Diabetes Mellitus, Type 2; Diamond; Diarylheptanoids; Dibenzofurans; Dibenzofurans, Polychlorinated; Diclofenac; Diet; Dietary Carbohydrates; Dietary Supplements; Diffusion Magnetic Resonance Imaging; Dioxins; Diphenylamine; Disease Outbreaks; Disease Susceptibility; Disulfides; Dithiothreitol; Dizocilpine Maleate; DNA Methylation; DNA-Binding Proteins; DNA, Bacterial; Dogs; Dose-Response Relationship, Drug; Double-Blind Method; Doublecortin Protein; Drosophila melanogaster; Droughts; Drug Carriers; Drug Combinations; Drug Delivery Systems; Drug Liberation; Drug Resistance; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Dust; Dynactin Complex; Dysferlin; Echo-Planar Imaging; Echocardiography; Edaravone; Egypt; Elasticity; Electrodes; Electrolytes; Emodin; Emtricitabine; Endometriosis; Endothelium, Vascular; Endotoxins; Energy Metabolism; Energy Transfer; Enterobacteriaceae; Enterococcus faecalis; Enterotoxigenic Escherichia coli; Environmental Monitoring; Enzyme Inhibitors; Epidemiologic Factors; Epigenesis, Genetic; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Vaccines; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Esterases; Esterification; Ethanol; Ethiopia; Ethnicity; Eucalyptus; Evidence-Based Practice; Exercise; Exercise Tolerance; Extracorporeal Membrane Oxygenation; Family; Fatty Acids; Feedback; Female; Ferric Compounds; Fibrin Fibrinogen Degradation Products; Filtration; Fish Diseases; Flavonoids; Flavonols; Fluorodeoxyglucose F18; Follow-Up Studies; Food Microbiology; Food Preservation; Forests; Fossils; Free Radical Scavengers; Freund's Adjuvant; Fruit; Fungi; Gallium; Gender Identity; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Genes, Bacterial; Genes, Plant; Genetic Predisposition to Disease; Genitalia; Genotype; Glomerulonephritis, IGA; Glottis; Glucocorticoids; Glucose; Glucuronides; Glutathione Transferase; Glycogen Synthase Kinase 3 beta; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Grassland; Guinea Pigs; Half-Life; Head Kidney; Heart Atria; Heart Rate; Heart Septum; HEK293 Cells; Hematopoietic Stem Cells; Hemodynamics; Hep G2 Cells; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Hepatocytes; Hesperidin; High-Frequency Ventilation; High-Temperature Requirement A Serine Peptidase 1; Hippocampus; Hirudins; History, 20th Century; History, 21st Century; HIV Infections; Homeostasis; Hominidae; Housing, Animal; Humans; Hydrocarbons, Brominated; Hydrogen Bonding; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydroxybutyrates; Hydroxyl Radical; Hypertension; Hypothyroidism; Image Interpretation, Computer-Assisted; Immunoconjugates; Immunogenic Cell Death; Indoles; Infant, Newborn; Infant, Premature; Infarction, Middle Cerebral Artery; Inflammation; Inflammation Mediators; Infrared Rays; Inhibitory Concentration 50; Injections, Intravenous; Interferon-gamma; Interleukin-23; Interleukin-4; Interleukin-6; Intermediate Filaments; Intermittent Claudication; Intestine, Small; Iridoid Glucosides; Iridoids; Iron; Isomerism; Isotope Labeling; Isoxazoles; Itraconazole; Kelch-Like ECH-Associated Protein 1; Ketoprofen; Kidney Failure, Chronic; Kinetics; Klebsiella pneumoniae; Lactams, Macrocyclic; Lactobacillus; Lactulose; Lakes; Lamivudine; Laparoscopy; Laparotomy; Laryngoscopy; Leucine; Limit of Detection; Linear Models; Lipid A; Lipopolysaccharides; Listeria monocytogenes; Liver; Liver Cirrhosis; Logistic Models; Longitudinal Studies; Losartan; Low Back Pain; Lung; Lupinus; Lupus Erythematosus, Systemic; Machine Learning; Macular Degeneration; Madin Darby Canine Kidney Cells; Magnetic Phenomena; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Magnetics; Malaria, Falciparum; Male; Mannans; MAP Kinase Signaling System; Mass Spectrometry; Melatonin; Membrane Glycoproteins; Membrane Proteins; Meniscectomy; Menisci, Tibial; Mephenytoin; Mesenchymal Stem Cells; Metal Nanoparticles; Metal-Organic Frameworks; Methionine; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Mice, Obese; Mice, Transgenic; Microbial Sensitivity Tests; Microcirculation; MicroRNAs; Microscopy, Video; Microtubules; Microvascular Density; Microwaves; Middle Aged; Minimally Invasive Surgical Procedures; Models, Animal; Models, Biological; Models, Molecular; Models, Theoretical; Molecular Docking Simulation; Molecular Structure; Molecular Weight; Morus; Mouth Floor; Multicenter Studies as Topic; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Muscle, Skeletal; Myocardial Ischemia; Myocardium; NAD; NADP; Nanocomposites; Nanoparticles; Naphthols; Nasal Lavage Fluid; Nasal Mucosa; Neisseria meningitidis; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasms, Experimental; Neural Stem Cells; Neuroblastoma; Neurofilament Proteins; Neurogenesis; Neurons; New York; NF-E2-Related Factor 2; NF-kappa B; Nicotine; Nitriles; Nitrogen; Nitrogen Fixation; North America; Observer Variation; Occupational Exposure; Ochrobactrum; Oils, Volatile; Olea; Oligosaccharides; Omeprazole; Open Field Test; Optimism; Oregon; Oryzias; Osmolar Concentration; Osteoarthritis; Osteoblasts; Osteogenesis; Ovarian Neoplasms; Ovariectomy; Oxadiazoles; Oxidation-Reduction; Oxidative Stress; Oxygen; Ozone; p38 Mitogen-Activated Protein Kinases; Pakistan; Pandemics; Particle Size; Particulate Matter; Patient-Centered Care; Pelargonium; Peptides; Perception; Peripheral Arterial Disease; Peroxides; Pets; Pharmaceutical Preparations; Pharmacogenetics; Phenobarbital; Phenols; Phenotype; Phosphates; Phosphatidylethanolamines; Phosphines; Phospholipids; Phosphorus; Phosphorylation; Photoacoustic Techniques; Photochemotherapy; Photosensitizing Agents; Phylogeny; Phytoestrogens; Pilot Projects; Plant Components, Aerial; Plant Extracts; Plant Immunity; Plant Leaves; Plant Oils; Plants, Medicinal; Plasmodium berghei; Plasmodium falciparum; Platelet Activation; Platelet Function Tests; Pneumonia, Viral; Poaceae; Pogostemon; Poloxamer; Poly I; Poly(ADP-ribose) Polymerase Inhibitors; Polychlorinated Biphenyls; Polychlorinated Dibenzodioxins; Polycyclic Compounds; Polyethylene Glycols; Polylysine; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Population Dynamics; Portasystemic Shunt, Transjugular Intrahepatic; Positron Emission Tomography Computed Tomography; Postoperative Complications; Postprandial Period; Potassium Cyanide; Predictive Value of Tests; Prefrontal Cortex; Pregnancy; Prepulse Inhibition; Prevalence; Procalcitonin; Prodrugs; Prognosis; Progression-Free Survival; Proline; Proof of Concept Study; Prospective Studies; Protein Binding; Protein Conformation; Protein Domains; Protein Folding; Protein Multimerization; Protein Sorting Signals; Protein Structure, Secondary; Proton Pump Inhibitors; Protozoan Proteins; Psychometrics; Pulse Wave Analysis; Pyridines; Pyrrolidines; Quality of Life; Quantum Dots; Quinoxalines; Quorum Sensing; Radiopharmaceuticals; Rain; Random Allocation; Randomized Controlled Trials as Topic; Rats; Rats, Sprague-Dawley; Rats, Wistar; RAW 264.7 Cells; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Receptor, PAR-1; Receptors, CXCR4; Receptors, Estrogen; Receptors, Glucocorticoid; Receptors, Interleukin-1; Receptors, Interleukin-17; Receptors, Notch; Recombinant Fusion Proteins; Recombinant Proteins; Reducing Agents; Reflex, Startle; Regional Blood Flow; Regression Analysis; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Tract Diseases; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Risk Assessment; Risk Factors; Rituximab; RNA, Messenger; RNA, Ribosomal, 16S; ROC Curve; Rosmarinic Acid; Running; Ruthenium; Rutin; Sarcolemma; Sarcoma; Sarcopenia; Sarcoplasmic Reticulum; SARS-CoV-2; Scavenger Receptors, Class A; Schools; Seasons; Seeds; Sequence Analysis, DNA; Severity of Illness Index; Sex Factors; Shock, Cardiogenic; Short Chain Dehydrogenase-Reductases; Signal Transduction; Silver; Singlet Oxygen; Sinusitis; Skin; Skin Absorption; Small Molecule Libraries; Smoke; Socioeconomic Factors; Soil; Soil Microbiology; Solid Phase Extraction; Solubility; Solvents; Spain; Spectrometry, Mass, Electrospray Ionization; Spectroscopy, Fourier Transform Infrared; Speech; Speech Perception; Spindle Poles; Spleen; Sporothrix; Staphylococcal Infections; Staphylococcus aureus; Stereoisomerism; Stomach Neoplasms; Stress, Physiological; Stroke Volume; Structure-Activity Relationship; Substrate Specificity; Sulfonamides; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Rate; T-Lymphocytes, Cytotoxic; Tandem Mass Spectrometry; Temperature; Tenofovir; Terpenes; Tetracycline; Tetrapleura; Textiles; Thermodynamics; Thiobarbituric Acid Reactive Substances; Thrombin; Thyroid Hormones; Thyroid Neoplasms; Tibial Meniscus Injuries; Time Factors; Tissue Distribution; Titanium; Toluidines; Tomography, X-Ray Computed; Tooth; Tramadol; Transcription Factor AP-1; Transcription, Genetic; Transfection; Transgender Persons; Translations; Treatment Outcome; Triglycerides; Ubiquinone; Ubiquitin-Specific Proteases; United Kingdom; United States; Up-Regulation; Vascular Stiffness; Veins; Ventricular Remodeling; Viral Load; Virulence Factors; Virus Replication; Vitis; Voice; Voice Quality; Wastewater; Water; Water Pollutants, Chemical; Water-Electrolyte Balance; Weather; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Young Adult; Zoogloea | 2022 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acrylic Resins; Actinobacillus; Acute Disease; Acute Kidney Injury; Adaptor Proteins, Signal Transducing; Adenosine; Adenosine Triphosphate; Administration, Inhalation; Administration, Oral; Adolescent; Adult; Advance Care Planning; Africa, Northern; Age Factors; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Air Pollution, Indoor; Albendazole; Aluminum Oxide; Anastomosis, Surgical; Ancylostoma; Ancylostomiasis; Androstadienes; Angiogenesis Inhibitors; Angiotensin II; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bispecific; Antibodies, Viral; Anticoagulants; Antihypertensive Agents; Antinematodal Agents; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antiporters; Antiviral Agents; Apoptosis; Aptamers, Nucleotide; Aromatase Inhibitors; Asian People; Astrocytes; Atrial Fibrillation; Auditory Threshold; Aurora Kinase B; Australia; Autophagy; Autophagy-Related Protein 5; Autotrophic Processes; Bacillus cereus; Bacillus thuringiensis; Bacterial Proteins; Beclin-1; Belgium; Benzene; Benzene Derivatives; Benzhydryl Compounds; beta Catenin; beta-Arrestin 2; Biliary Tract Diseases; Biofilms; Biofuels; Biomarkers; Biomarkers, Tumor; Biomass; Biomechanical Phenomena; Bioreactors; Biosensing Techniques; Biosynthetic Pathways; Bismuth; Blood Platelets; Bone and Bones; Bone Regeneration; Bortezomib; Botulinum Toxins, Type A; Brain; Brain Injuries; Brain Ischemia; Brain Neoplasms; Breast Neoplasms; Breath Tests; Bronchodilator Agents; Calcium Phosphates; Cannabis; Carbon Dioxide; Carbon Isotopes; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cardiac Resynchronization Therapy; Cardiac Resynchronization Therapy Devices; Cardiomyopathies; Cardiovascular Diseases; Cariostatic Agents; Case Managers; Case-Control Studies; Catalysis; Cation Transport Proteins; CD8-Positive T-Lymphocytes; Cecropia Plant; Cell Adhesion; Cell Count; Cell Differentiation; Cell Division; Cell Line; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Self Renewal; Cell Survival; Cells, Cultured; Cellular Reprogramming; Cellulose; Charcoal; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemokines; Chemoradiotherapy; Chemoreceptor Cells; Child; Child Abuse; Child, Preschool; China; Chlorogenic Acid; Chloroquine; Chromatography, Gas; Chronic Disease; Clinical Competence; Coated Materials, Biocompatible; Cochlea; Cohort Studies; Color; Comorbidity; Computer Simulation; Computer-Aided Design; Contraception; Contraceptive Agents, Female; Contrast Media; COP-Coated Vesicles; Coronavirus Infections; Cost of Illness; Coturnix; COVID-19; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Culex; Curriculum; Cyclic N-Oxides; Cytokines; Cytoplasm; Cytotoxicity, Immunologic; Cytotoxins; Databases, Factual; Deep Learning; Delivery, Obstetric; Denitrification; Dental Caries; Denture, Complete; Dexamethasone; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dielectric Spectroscopy; Diet, High-Fat; Dietary Fiber; Disease Models, Animal; Disease Progression; DNA; DNA Copy Number Variations; DNA, Mitochondrial; Dog Diseases; Dogs; Dopaminergic Neurons; Double-Blind Method; Down-Regulation; Doxorubicin; Drug Carriers; Drug Design; Drug Interactions; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Dry Powder Inhalers; Dust; E2F1 Transcription Factor; Ecosystem; Education, Nursing; Education, Nursing, Baccalaureate; Electric Impedance; Electricity; Electrocardiography; Electrochemical Techniques; Electrochemistry; Electrodes; Electrophoresis, Polyacrylamide Gel; Endoplasmic Reticulum; Endothelial Cells; Environmental Monitoring; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Estrogen Receptor Modulators; Europe; Evoked Potentials, Auditory, Brain Stem; Exosomes; Feasibility Studies; Female; Ferricyanides; Ferrocyanides; Fibrinogen; Finite Element Analysis; Fistula; Fluorescent Dyes; Fluorides, Topical; Fluorodeoxyglucose F18; Fluticasone; Follow-Up Studies; Food Contamination; Food Microbiology; Foods, Specialized; Forensic Medicine; Frail Elderly; France; Free Radicals; Fresh Water; Fungi; Fungicides, Industrial; Galactosamine; Gastrointestinal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Frequency; Genetic Predisposition to Disease; Genotype; Gingival Hemorrhage; Glioblastoma; Glioma; Glomerular Filtration Rate; Glomerulosclerosis, Focal Segmental; Glucose; Glucose Transport Proteins, Facilitative; Glucosides; Glutamine; Glycolysis; Gold; GPI-Linked Proteins; Gram-Negative Bacteria; Gram-Positive Bacteria; Graphite; Haplotypes; HCT116 Cells; Healthy Volunteers; Hearing Loss; Heart Failure; Hedgehog Proteins; HEK293 Cells; HeLa Cells; Hemodynamics; Hemorrhage; Hepatocytes; Hippo Signaling Pathway; Histone Deacetylases; Homeostasis; Hospital Mortality; Hospitalization; Humans; Hydantoins; Hydrazines; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Hydroxylamines; Hypoglycemic Agents; Immunity, Innate; Immunoglobulin G; Immunohistochemistry; Immunologic Factors; Immunomodulation; Immunophenotyping; Immunotherapy; Incidence; Indazoles; Indonesia; Infant; Infant, Newborn; Infarction, Middle Cerebral Artery; Inflammation; Injections, Intramuscular; Insecticides; Insulin-Like Growth Factor I; Insurance, Health; Intention to Treat Analysis; Interleukin-1 Receptor-Associated Kinases; Interleukin-6; Intrauterine Devices; Intrauterine Devices, Copper; Iron; Ischemia; Jordan; Keratinocytes; Kidney; Kidney Diseases; Kir5.1 Channel; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Laparoscopy; Lasers; Lasers, Semiconductor; Lenalidomide; Leptin; Lethal Dose 50; Levonorgestrel; Limit of Detection; Lipid Metabolism; Lipid Metabolism Disorders; Lipogenesis; Lipopolysaccharides; Liquid Biopsy; Liver; Liver Abscess, Pyogenic; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Longevity; Lung Neoplasms; Luteolin; Lymph Nodes; Lymphocyte Activation; Macaca fascicularis; Macrophages; Mad2 Proteins; Magnetic Resonance Imaging; Male; Mammary Glands, Human; Manganese; Manganese Compounds; MAP Kinase Signaling System; Materials Testing; Maternal Health Services; MCF-7 Cells; Medicaid; Medicine, Chinese Traditional; Melanoma; Membrane Proteins; Mental Health; Mercury; Metal Nanoparticles; Metals, Heavy; Metformin; Methionine Adenosyltransferase; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Mice, Nude; Microalgae; Microbial Sensitivity Tests; Microglia; MicroRNAs; Microscopy, Atomic Force; Microscopy, Electron, Scanning; Middle Aged; Mitochondria; Mitochondrial Proteins; Mitral Valve; Mitral Valve Insufficiency; Models, Anatomic; Molecular Structure; Molybdenum; Monocarboxylic Acid Transporters; Moths; MPTP Poisoning; Multigene Family; Multiparametric Magnetic Resonance Imaging; Multiple Myeloma; Muscle, Skeletal; Mutagens; Mutation; Myeloid Cells; Nanocomposites; Nanofibers; Nanomedicine; Nanoparticles; Nanowires; Neoadjuvant Therapy; Neomycin; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms; Neoplastic Stem Cells; Neostriatum; Neovascularization, Pathologic; Netherlands; Neuromuscular Agents; Neurons; NF-E2-Related Factor 2; NF-kappa B; Nickel; Nitrogen Oxides; Non-alcoholic Fatty Liver Disease; Nucleosides; Nucleotidyltransferases; Nutritional Status; Obesity, Morbid; Ofloxacin; Oils, Volatile; Oligopeptides; Oncogene Protein v-akt; Optical Imaging; Organic Cation Transport Proteins; Organophosphonates; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Osteoblasts; Osteogenesis; Oxidation-Reduction; Oxidative Stress; Oxides; Oxygen Isotopes; Pancreas; Pancreaticoduodenectomy; Pandemics; Particle Size; Particulate Matter; Patient Acceptance of Health Care; Patient Compliance; PC-3 Cells; Peptide Fragments; Peptides; Periodontal Attachment Loss; Periodontal Index; Periodontal Pocket; Periodontitis; Peroxides; Peru; Pest Control, Biological; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phylogeny; Pilot Projects; Piperidines; Plant Bark; Plant Extracts; Plant Leaves; Plasmids; Platelet Function Tests; Pneumonia, Viral; Podocytes; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Terephthalates; Polymers; Polymorphism, Single Nucleotide; Porosity; Portugal; Positron-Emission Tomography; Postoperative Complications; Postural Balance; Potassium Channels, Inwardly Rectifying; Povidone; Powders; Precancerous Conditions; Precision Medicine; Predictive Value of Tests; Pregnancy; Prenatal Care; Prognosis; Promoter Regions, Genetic; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Proteasome Inhibitors; Protective Agents; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Psychiatric Nursing; PTEN Phosphohydrolase; Pulmonary Embolism; Pyrimethamine; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reactive Oxygen Species; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, G-Protein-Coupled; Recombinational DNA Repair; Recovery of Function; Regional Blood Flow; Renal Dialysis; Renin; Renin-Angiotensin System; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Distress Syndrome; Retrospective Studies; Rhodamines; Risk Assessment; Risk Factors; RNA, Long Noncoding; RNA, Messenger; Running; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salinity; Salmeterol Xinafoate; Sarcoma; Seasons; Shoulder Injuries; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Sirtuins; Skull Fractures; Social Determinants of Health; Sodium; Sodium Fluoride; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Soil; Soil Pollutants; Spain; Spectrophotometry; Spectroscopy, Fourier Transform Infrared; Staphylococcal Protein A; Staphylococcus aureus; Stem Cells; Stereoisomerism; Stomach Neoplasms; Streptomyces; Strontium; Structure-Activity Relationship; Students, Nursing; Substance-Related Disorders; Succinic Acid; Sulfur; Surface Properties; Survival Rate; Survivin; Symporters; T-Lymphocytes; Temozolomide; Tensile Strength; Thiazoles; Thiobacillus; Thiohydantoins; Thiourea; Thrombectomy; Time Factors; Titanium; Tobacco Mosaic Virus; Tobacco Use Disorder; Toll-Like Receptor 4; Toluene; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Toxicity Tests, Acute; Toxicity Tests, Subacute; Transcriptional Activation; Treatment Outcome; Troponin I; Tumor Cells, Cultured; Tumor Escape; Tumor Hypoxia; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Tyrosine; Ubiquitin-Protein Ligases; Ubiquitination; Ultrasonic Waves; United Kingdom; United States; United States Department of Veterans Affairs; Up-Regulation; Urea; Uric Acid; Urinary Bladder Neoplasms; Urinary Bladder, Neurogenic; Urine; Urodynamics; User-Computer Interface; Vemurafenib; Verbenaceae; Veterans; Veterans Health; Viral Load; Virtual Reality; Vitiligo; Water Pollutants, Chemical; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Xylenes; Young Adult; Zinc; Zinc Oxide; Zinc Sulfate; Zoonoses | 2021 |
Randomized Phase II Study of PET Response-Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Combined Modality Therapy; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Male; Middle Aged; Oxaliplatin; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Survival Rate; Young Adult | 2021 |
Preoperative Capecitabine, Oxaliplatin, and Irinotecan in Resectable Gastric or Gastroesophageal Junction Cancer: Pathological Response as Primary Endpoint and FDG-PET Predictions.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Capecitabine; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorodeoxyglucose F18; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Positron Emission Tomography Computed Tomography; Postoperative Care; Preoperative Care; Stomach Neoplasms | 2017 |
Respiratory-gated (4D) contrast-enhanced FDG PET-CT for radiotherapy planning of lower oesophageal carcinoma: feasibility and impact on planning target volume.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carcinoma; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Four-Dimensional Computed Tomography; Humans; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Respiratory-Gated Imaging Techniques; Young Adult | 2017 |
Effect of long fasting on myocardial accumulation in 18F-fluorodeoxyglucose positron emission tomography after chemoradiotherapy for esophageal carcinoma.
Topics: Adult; Aged; Chemoradiotherapy; Esophageal Neoplasms; Fasting; Female; Fluorodeoxyglucose F18; Heart Ventricles; Humans; Male; Middle Aged; Myocardium; Positron-Emission Tomography | 2018 |
[
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoadjuvant Therapy; Positron Emission Tomography Computed Tomography; Prospective Studies; Radiopharmaceuticals; ROC Curve; Treatment Outcome | 2018 |
The Role of PET-Based Radiomic Features in Predicting Local Control of Esophageal Cancer Treated with Concurrent Chemoradiotherapy.
Topics: Adult; Aged; Chemoradiotherapy; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Logistic Models; Machine Learning; Male; Middle Aged; Positron-Emission Tomography; ROC Curve; Support Vector Machine | 2018 |
Intratreatment Response Assessment With 18F-FDG PET: Correlation of Semiquantitative PET Features With Pathologic Response of Esophageal Cancer to Neoadjuvant Chemoradiotherapy.
Topics: Aged; Aged, 80 and over; Chemoradiotherapy; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Neoadjuvant Therapy; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Treatment Outcome | 2018 |
18F FDG-PET/CT evaluation of histological response after neoadjuvant treatment in patients with cancer of the esophagus or gastroesophageal junction.
Topics: Adult; Aged; Esophageal Neoplasms; Esophagogastric Junction; Esophagus; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoadjuvant Therapy; Norway; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Sweden | 2019 |
Propensity score analysis of 18-FDG PET/CT-enhanced staging in patients undergoing surgery for esophageal cancer.
Topics: Adult; Aged; Aged, 80 and over; Disease-Free Survival; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Propensity Score; Recurrence | 2019 |
Involvement of increased p53 expression in the decrease of mitochondrial DNA copy number and increase of SUV
Topics: Aged; DNA Copy Number Variations; DNA, Mitochondrial; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorodeoxyglucose F18; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Positron-Emission Tomography; Tumor Suppressor Protein p53 | 2019 |
The predictive value of treatment response using FDG PET performed on day 21 of chemoradiotherapy in patients with oesophageal squamous cell carcinoma. A prospective, multicentre study (RTEP3).
Topics: Adult; Aged; Carcinoma, Squamous Cell; Chemoradiotherapy; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Positron-Emission Tomography; Predictive Value of Tests; Prospective Studies; Radiopharmaceuticals; Treatment Outcome | 2013 |
Systemic control and evaluation of the response to neoadjuvant chemotherapy in resectable thoracic esophageal squamous cell carcinoma with ¹⁸F-fluorodeoxyglucose positron emission tomography-positive lymph nodes.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Treatment Outcome; Young Adult | 2015 |
FDG-PET/CT during concomitant chemo radiotherapy for esophageal cancer: Reducing target volumes to deliver higher radiotherapy doses.
Topics: Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Chemoradiotherapy; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Lung; Male; Middle Aged; Multimodal Imaging; Organs at Risk; Positron-Emission Tomography; Prospective Studies; Radiation Dosage; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Spinal Cord; Time Factors; Tomography, X-Ray Computed | 2015 |
Safety of dose escalation by simultaneous integrated boosting radiation dose within the primary tumor guided by (18)FDG-PET/CT for esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dose-Response Relationship, Radiation; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2015 |
Whole Body MRI in the Staging of Esophageal Cancer--A Prospective Comparison with Whole Body 18F-FDG PET-CT.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, X-Ray Computed | 2015 |
18-fluorodeoxy-glucose positron emission computed tomography as predictive of response after chemoradiation in oesophageal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Chemoradiotherapy; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multimodal Imaging; Organoplatinum Compounds; Outcome Assessment, Health Care; Oxaliplatin; Positron-Emission Tomography; Prognosis; Proportional Hazards Models; Prospective Studies; Remission Induction; Taxoids; Tomography, X-Ray Computed | 2015 |
Comparison of characteristics of 18F-fluorodeoxyglucose and 18F-fluorothymidine PET during staging of esophageal squamous cell carcinoma.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Dideoxynucleosides; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography | 2015 |
Prediction of disease-free survival using relative change in FDG-uptake early during neoadjuvant chemoradiotherapy for potentially curable esophageal cancer: A prospective cohort study.
Topics: Adult; Aged; Chemoradiotherapy, Adjuvant; Disease Progression; Disease-Free Survival; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Positron-Emission Tomography; Predictive Value of Tests; Prospective Studies; Radiopharmaceuticals; Treatment Outcome | 2017 |
Lack of fludeoxyglucose F 18 uptake in posttreatment positron emission tomography as a significant predictor of survival after subsequent surgery in multimodality treatment for patients with locally advanced esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Positron-Emission Tomography; Postoperative Period; Predictive Value of Tests; Prognosis; Prospective Studies; Radiotherapy, Adjuvant; Risk Factors; Survival Rate; Treatment Outcome | 2008 |
Lymph node analysis in esophageal resection: American College of Surgeons Oncology Group Z0060 trial.
Topics: Adenocarcinoma; Carcinoma, Squamous Cell; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Fluorodeoxyglucose F18; Humans; Lymph Node Excision; Lymph Nodes; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2008 |
Tumour length measured on PET-CT predicts the most appropriate stage-dependent therapeutic approach in oesophageal cancer.
Topics: Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Staging; Patient Selection; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Subtraction Technique; Tomography, X-Ray Computed | 2008 |
Use of positron emission tomography in surgery follow-up of esophageal cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma; Disease-Free Survival; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Positron-Emission Tomography; Predictive Value of Tests; Prospective Studies; Radiopharmaceuticals | 2009 |
Limited predictive value of FDG-PET for response assessment in the preoperative treatment of esophageal cancer: results of a prospective multi-center trial (SAKK 75/02).
Topics: Adult; Aged; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Germany; Humans; Male; Middle Aged; Positron-Emission Tomography; Preoperative Care; Prognosis; Prospective Studies; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Switzerland; Treatment Outcome | 2009 |
Measuring tumor cell proliferation with 18F-FLT PET during radiotherapy of esophageal squamous cell carcinoma: a pilot clinical study.
Topics: Aged; Aged, 80 and over; Bone Marrow Cells; Carcinoma, Squamous Cell; Cell Proliferation; Diagnosis, Differential; Dideoxynucleosides; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Inflammation; Lymphatic Metastasis; Male; Middle Aged; Neoplasm, Residual; Pilot Projects; Positron-Emission Tomography; Tomography, X-Ray Computed | 2010 |
Influence of ROI definition, partial volume correction and SUV normalization on SUV-survival correlation in oesophageal cancer.
Topics: Adult; Aged; Aged, 80 and over; Biological Transport; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Positron-Emission Tomography; Prospective Studies; Survival Analysis | 2010 |
Whole body 18F-FDG PET predicts progression free and overall survival in squamous cell carcinoma of the esophagus: results of a prospective trial.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cohort Studies; Disease-Free Survival; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Positron-Emission Tomography; Predictive Value of Tests; Prospective Studies; Radiopharmaceuticals; Whole Body Imaging | 2010 |
Positive correlations between tumor uptake on FDG PET and energy expenditure of patients with esophageal cancer.
Topics: Aged; Aged, 80 and over; Biological Transport; Energy Metabolism; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Positron-Emission Tomography; Rest; Tomography, X-Ray Computed | 2011 |
Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Esophageal Neoplasms; Esophagectomy; Fluorodeoxyglucose F18; Humans; Neoadjuvant Therapy; Paclitaxel; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Radiotherapy, Adjuvant; ROC Curve; Treatment Outcome | 2011 |
(18)F-FDG PET-guided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esophagogastric junction: the MUNICON II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorodeoxyglucose F18; Glucose; Humans; Male; Middle Aged; Positron-Emission Tomography; Radiotherapy, Adjuvant; Remission Induction; Salvage Therapy; Treatment Outcome | 2011 |
Accuracy and reproducibility of 3D-CT measurements for early response assessment of chemoradiotherapy in patients with oesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Contrast Media; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Fluorodeoxyglucose F18; Humans; Imaging, Three-Dimensional; Lymph Node Excision; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Observer Variation; Positron-Emission Tomography; Predictive Value of Tests; ROC Curve; Sample Size; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
Comparison of the diagnostic value of 3-deoxy-3-18F-fluorothymidine and 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the assessment of regional lymph node in thoracic esophageal squamous cell carcinoma: a pilot study.
Topics: Aged; Carcinoma, Squamous Cell; Dideoxynucleosides; Esophageal Neoplasms; False Negative Reactions; False Positive Reactions; Female; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Pilot Projects; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, X-Ray Computed | 2012 |
Metabolic response at repeat PET/CT predicts pathological response to neoadjuvant chemotherapy in oesophageal cancer.
Topics: Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Metabolic Clearance Rate; Multimodal Imaging; Neoadjuvant Therapy; Positron-Emission Tomography; Radiopharmaceuticals; Tissue Distribution; Tomography, X-Ray Computed; Treatment Failure; Treatment Outcome | 2012 |
The analysis of factors affecting the threshold on repeated 18F-FDG-PET/CT investigations measured by the PERCIST protocol in patients with esophageal carcinoma.
Topics: Adult; Aged; Biological Transport; Body Mass Index; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Liver; Male; Middle Aged; Multimodal Imaging; Neoadjuvant Therapy; Positron-Emission Tomography; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Confirmation of histology of PET positive lymph nodes recovered by hand-video-assisted thoracoscopy surgery.
Topics: Adult; Aged; Aged, 80 and over; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Thoracic Surgery, Video-Assisted; Tomography, X-Ray Computed | 2012 |
The usefulness of 18F-FDG PET images obtained 2 hours after intravenous injection in liver tumor.
Topics: Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Colorectal Neoplasms; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Injections, Intravenous; Liver Neoplasms; Male; Middle Aged; Radionuclide Imaging; Radiopharmaceuticals; Sensitivity and Specificity; Time Factors | 2002 |
Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Metastasis; Predictive Value of Tests; Prospective Studies; Radiopharmaceuticals; Tomography, Emission-Computed; Treatment Outcome | 2003 |
Gamma camera coincidence imaging with [18F]fluorodeoxyglucose in the pretreatment evaluation of patients with oesophageal cancer.
Topics: Aged; Aged, 80 and over; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasms, Squamous Cell; Radiography; Radionuclide Imaging; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tomography, Emission-Computed | 2003 |
Pitfalls of positive findings in staging esophageal cancer with F-18-fluorodeoxyglucose positron emission tomography.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Esophageal Neoplasms; False Positive Reactions; Female; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Radiopharmaceuticals; Retrospective Studies; Tomography, Emission-Computed | 2003 |
Detection of distant metastases in esophageal cancer with (18)F-FDG PET.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tomography, Emission-Computed | 2004 |
18F-FDG PET in patients with esophageal squamous cell carcinoma undergoing curative surgery: prognostic implications.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Disease-Free Survival; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Korea; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Reproducibility of Results; Risk Assessment; Risk Factors; Sensitivity and Specificity; Survival Analysis; Treatment Outcome | 2004 |
The incremental effect of positron emission tomography on diagnostic accuracy in the initial staging of esophageal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma; Combined Modality Therapy; Decision Making; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed | 2005 |
Is there a role for FGD-PET in radiotherapy planning in esophageal carcinoma?
Topics: Adult; Aged; Carcinoma; Endosonography; Esophageal Neoplasms; False Negative Reactions; Female; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Patient Care Planning; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Sensitivity and Specificity; Tomography, X-Ray Computed | 2004 |
Comparison of 18F-FLT PET and 18F-FDG PET in esophageal cancer.
Topics: Aged; Dideoxynucleosides; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Pilot Projects; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity | 2005 |
The additional value of PET/CT over PET in FDG imaging of oesophageal cancer.
Topics: Adult; Aged; Aged, 80 and over; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Image Enhancement; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Subtraction Technique; Tomography, X-Ray Computed | 2005 |
FDG-PET in the prediction of pathologic response after neoadjuvant chemoradiotherapy in locally advanced, resectable esophageal cancer.
Topics: Aged; Chemotherapy, Adjuvant; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Radiotherapy, Adjuvant; Sensitivity and Specificity; Treatment Outcome | 2005 |
[Impact of computed tomography (CT) and 18F-deoxyglucose positron emission tomography (FDG-PET) image fusion for conformal radiotherapy in esophageal carcinoma].
Topics: Adult; Aged; Carcinoma; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Patient Care Planning; Positron-Emission Tomography; Radiometry; Radiopharmaceuticals; Radiotherapy, Conformal; Tomography, X-Ray Computed | 2005 |
Synchronous primary neoplasms detected on 18F-FDG PET in staging of patients with esophageal cancer.
Topics: Aged; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Incidence; Incidental Findings; Male; Middle Aged; Neoplasm Staging; Neoplasms, Multiple Primary; Netherlands; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Retrospective Studies; Sensitivity and Specificity | 2005 |
A prospective evaluation of the impact of 18-F-fluoro-deoxy-D-glucose positron emission tomography staging on survival for patients with locally advanced esophageal cancer.
Topics: Adult; Aged; Cohort Studies; Combined Modality Therapy; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Prospective Studies; Radiopharmaceuticals; Survival Rate; Tomography, Emission-Computed | 2006 |
Significant clinical impact and prognostic stratification provided by FDG-PET in the staging of oesophageal cancer.
Topics: Adult; Aged; Aged, 80 and over; Australia; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Middle Aged; Outcome Assessment, Health Care; Positron-Emission Tomography; Prevalence; Prognosis; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Survival Analysis; Survival Rate; Treatment Outcome | 2006 |
A prospective study to evaluate the impact of FDG-PET on CT-based radiotherapy treatment planning for oesophageal cancer.
Topics: Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Imaging, Three-Dimensional; Male; Positron-Emission Tomography; Prospective Studies; Radiometry; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Computer-Assisted; Radiotherapy, Conformal; Tomography, X-Ray Computed; Treatment Outcome | 2006 |
FDG-PET status following chemoradiotherapy provides high management impact and powerful prognostic stratification in oesophageal cancer.
Topics: Adult; Aged; Aged, 80 and over; Australia; Combined Modality Therapy; Drug Therapy; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Middle Aged; Outcome Assessment, Health Care; Positron-Emission Tomography; Prevalence; Prognosis; Radiopharmaceuticals; Radiotherapy; Reproducibility of Results; Sensitivity and Specificity; Survival Analysis; Survival Rate; Treatment Outcome | 2006 |
Predictive value of 18-fluoro-deoxy-glucose-positron emission tomography (18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged, 80 and over; Carcinoma, Squamous Cell; Combined Modality Therapy; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Humans; Male; Neoadjuvant Therapy; Positron-Emission Tomography; Predictive Value of Tests; Prospective Studies; Radiopharmaceuticals; Radiotherapy Dosage | 2006 |
The added value of metabolic imaging with FDG-PET in oesophageal cancer: prognostic role and prediction of response to treatment.
Topics: Adult; Aged; Aged, 80 and over; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Staging; Outcome Assessment, Health Care; Positron-Emission Tomography; Prevalence; Prognosis; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Treatment Outcome | 2006 |
Additional value of PET/CT over PET in assessment of locoregional lymph nodes in thoracic esophageal squamous cell cancer.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Positron-Emission Tomography; Thoracic Neoplasms; Tomography, X-Ray Computed | 2006 |
The utility of positron emission tomography in staging of potentially operable carcinoma of the thoracic esophagus: results of the American College of Surgeons Oncology Group Z0060 trial.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Biopsy, Needle; Carcinoma; Confidence Intervals; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Humans; Immunohistochemistry; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Risk Assessment; Sensitivity and Specificity; Sex Factors; Survival Rate; Thoracotomy | 2007 |
Value of complete metabolic response by (18)F-fluorodeoxyglucose-positron emission tomography in oesophageal cancer for prediction of pathologic response and survival after preoperative chemoradiotherapy.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Combined Modality Therapy; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Survival Analysis | 2007 |
PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial.
Topics: Adenocarcinoma; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Esophageal Neoplasms; Esophagogastric Junction; Feasibility Studies; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoadjuvant Therapy; Positron-Emission Tomography; Prognosis; Survival Rate | 2007 |
Evaluation of 18F-FDG positron emission tomography in gastric and oesophageal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Staging; Radiopharmaceuticals; Stomach Neoplasms; Tomography, Emission-Computed; Tomography, X-Ray Computed | 1999 |
Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma.
Topics: Adenocarcinoma; Carcinoma, Squamous Cell; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Neoplasm Metastasis; Neoplasm Staging; Prospective Studies; Radionuclide Imaging; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, X-Ray Computed; Ultrasonography | 2000 |
553 other study(ies) available for fluorodeoxyglucose f18 and Cancer of Esophagus
| Article | Year |
|---|---|
Esophageal papillomatosis presenting with complete esophageal obstruction and high positron emission tomography avidity.
Topics: Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Neoplasm Staging; Papilloma; Positron-Emission Tomography; Radiopharmaceuticals | 2022 |
PET Imaging and Rate of Pathologic Complete Response in Esophageal Squamous Cell Carcinoma.
Topics: Chemoradiotherapy; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Fluorodeoxyglucose F18; Humans; Neoadjuvant Therapy; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies | 2022 |
Clinical Significance of [
Topics: Esophageal Neoplasms; Fluorodeoxyglucose F18; Glucose; Humans; Lymph Nodes; Lymphatic Metastasis; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals | 2022 |
Unusual Metastases of Esophageal Squamous Cell Carcinoma.
Topics: Aged; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorodeoxyglucose F18; Humans; Male; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography | 2022 |
A design of forceps-type coincidence radiation detector for intraoperative LN diagnosis: clinical impact estimated from LNs data of 20 esophageal cancer patients.
Topics: Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Lymphatic Metastasis; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Surgical Instruments | 2022 |
Maximum standardized uptake value change rate before and after neoadjuvant chemotherapy can predict early recurrence in patients with locally advanced esophageal cancer: a multi-institutional cohort study of 220 patients in Japan.
Topics: Cohort Studies; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Japan; Neoadjuvant Therapy; Positron-Emission Tomography | 2022 |
FDG PET/CT in a Case of Diffuse Esophageal Adenocarcinoma.
Topics: Adenocarcinoma; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals | 2022 |
Cardiac metabolic changes on
Topics: Esophageal Neoplasms; Fluorodeoxyglucose F18; Heart; Humans; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies | 2023 |
Retroperitoneal venous malformation mimicking a nodal metastasis in oesophageal cancer on staging F18-FDG PET/CT.
Topics: Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Sensitivity and Specificity | 2022 |
18F-FDG PET/CT as predictive and prognostic factor in esophageal cancer treated with combined modality treatment.
Topics: Carcinoma, Squamous Cell; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Tumor Burden | 2022 |
Measuring distance from the incisors to the esophageal cancer by FDG PET/CT: endoscopy as the reference.
Topics: Endoscopy, Gastrointestinal; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Incisor; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Retrospective Studies; Tomography, X-Ray Computed | 2022 |
Detecting Interval Distant Metastases With 18F-FDG PET/CT After Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Cancer.
Topics: Carcinoma, Squamous Cell; Chemoradiotherapy; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Second Primary; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Retrospective Studies | 2022 |
Significance of mid-radiotherapy 18F-fluorodeoxyglucose positron emission tomography/computed tomography in esophageal cancer.
Topics: Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Neoplasm Recurrence, Local; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Tumor Burden | 2022 |
Radiation Induced Liver Injury: Collateral Damage Radiologically Simulating Interval Metastasis in Carcinoma Esophagus; a Diagnostic Dilemma Resolved Through Liver Biopsy.
Topics: Aged; Biopsy; Carcinoma; Chemical and Drug Induced Liver Injury, Chronic; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorodeoxyglucose F18; Humans; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Radiation Injuries; Retrospective Studies | 2022 |
Prognostic value of quantitative parameters for esophageal squamous cell carcinoma determined by preoperative FDG-PET after trimodal therapy.
Topics: Carcinoma, Squamous Cell; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorodeoxyglucose F18; Glycolysis; Humans; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Tumor Burden | 2022 |
Combined 18 F-FDG PET/CT Radiomics and Sarcopenia Score in Predicting Relapse-Free Survival and Overall Survival in Patients With Esophagogastric Cancer.
Topics: Adenocarcinoma; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Neoplasm Recurrence, Local; Positron Emission Tomography Computed Tomography; Retrospective Studies; Sarcopenia; Stomach Neoplasms | 2022 |
Hypermetabolic Esophagitis Dessicans Superficialis Mimicking Esophageal Cancer on FDG PET/CT.
Topics: Aged, 80 and over; Esophageal Neoplasms; Esophagitis; Fluorodeoxyglucose F18; Humans; Male; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals | 2022 |
The prognostic effect of pretreatment 18F-FDG PET/CT metabolic parameters in locally advanced Esophageal Squamous Cell Carcinoma treated with definitive chemoradiotherapy.
Topics: Chemoradiotherapy; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Tumor Burden | 2022 |
Prognostic factors associated with
Topics: Carcinoma, Squamous Cell; Chemoradiotherapy; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Fluorodeoxyglucose F18; Humans; Neoadjuvant Therapy; Positron Emission Tomography Computed Tomography; Prognosis; Retrospective Studies | 2022 |
PET-directed combined modality therapy for gastroesophageal junction cancer: Results of the multicentre prospective MEMORI trial of the German Cancer Consortium (DKTK).
Topics: Adenocarcinoma; Combined Modality Therapy; Esophageal Neoplasms; Esophagogastric Junction; Fluorodeoxyglucose F18; Humans; Neoadjuvant Therapy; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals | 2022 |
The feasibility of dose escalation using intensity-modulated radiotherapy (IMRT) and intensity-modulated proton therapy (IMPT) with FDG PET/CT guided in esophageal cancer.
Topics: Esophageal Neoplasms; Feasibility Studies; Fluorodeoxyglucose F18; Humans; Organs at Risk; Positron Emission Tomography Computed Tomography; Proton Therapy; Radiation Injuries; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Intensity-Modulated | 2022 |
An incidental male breast cancer of
Topics: Breast Neoplasms; Breast Neoplasms, Male; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Male; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography | 2023 |
Quantitative CT analysis to predict esophageal fistula in patients with advanced esophageal cancer treated by chemotherapy or chemoradiotherapy.
Topics: Chemoradiotherapy; Esophageal Fistula; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Retrospective Studies; Tomography, X-Ray Computed; Ulcer | 2022 |
The prognostic value of positron emission tomography/computed tomography-based parameters in locally advanced esophageal squamous cell carcinoma treated with chemoradiation therapy.
Topics: Chemoradiotherapy; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorodeoxyglucose F18; Glycolysis; Humans; Positron Emission Tomography Computed Tomography; Prognosis; Prospective Studies; Radiopharmaceuticals; Retrospective Studies; Tumor Burden | 2022 |
The usefulness of the total metabolic tumor volume for predicting the postoperative recurrence of thoracic esophageal squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Retrospective Studies; Tumor Burden | 2022 |
Noninvasive Assessment of Human Epidermal Growth Factor Receptor 2 (HER2) in Esophagogastric Cancer Using
Topics: Breast Neoplasms; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Pilot Projects; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab | 2023 |
ACR Appropriateness Criteria® Staging and Follow-Up of Esophageal Cancer.
Topics: Esophageal Neoplasms; Evidence-Based Medicine; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Positron Emission Tomography Computed Tomography; Societies, Medical | 2022 |
Correlation Between Tumor Uptake on FDG-PET and Malignant Features in Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemotherapy Followed by Surgery.
Topics: Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorodeoxyglucose F18; Humans; Neoadjuvant Therapy; Positron-Emission Tomography | 2022 |
Automatic segmentation of esophageal gross tumor volume in
Topics: Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorodeoxyglucose F18; Humans; Positron Emission Tomography Computed Tomography; Tumor Burden | 2023 |
FDG PET/CT in a Case of Esophageal Extranodal NK/T-Cell Lymphoma, Nasal Type.
Topics: Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Lymphoma, Extranodal NK-T-Cell; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography | 2023 |
Role of 68Ga-FAPI-04 PET/CT in the Initial Staging of Esophageal Cancer.
Topics: Esophageal Neoplasms; Fluorodeoxyglucose F18; Gallium Radioisotopes; Humans; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals | 2023 |
Risk stratification of oesophageal squamous cell carcinoma using change in total lesion glycolysis and number of PET-positive lymph nodes.
Topics: Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorodeoxyglucose F18; Glycolysis; Humans; Lymph Nodes; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Risk Assessment; Tumor Burden | 2023 |
Metabolic tumour and nodal response to neoadjuvant chemotherapy on FDG PET-CT as a predictor of pathological response and survival in patients with oesophageal adenocarcinoma.
Topics: Adenocarcinoma; Cohort Studies; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Neoadjuvant Therapy; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals | 2023 |
Outcomes of solitary postoperative recurrence of esophageal squamous cell carcinoma diagnosed with FDG-PET/CT and treated with definitive radiation therapy.
Topics: Carcinoma, Squamous Cell; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorodeoxyglucose F18; Humans; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Recurrence; Retrospective Studies | 2023 |
Multiple staging investigations may not change management in patients with high-grade dysplasia or early esophageal adenocarcinoma.
Topics: Adenocarcinoma; Endosonography; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prospective Studies | 2023 |
Prognostic value of
Topics: Bone Marrow; Esophageal Neoplasms; Esophagectomy; Fluorodeoxyglucose F18; Humans; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies | 2023 |
External validation of 18 F-FDG PET-based radiomic models on identification of residual oesophageal cancer after neoadjuvant chemoradiotherapy.
Topics: Aged; Chemoradiotherapy; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Male; Neoadjuvant Therapy; Prospective Studies; Retrospective Studies | 2023 |
Identification of
Topics: Esophageal Neoplasms; Fluorodeoxyglucose F18; Glycolysis; Humans; Positron Emission Tomography Computed Tomography; Prognosis; Retrospective Studies; Tumor Burden; Weight Loss | 2023 |
Impact of retention index on the neoadjuvant chemotherapy effect and the prognosis in oesophageal cancer.
Topics: Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies | 2023 |
A Case of Primary Esophageal Sarcomatoid Carcinoma Detected by 18F-FDG PET/CT.
Topics: Carcinoma; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Positron Emission Tomography Computed Tomography | 2023 |
Elevated FAPI Activity in Ulcerative Fungal Esophagitis.
Topics: Biological Transport; Diagnosis, Differential; Esophageal Neoplasms; Esophagitis; Fluorodeoxyglucose F18; Humans; Positron Emission Tomography Computed Tomography | 2023 |
Giant Fibrovascular Polyp Mimicking Esophageal Malignancy on 18 F-FDG PET/CT.
Topics: Endoscopy; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Polyps; Positron Emission Tomography Computed Tomography | 2023 |
Condition control training-based ConVMLP-ResU-Net for semantic segmentation of esophageal cancer in
Topics: Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Positron Emission Tomography Computed Tomography; Semantics | 2023 |
Baseline and interim [18F]FDG-PET/MRI to assess treatment response and survival in patients with M0 esophageal squamous cell carcinoma treated by curative-intent therapy.
Topics: Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Tumor Burden | 2023 |
Topics: B7-H1 Antigen; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorodeoxyglucose F18; Humans; Positron Emission Tomography Computed Tomography; Prospective Studies | 2023 |
Role of intravoxel incoherent motion parameters in gastroesophageal cancer: relationship with 18F-FDG-positron emission tomography, computed tomography perfusion and magnetic resonance perfusion imaging parameters.
Topics: Adult; Aged; Aged, 80 and over; Blood Circulation; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multimodal Imaging; Perfusion Imaging; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Tumor Burden | 2021 |
Lymph Node Metastases Diagnosed by
Topics: Aged; Carcinoma, Squamous Cell; Chemoradiotherapy; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Prognosis; Treatment Outcome | 2019 |
Clinical significance of pulmonary nodules in decision-making and management of patients diagnosed with esophageal cancer.
Topics: Chemoradiotherapy; Clinical Decision-Making; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Humans; Incidental Findings; Lung Neoplasms; Male; Middle Aged; Multiple Pulmonary Nodules; Prognosis; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed; United Kingdom | 2020 |
Predominance and homogeneity patterns of physiological FDG accumulation in thoracic and lumbar vertebrae: suspected mechanism of "bone pseudometastasis" on FDG-PET in Japanese patients with esophageal cancer.
Topics: Aged; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Lumbar Vertebrae; Middle Aged; Neoplasm Metastasis; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Thoracic Vertebrae | 2020 |
Esophageal Adenocarcinoma With Subscalp Metastasis as the First Manifestation Detected by 18F-FDG PET/CT.
Topics: Adenocarcinoma; Aged; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals | 2020 |
Association of the primary tumor's SUVmax with survival after surgery for clinical stage IA esophageal cancer: a single-center retrospective study.
Topics: Aged; Aged, 80 and over; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Female; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Male; Middle Aged; Positron-Emission Tomography; Preoperative Care; Prognosis; Radiopharmaceuticals; Retrospective Studies; ROC Curve | 2020 |
Complete Metabolic Response Assessed by FDG PET/CT to Paclitaxel-Ramucirumab in Patients With Metastatic Gastroesophageal Junction Cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorodeoxyglucose F18; Humans; Middle Aged; Paclitaxel; Positron Emission Tomography Computed Tomography; Ramucirumab | 2020 |
Commentary: Esophageal squamous cell carcinoma: A disease requiring more research.
Topics: Carcinoma, Squamous Cell; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorodeoxyglucose F18; Humans; Positron Emission Tomography Computed Tomography | 2020 |
Does [18F] fluorodeoxyglucose-positron emission tomography/computed tomography have a role in cervical nodal staging for esophageal squamous cell carcinoma?
Topics: Aged; China; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Female; Fluorodeoxyglucose F18; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Predictive Value of Tests; Prospective Studies; Radiopharmaceuticals | 2020 |
Commentary: Fluorodeoxyglucose-positron emission tomography/computed tomography for cervical adenopathy in esophageal carcinoma, an option for the selective surgeon.
Topics: Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorodeoxyglucose F18; Humans; Lymphadenopathy; Surgeons | 2020 |
Tumor SUVs on 18F-FDG PET/CT and Aggressive Pathological Features in Esophageal Squamous Cell Carcinoma.
Topics: Aged; Biological Transport; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Positron Emission Tomography Computed Tomography; Retrospective Studies; ROC Curve | 2020 |
Rare Esophageal Leptomeningeal Metastases Detected on 18F-FDG PET/CT.
Topics: Adenocarcinoma; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Male; Meningeal Neoplasms; Middle Aged; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals | 2020 |
Combined tumor plus nontumor interim FDG-PET parameters are prognostic for response to chemoradiation in squamous cell esophageal cancer.
Topics: Aged; Chemoradiotherapy; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Progression-Free Survival; Radiopharmaceuticals; Retrospective Studies; Survival Rate | 2020 |
Assessment of tumor response to definitive chemoradiotherapy and prognosis prediction in patients with esophageal cancer judged by PET response criteria in solid tumors: multicenter study in Japan.
Topics: Adult; Aged; Aged, 80 and over; Chemoradiotherapy; Disease-Free Survival; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Japan; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Retrospective Studies; Treatment Outcome; Tumor Burden | 2020 |
Definitive chemoradiotherapy for squamous cell carcinoma of the esophagus: outcomes for borderline-resectable disease.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bronchoscopy; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Esophageal Neoplasms; Esophagus; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Retrospective Studies; Treatment Outcome | 2020 |
Clinical Implications of 18F-FDG PET/CT in Malignant Glomus Tumors of the Esophagus.
Topics: Esophageal Neoplasms; Fluorodeoxyglucose F18; Glomus Tumor; Humans; Male; Middle Aged; Neoplasm Staging; Positron Emission Tomography Computed Tomography | 2020 |
Predictions of Pathological Features and Recurrence Based on FDG-PET Findings of Esophageal Squamous Cell Carcinoma after Trimodal Therapy.
Topics: Chemoradiotherapy; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorodeoxyglucose F18; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals | 2020 |
ASO Author Reflections: Prediction of Pathological Features of Esophageal Cancer Using FDG-PET.
Topics: Esophageal Neoplasms; Esophagectomy; Fluorodeoxyglucose F18; Humans; Neoadjuvant Therapy; Positron-Emission Tomography; Radiopharmaceuticals; Rare Diseases | 2020 |
Prognostic value of lymph node to primary tumor standardized uptake value ratio in unresectable esophageal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Chemoradiotherapy; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Lymph Nodes; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Prognosis; Proportional Hazards Models; Radiopharmaceuticals; Retrospective Studies; ROC Curve; Treatment Outcome | 2020 |
Clinical response assessment on DW-MRI compared with FDG-PET/CT after neoadjuvant chemoradiotherapy in patients with oesophageal cancer.
Topics: Chemoradiotherapy; Diffusion Magnetic Resonance Imaging; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Neoadjuvant Therapy; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals | 2021 |
Pulmonary artery enlargement on routine staging
Topics: Aged; Aorta; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Hypertension, Pulmonary; Hypertrophy; Lung Neoplasms; Male; Positron Emission Tomography Computed Tomography; Pulmonary Artery; Radiopharmaceuticals; Retrospective Studies; Sex Factors | 2020 |
Total Lesion Glycolysis Ratio in Positron Emission Tomography/Computed Tomography Images During Neoadjuvant Chemotherapy Can Predict Pathological Tumor Regression Grade and Prognosis in Patients with Locally Advanced Squamous Cell Carcinoma of the Esophag
Topics: Carcinoma, Squamous Cell; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorodeoxyglucose F18; Glycolysis; Humans; Neoadjuvant Therapy; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Tumor Burden | 2021 |
ASO Author Reflections: Total Lesion Glycolysis Ratio in Positron Emission Tomography and Computed Tomography Images During Neoadjuvant Chemotherapy: Usefulness and Perspectives as an Evaluation Tool for the Effect of Neoadjuvant Treatment on Esophageal S
Topics: Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Fluorodeoxyglucose F18; Glycolysis; Humans; Neoadjuvant Therapy; Positron-Emission Tomography; Radiopharmaceuticals; Treatment Outcome | 2020 |
Incidental Detection of Elastofibroma Dorsi With 68Ga-FAPI-46 and 18F-FDG PET/CT in a Patient With Esophageal Cancer.
Topics: Aged; Carcinoma, Squamous Cell; Elastic Tissue; Esophageal Neoplasms; Esophagectomy; Fluorodeoxyglucose F18; Humans; Incidental Findings; Male; Neoplasm Staging; Neoplasms, Connective Tissue; Positron Emission Tomography Computed Tomography; Quinolines | 2021 |
One-by-One Comparison of Lymph Nodes Between 18F-FDG Uptake and Pathological Diagnosis in Esophageal Cancer.
Topics: Aged; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Sensitivity and Specificity | 2020 |
Role of 18F-FDG PET/CT in restaging of esophageal cancer after curative-intent surgical resection.
Topics: Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Staging; Retrospective Studies | 2020 |
The superiority of [
Topics: Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorodeoxyglucose F18; Gallium Radioisotopes; Humans; Positron Emission Tomography Computed Tomography; Quinolines | 2021 |
Fat density is a novel prognostic marker in patients with esophageal cancer.
Topics: Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Positron Emission Tomography Computed Tomography; Prognosis; Retrospective Studies | 2020 |
Utility of positron emission-computed tomography for predicting pathological response in resectable oesophageal squamous cell carcinoma after neoadjuvant chemoradiation.
Topics: Chemoradiotherapy; Electrons; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorodeoxyglucose F18; Humans; Neoadjuvant Therapy; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Quality of Life; Radiopharmaceuticals; Reproducibility of Results | 2020 |
A malignant birthmark detected by
Topics: Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals | 2021 |
Novel 5-point 18-FDG-PET/CT visual scoring system for assessing treatment response in patients with oesophageal or gastro-oesophageal junction carcinoma.
Topics: Carcinoma, Squamous Cell; Esophageal Neoplasms; Esophagogastric Junction; Fluorodeoxyglucose F18; Humans; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Reproducibility of Results; Retrospective Studies; Stomach Neoplasms | 2021 |
A FDG-PET radiomics signature detects esophageal squamous cell carcinoma patients who do not benefit from chemoradiation.
Topics: Adult; Aged; Aged, 80 and over; Chemoradiotherapy; Disease-Free Survival; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Retrospective Studies; Survival Analysis; Treatment Failure | 2020 |
Use of
Topics: Adult; Aged; Chemoradiotherapy; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorodeoxyglucose F18; Humans; India; Male; Middle Aged; Neoadjuvant Therapy; Polymerase Chain Reaction; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Retrospective Studies; ROC Curve; Sensitivity and Specificity; Survival Rate | 2021 |
Addition of HER2 and CD44 to
Topics: Chemoradiotherapy; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Hyaluronan Receptors; Neoadjuvant Therapy; Positron-Emission Tomography; Radiopharmaceuticals; Receptor, ErbB-2; Treatment Outcome | 2021 |
Complete pathological response (pCR) in gastroesophageal cancer: Correlation with metabolic response.
Topics: Adenocarcinoma; Aged; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoadjuvant Therapy; Positron Emission Tomography Computed Tomography; Preoperative Care; Radiopharmaceuticals; Retrospective Studies; Sensitivity and Specificity; Treatment Outcome; Watchful Waiting | 2020 |
Incremental value of endoscopic brush cytology in response assessment after chemo-irradiation for Esophageal cancer.
Topics: Adult; Aged; Endoscopy; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Retrospective Studies | 2022 |
Pretreatment CT and
Topics: Chemoradiotherapy; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Neoadjuvant Therapy; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Retrospective Studies | 2021 |
Prognostic value of 18F-fluorodeoxyglucose PET/computed tomography metabolic parameters measured in the primary tumor and suspicious lymph nodes before neoadjuvant therapy in patients with esophageal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Positron Emission Tomography Computed Tomography; Prognosis | 2021 |
Impact of PET/CT on management of patients with esophageal cancer - results from a PET/CT registry study.
Topics: Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prognosis; Registries | 2021 |
Efficacy of cell proliferation imaging with 4DST PET/CT for predicting the prognosis of patients with esophageal cancer: a comparison study with FDG PET/CT.
Topics: Aged; Cell Proliferation; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Middle Aged; Positron Emission Tomography Computed Tomography; Prognosis; Prospective Studies; Retrospective Studies; Tumor Burden | 2021 |
An Unusual Case of Esophageal Carcinosarcoma on 18F-FDG PET/CT.
Topics: Carcinosarcoma; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Positron Emission Tomography Computed Tomography | 2021 |
Pentixafor PET/CT for imaging of chemokine receptor 4 expression in esophageal cancer - a first clinical approach.
Topics: Aged; Coordination Complexes; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Molecular Imaging; Peptides, Cyclic; Positron Emission Tomography Computed Tomography; Receptors, CXCR4; Retrospective Studies | 2021 |
Incidentally Diagnosed Esophago-Pulmonary Fistula on 18F-FDG PET/CT in a Case of Carcinoma Esophagus: A Life-Threatening Emergency.
Topics: Emergencies; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Incidental Findings; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Respiratory Tract Fistula | 2021 |
Value of regular endosonography and [18F]fluorodeoxyglucose PET-CT after surgery for gastro-oesophageal junction, stomach or pancreatic cancer.
Topics: Adenocarcinoma; Aged; Biopsy, Fine-Needle; Endosonography; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Stomach Neoplasms | 2021 |
Intratumoral Metabolic Heterogeneity and Other Quantitative
Topics: Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Prognosis; Retrospective Studies | 2021 |
Motion-compensated FDG PET/CT for oesophageal cancer.
Topics: Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Lymphatic Metastasis; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals | 2021 |
Predicting tumor response and prognosis to neoadjuvant chemotherapy in esophageal squamous cell carcinoma patients using PERCIST: a multicenter study in Japan.
Topics: Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Japan; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Tomography, X-Ray Computed | 2021 |
Difficulties encountered in the diagnosis of primary esophageal malignant melanoma by 18F-fluorodeoxyglucose positron emission tomography/computed tomography: a case report.
Topics: Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Melanoma; Middle Aged; Positron Emission Tomography Computed Tomography; Skin Neoplasms | 2021 |
Prognostic Significance of Pretreatment Staging With 18F-FDG PET in Esophageal Cancer: A Nationwide Population-Based Study.
Topics: Adult; Aged; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Proportional Hazards Models | 2021 |
Good prediction of treatment responses to neoadjuvant chemoradiotherapy for esophageal cancer based on preoperative inflammatory status and tumor glucose metabolism.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Biomarkers; Carcinoma, Squamous Cell; Chemoradiotherapy; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Glucose; Humans; Inflammation; Leukocyte Count; Lymphocytes; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Staging; Neutrophils; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Sex Factors; Survival Analysis; Treatment Outcome | 2021 |
Comparison of endoscopically determined gross tumor volume and metabolic tumor volume in esophageal cancer.
Topics: Aged; Aged, 80 and over; Endosonography; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fiducial Markers; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Retrospective Studies; Tumor Burden | 2021 |
[Prediction of pathologic complete response in esophageal cancer after neoadjuvant radiochemotherapy using FDG-PET/CT and diffusion-weighted MRI].
Topics: Chemoradiotherapy; Diffusion Magnetic Resonance Imaging; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Neoadjuvant Therapy; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography | 2021 |
Combining Preoperative Immunoinflammatory Scores and
Topics: Aged; Biomarkers; Blood Platelets; C-Reactive Protein; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Humans; Inflammation; Kaplan-Meier Estimate; Lymphocytes; Male; Middle Aged; Neutrophils; Positron-Emission Tomography; Preoperative Period; Prognosis; Retrospective Studies; Salvage Therapy; Serum Albumin | 2021 |
PET-Uptake Reduction into Lymph Nodes After Neoadjuvant Therapy is Highly Predictive of Prognosis for Patients Who have Thoracic Esophageal Squamous Cell Carcinoma Treated with Chemoradiotherapy Plus Esophagectomy.
Topics: Carcinoma, Squamous Cell; Chemoradiotherapy; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Neoadjuvant Therapy; Prognosis; Radiopharmaceuticals; Treatment Outcome | 2022 |
Trimodality therapy for locally advanced esophageal squamous cell carcinoma: the role of volume-based PET/CT in patient management and prognostication.
Topics: Chemoradiotherapy; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorodeoxyglucose F18; Humans; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Tumor Burden | 2022 |
Colonic Metastasis From Esophageal Squamous Cell Carcinoma Demonstrated With 18F-FDG PET/CT.
Topics: Carcinoma, Squamous Cell; Colonic Neoplasms; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Positron Emission Tomography Computed Tomography | 2017 |
18F-deoxyglucose positron emission tomography/computed tomography to predict local failure in esophageal squamous cell carcinoma.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Treatment Failure | 2017 |
Involved-field irradiation concurrently combined with nedaplatin/5-fluorouracil for inoperable esophageal cancer on basis of 18FDG-PET scans: A long follow-up results of phase II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Esophageal Neoplasms; Fluorodeoxyglucose F18; Fluorouracil; Follow-Up Studies; Humans; Organoplatinum Compounds; Positron-Emission Tomography | 2017 |
Performance of 18-fluoro-2-deoxyglucose positron emission tomography for esophageal cancer screening.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Mass Screening; Middle Aged; Positron-Emission Tomography; Predictive Value of Tests; Retrospective Studies | 2017 |
[Radiotherapy volume delineation based on (
Topics: Aged; Aged, 80 and over; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Retrospective Studies | 2017 |
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Chemoradiotherapy; Combined Modality Therapy; Disease-Free Survival; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Induction Chemotherapy; Male; Middle Aged; Positron-Emission Tomography; Propensity Score; Prospective Studies; Radiopharmaceuticals; Survival Analysis | 2017 |
Significance of baseline FDG-PET/CT scan as a method of staging regional lymph nodes in patients with operable distal oesophageal or gastroesophageal junction adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Neoplasm Recurrence, Local; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies | 2017 |
Predictive value of nodal maximum standardized uptake value of pretreatment [18F]fluorodeoxyglucose positron emission tomography imaging in patients with esophageal cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Chemoradiotherapy; Disease-Free Survival; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Female; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Male; Middle Aged; Positron-Emission Tomography; Predictive Value of Tests; Prognosis; Radiopharmaceuticals; Reference Values; Retrospective Studies; Treatment Outcome | 2017 |
Is
Topics: Adult; Aged; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; ROC Curve; Tomography, X-Ray Computed | 2017 |
Increased FDG uptake on late-treatment PET in non-tumour-affected oesophagus is prognostic for pathological complete response and disease recurrence in patients undergoing neoadjuvant radiochemotherapy.
Topics: Carcinoma; Chemoradiotherapy, Adjuvant; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Positron-Emission Tomography; Radiopharmaceuticals | 2017 |
Adaptive region-growing with maximum curvature strategy for tumor segmentation in
Topics: Algorithms; Calibration; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Lymphoma, Non-Hodgkin; Phantoms, Imaging; Positron-Emission Tomography | 2017 |
Importance of positron emission tomography for assessing the response of primary and metastatic lesions to induction treatments in T4 esophageal cancer.
Topics: Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Induction Chemotherapy; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Treatment Outcome | 2017 |
Radiation-Induced Cardiomyopathy Incidentally Detected on Oncology
Topics: Cardiomyopathies; Deglutition Disorders; Echocardiography; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Incidental Findings; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Radiotherapy | 2018 |
FDG PET/CT in 2 Cases of Renal Metastasis From Esophageal Squamous Cell Carcinoma.
Topics: Carcinoma, Squamous Cell; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorodeoxyglucose F18; Humans; Kidney Neoplasms; Male; Middle Aged; Positron Emission Tomography Computed Tomography | 2017 |
Efficacy and Safety of Neoadjuvant Chemoradiotherapy Following Esophagectomy with Japanese-style Extended 3-Field Lymphadenectomy for Thoracic Esophageal Cancer.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Female; Fluorodeoxyglucose F18; Humans; Japan; Lymph Node Excision; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Time Factors; Treatment Outcome | 2017 |
Correlation between functional imaging markers derived from diffusion-weighted MRI and 18F-FDG PET/CT in esophageal cancer.
Topics: Aged; Biological Transport; Biomarkers, Tumor; Diffusion Magnetic Resonance Imaging; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Tumor Burden | 2018 |
Radiation-induced liver injury mimicking liver metastases on FDG-PET-CT after chemoradiotherapy for esophageal cancer : A retrospective study and literature review.
Topics: Adenocarcinoma; Adult; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Esophageal Neoplasms; False Positive Reactions; Female; Fluorodeoxyglucose F18; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Radiation Injuries; Retrospective Studies | 2018 |
Whole-body total lesion glycolysis is an independent predictor in patients with esophageal cancer treated with definitive chemoradiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Chemoradiotherapy; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Glycolysis; Humans; Male; Middle Aged; Multivariate Analysis; Positron Emission Tomography Computed Tomography; Prognosis; Proportional Hazards Models; Radiopharmaceuticals; Retrospective Studies; Tumor Burden | 2018 |
Topics: Adenocarcinoma; Aged; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Positron Emission Tomography Computed Tomography; Predictive Value of Tests; Radiopharmaceuticals; Retrospective Studies; Sensitivity and Specificity; Tomography, X-Ray Computed | 2018 |
18F-FAMT PET Is Useful to Distinguish between Specific Uptake and Nonspecific Uptake Compared to 18F-Flourodeoxyglucose Position Emission Tomography in Esophageal Cancer Patients.
Topics: Adult; Aged; Aged, 80 and over; alpha-Methyltyrosine; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals | 2018 |
Solitary Orbital Metastasis in Carcinoma Esophagus: Findings on Serial 18F-FDG PET/CT Scans.
Topics: Aged; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Male; Orbital Neoplasms; Positron Emission Tomography Computed Tomography; Time Factors | 2018 |
Favorable versus unfavorable prognostic groups by post-chemoradiation FDG-PET imaging in node-positive esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy.
Topics: Carcinoma, Squamous Cell; Chemoradiotherapy; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prognosis; Retrospective Studies | 2018 |
Pilot study of serial FLT and FDG-PET/CT imaging to monitor response to neoadjuvant chemoradiotherapy of esophageal adenocarcinoma: correlation with histopathologic response.
Topics: Adenocarcinoma; Aged; Chemoradiotherapy, Adjuvant; Esophageal Neoplasms; Esophagectomy; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Minimally Invasive Surgical Procedures; Pilot Projects; Positron Emission Tomography Computed Tomography; Prospective Studies; Radiopharmaceuticals | 2018 |
Neoadjuvant chemoradiation for esophageal cancer : Surgery improves locoregional control while response based on FDG-PET/CT predicts survival.
Topics: Adult; Aged; Chemoradiotherapy, Adjuvant; Combined Modality Therapy; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Positron Emission Tomography Computed Tomography | 2018 |
Pulmonary actinomycosis mimicking a lung metastasis from esophageal cancer; a case report.
Topics: Actinomycosis; Aged; Biopsy, Needle; Diagnosis, Differential; Endoscopy, Digestive System; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Neoplasm Metastasis; Pleural Effusion; Pneumonia, Bacterial; Positron Emission Tomography Computed Tomography | 2018 |
Active Bone Marrow With Focal FDG Accumulation Mimicking Bone Metastasis With a Case of Early Esophageal Cancer.
Topics: Aged; Biological Transport; Bone Marrow; Bone Neoplasms; Esophageal Neoplasms; False Positive Reactions; Fluorodeoxyglucose F18; Humans; Male; Positron Emission Tomography Computed Tomography; Time Factors | 2018 |
FDG-Avid Focal Liver Reaction From Proton Therapy in a Patient With Primary Esophageal Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Liver Neoplasms; Male; Positron Emission Tomography Computed Tomography; Proton Therapy; Radiopharmaceuticals | 2018 |
Preoperative Nomogram to Risk Stratify Patients for the Benefit of Trimodality Therapy in Esophageal Adenocarcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Signet Ring Cell; Chemoradiotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Nomograms; Oxaliplatin; Positron Emission Tomography Computed Tomography; Preoperative Period; Radiopharmaceuticals; Radiotherapy Dosage; Risk Assessment; Sex Factors; Survival Rate | 2018 |
Tumor response to neoadjuvant chemotherapy in patients with esophageal cancer assessed with CT and FDG-PET/CT - RECIST 1.1 vs. PERCIST 1.0.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Fluorouracil; Glycolysis; Humans; Infusions, Intravenous; Male; Middle Aged; Neoadjuvant Therapy; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Response Evaluation Criteria in Solid Tumors; Sensitivity and Specificity; Treatment Outcome; Tumor Burden | 2018 |
Topics: Breast Neoplasms; Carcinoma, Ductal; Carcinoma, Lobular; Esophageal Neoplasms; Esophagoscopy; Female; Fluorodeoxyglucose F18; Humans; Incidental Findings; Lymphatic Metastasis; Mammography; Middle Aged; Neoplasm Staging; Neoplasms, Multiple Primary; Positron Emission Tomography Computed Tomography; Ultrasonography, Mammary | 2018 |
A comparative study of quantitative assessment with fluorine-18-fluorodeoxyglucose positron-emission tomography and endoscopic ultrasound in oesophageal cancer.
Topics: Aged; Endosonography; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Positron Emission Tomography Computed Tomography; Tumor Burden | 2018 |
Multimodal Imaging of Pathologic Response to Chemoradiation in Esophageal Cancer.
Topics: Aged; Chemoradiotherapy; Diffusion Magnetic Resonance Imaging; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Glycolysis; Humans; Male; Middle Aged; Multimodal Imaging; Positron Emission Tomography Computed Tomography; Prospective Studies | 2018 |
Total FDG lesion number on PET/CT predicts survival of esophageal carcinoma patients with recurrence following curative surgery.
Topics: Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Prognosis; Recurrence; Retrospective Studies; Survival Analysis | 2020 |
Radiotherapy volume delineation using 18F-FDG-PET/CT modifies gross node volume in patients with oesophageal cancer.
Topics: Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Chemoradiotherapy; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiotherapy Planning, Computer-Assisted; Retrospective Studies; Tumor Burden | 2018 |
Metabolic Tumor Volume Change Predicts Long-term Survival and Histological Response to Preoperative Chemotherapy in Locally Advanced Esophageal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoadjuvant Therapy; Positron Emission Tomography Computed Tomography; Predictive Value of Tests; Radiopharmaceuticals; Survival Rate; Treatment Outcome; Tumor Burden | 2019 |
Topics: Aged; Clinical Decision-Making; Decision Trees; Disease Management; Endoscopic Mucosal Resection; Esophageal Neoplasms; Esophagectomy; Esophagoscopy; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography | 2018 |
Patterns of Failure Following Dose-escalated Chemoradiotherapy for Fluorodeoxyglucose Positron Emission Tomography Staged Squamous Cell Carcinoma of the Oesophagus.
Topics: Adult; Aged; Chemoradiotherapy; Disease Progression; Disease-Free Survival; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Dosage; Retrospective Studies; Survival Rate; Treatment Failure | 2018 |
Clinical significance of SUVmax on preoperative 18F-fluorodeoxyglucose positron emission tomography in patients who underwent R0-esophagectomy for esophageal cancer.
Topics: Adult; Aged; Aged, 80 and over; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Positron-Emission Tomography | 2018 |
Bone Sequestration as a Consequence of Esophageal Carcinoma Metastasis Detected by 18F-FDG PET/CT.
Topics: Carcinoma, Squamous Cell; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Metastasis; Osteolysis; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals | 2018 |
Accurate FDG PET tumor segmentation using the peritumoral halo layer method: a study in patients with esophageal squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results | 2018 |
Texture analysis of computed tomography data using morphologic and metabolic delineation of esophageal cancer-relation to tumor type and neoadjuvant therapy response.
Topics: Adenocarcinoma; Aged; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoadjuvant Therapy; Positron-Emission Tomography; Prognosis; Radiographic Image Interpretation, Computer-Assisted; Radiopharmaceuticals; Retrospective Studies; Statistics, Nonparametric; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden | 2019 |
Pediatric Esophageal Squamous Cell Carcinoma Staged With 18F-FDG PET/CT.
Topics: Adolescent; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Male; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals | 2018 |
Positron-Emission Tomography Scan-Directed Chemoradiation for Esophageal Squamous Cell Carcinoma: No Benefit for a Change in Chemotherapy in Positron-Emission Tomography Nonresponders.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Induction Chemotherapy; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Survival Rate; Young Adult | 2019 |
Ectopic Papillary Thyroid Carcinoma Mimicking Esophageal Cancer in FDG PET: A Case Report.
Topics: Adult; Carcinoma, Papillary; Choristoma; Diagnosis, Differential; Esophageal Neoplasms; Esophagus; Female; Fluorodeoxyglucose F18; Humans; Positron-Emission Tomography; Radiopharmaceuticals; Thyroid Neoplasms | 2019 |
A Diagnostic Algorithm That Combines Quantitative 18F-FDG PET Parameters and Contrast-Enhanced CT Improves Posttherapeutic Locoregional Restaging and Prognostication of Survival in Patients With Esophageal Cancer.
Topics: Adult; Aged; Algorithms; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals | 2019 |
Positron Emission Tomography 18F-Fluorodeoxyglucose Uptake Correlates with KRAS and EMT Gene Signatures in Operable Esophageal Adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Gene Ontology; Glycolysis; Humans; Male; Middle Aged; Organic Cation Transport Proteins; Positron-Emission Tomography; Proto-Oncogene Proteins p21(ras) | 2018 |
Baseline 18F-FDG PET/CT as predictor of the pathological response to neoadjuvant therapy in esophageal cancer: A retrospective study.
Topics: Aged; Chemoradiotherapy; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoadjuvant Therapy; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies | 2018 |
Post-chemoradiotherapy FDG PET with qualitative interpretation criteria for outcome stratification in esophageal squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Chemoradiotherapy; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Outcome Assessment, Health Care; Positron Emission Tomography Computed Tomography; Proportional Hazards Models; Retrospective Studies; Tomography, X-Ray Computed | 2019 |
Early metabolic response to chemoradiotherapy by interim FDG PET/CT is associated with better overall survival and histological response in esophageal cancers.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Chemoradiotherapy; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; France; Humans; Male; Middle Aged; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Survival Analysis; Treatment Outcome; Young Adult | 2019 |
Application of positron emission tomography imaging to personalize esophagogastric cancer care.
Topics: Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Neoplasm Staging; Positron-Emission Tomography; Precision Medicine; Radiopharmaceuticals; Sensitivity and Specificity; Stomach Neoplasms; Treatment Outcome | 2019 |
Clinical Significance of
Topics: Carcinoma, Squamous Cell; Chemoradiotherapy; Combined Modality Therapy; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lymph Nodes; Male; Middle Aged; Neoadjuvant Therapy; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Survival Rate | 2019 |
Metabolic parameters of sequential 18F-FDG PET/CT predict overall survival of esophageal cancer patients treated with (chemo-) radiation.
Topics: Adult; Aged; Aged, 80 and over; Chemoradiotherapy; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Prognosis; Proportional Hazards Models; Retrospective Studies | 2019 |
Perioperative EOX treatment in operable locally advanced gastroesophageal adenocarcinoma: Prediction of tumor response by FDG -PET and histopathology.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Epirubicin; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Male; Middle Aged; Oxaliplatin; Perioperative Care; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Stomach Neoplasms; Survival Rate; Young Adult | 2019 |
FDG-PET might not contribute to improving survival in patients with locally advanced inoperable esophageal cancer.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Chemoradiotherapy; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Survival Rate; Tomography, X-Ray Computed; Young Adult | 2019 |
Impact of hybrid FDG-PET/CT on gross tumor volume definition of cervical esophageal cancer: reducing interobserver variation.
Topics: Aged; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Observer Variation; Positron Emission Tomography Computed Tomography; Tumor Burden | 2019 |
Utility of fiducial markers for target positioning in proton radiotherapy of oesophageal carcinoma.
Topics: Aged; Cohort Studies; Esophageal Neoplasms; Fiducial Markers; Fluorodeoxyglucose F18; Gold; Humans; Male; Middle Aged; Positron-Emission Tomography; Proton Therapy; Protons; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Image-Guided; Retrospective Studies | 2019 |
[Role of 18F-FDG PET/CT in comparison with CECT for whole-body assessment of patients with esophageal cancer.]
Topics: Adult; Aged; Aged, 80 and over; Contrast Media; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Reproducibility of Results; Retrospective Studies; Sensitivity and Specificity; Tomography, X-Ray Computed | 2019 |
Cyclo-oxygenase-2 expression is associated with mean standardised uptake value on 18F-Fluorodeoxyglucose positron emission tomography in oesophageal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Biomarkers; Cyclooxygenase 2; Esophageal Neoplasms; Esophagus; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pilot Projects; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies | 2019 |
Chemoradiation induces epithelial-to-mesenchymal transition in esophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Line, Tumor; Chemoradiotherapy; Disease Progression; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Esophageal Mucosa; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Lymph Nodes; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Positron-Emission Tomography; Primary Cell Culture; Progression-Free Survival; Signal Transduction; Transforming Growth Factor beta; Treatment Outcome; Xenograft Model Antitumor Assays | 2019 |
Bone Pseudometastasis on 18F-FDG PET in Japanese Patients With Esophageal Cancer.
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Diagnosis, Differential; Esophageal Neoplasms; False Positive Reactions; Female; Fluorodeoxyglucose F18; Humans; Japan; Magnetic Resonance Imaging; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Retrospective Studies | 2019 |
Diagnostic value of surveillance
Topics: Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasms, Second Primary; Recurrence; Retrospective Studies; Treatment Outcome | 2019 |
Assessing radiomic feature robustness to interpolation in
Topics: Adenocarcinoma; Algorithms; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Phantoms, Imaging; Positron-Emission Tomography; Radiopharmaceuticals | 2019 |
Temporal validation of metabolic nodal response of esophageal cancer to neoadjuvant chemotherapy as an independent predictor of unresectable disease, survival, and recurrence.
Topics: Aged; Disease-Free Survival; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Positron Emission Tomography Computed Tomography; Predictive Value of Tests; Proportional Hazards Models; Radiopharmaceuticals; Reproducibility of Results; Treatment Outcome | 2019 |
Staging and Response Evaluation to Neo-Adjuvant Chemoradiation in Esophageal Cancers Using 18FDG PET/ CT with Standardized Protocol.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Prospective Studies; Radiopharmaceuticals | 2019 |
ASO Author Reflections: Evaluation of Lymph Nodes by FDG-PET for Esophageal Cancer.
Topics: Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Positron-Emission Tomography; Radiopharmaceuticals | 2019 |
Ineffectiveness of ¹⁸F-fluorodeoxyglucose positron emission tomography in the evaluation of tumor response after completion of neoadjuvant chemoradiation in esophageal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Data Interpretation, Statistical; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Treatment Outcome | 2013 |
Diagnostic accuracy of lymph node metastasis depends on metabolic activity of the primary lesion in thoracic squamous esophageal cancer.
Topics: Adult; Aged; Aged, 80 and over; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Neoplasms, Squamous Cell; Positron-Emission Tomography; Retrospective Studies; Sensitivity and Specificity; Thorax; Tomography, X-Ray Computed | 2013 |
Prediction of outcome with FDG-PET in definitive chemoradiotherapy for esophageal cancer.
Topics: Adult; Aged; Aged, 80 and over; Chemoradiotherapy; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Japan; Male; Middle Aged; Positron-Emission Tomography; Prevalence; Prognosis; Radiopharmaceuticals; Reproducibility of Results; Retrospective Studies; Risk Assessment; Sensitivity and Specificity; Survival Rate; Treatment Outcome | 2013 |
Assessment of diffusion-weighted MRI and 18F-fluoro-deoxyglucose PET/CT in monitoring early response to neoadjuvant chemotherapy in adenocarcinoma of the esophagogastric junction.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Diffusion Magnetic Resonance Imaging; Drug Monitoring; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Neoadjuvant Therapy; Neoplasm Staging; Prognosis; Prospective Studies; Radionuclide Imaging; Radiopharmaceuticals; Treatment Outcome | 2013 |
Time in radiation oncology - keep it short!
Topics: Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Multimodal Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Time-to-Treatment; Tomography, X-Ray Computed | 2013 |
[Penile metastasis from esophageal cancer: a case report].
Topics: Carcinoma, Squamous Cell; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Multimodal Imaging; Penile Neoplasms; Positron-Emission Tomography; Tomography, X-Ray Computed | 2013 |
Prognostic significance of 18F-fluorodeoxyglucose positron emission tomography (PET)-based parameters in neoadjuvant chemoradiation treatment of esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Chemoradiotherapy; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Prospective Studies; Radiopharmaceuticals; Survival Rate | 2013 |
Evaluation of strategies towards harmonization of FDG PET/CT studies in multicentre trials: comparison of scanner validation phantoms and data analysis procedures.
Topics: Colorectal Neoplasms; Data Interpretation, Statistical; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Multicenter Studies as Topic; Multimodal Imaging; Phantoms, Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Tomography Scanners, X-Ray Computed; Tomography, X-Ray Computed | 2013 |
Real-time FDG PET/CT-guided bone biopsy in a patient with two primary malignancies.
Topics: Aged, 80 and over; Bone Neoplasms; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Image-Guided Biopsy; Male; Multimodal Imaging; Positron-Emission Tomography; Tomography, X-Ray Computed | 2013 |
Robustness of intratumour ¹⁸F-FDG PET uptake heterogeneity quantification for therapy response prediction in oesophageal carcinoma.
Topics: Aged; Aged, 80 and over; Carcinoma; Data Interpretation, Statistical; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden | 2013 |
Evaluating the role of fluorodeoxyglucose positron emission tomography-computed tomography in multi-disciplinary team recommendations for oesophago-gastric cancer.
Topics: Aged; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Multimodal Imaging; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Retrospective Studies; Stomach Neoplasms; Tomography, X-Ray Computed | 2013 |
[Clinical target volume delineation for radiotherapy of the esophagus].
Topics: Endosonography; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Lymphatic Metastasis; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals | 2013 |
Relevance of [18F]fluorodeoxyglucose positron emission tomography-positive lymph nodes after neoadjuvant chemotherapy for squamous cell oesophageal cancer.
Topics: Carcinoma, Squamous Cell; Disease-Free Survival; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Neoadjuvant Therapy; Radionuclide Imaging; Radiopharmaceuticals; Treatment Outcome | 2013 |
Diagnostic value of ¹⁸F-FDG PET/CT for lymph node metastasis of esophageal squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Sensitivity and Specificity; Tomography, X-Ray Computed | 2014 |
Predicting pathologic tumor response to chemoradiotherapy with histogram distances characterizing longitudinal changes in 18F-FDG uptake patterns.
Topics: Biological Transport; Chemoradiotherapy, Adjuvant; Cohort Studies; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Glycolysis; Humans; Longitudinal Studies; Male; Positron-Emission Tomography; Treatment Outcome | 2013 |
The difference in relationship between 18F-FDG uptake and clinicopathological factors on thyroid, esophageal, and lung cancers.
Topics: Adult; Aged; Aged, 80 and over; Biological Transport; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Radionuclide Imaging; Retrospective Studies; Thyroid Neoplasms; Young Adult | 2014 |
Modeling pathologic response of esophageal cancer to chemoradiation therapy using spatial-temporal 18F-FDG PET features, clinical parameters, and demographics.
Topics: Adenocarcinoma; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Logistic Models; Male; Middle Aged; Models, Biological; Multimodal Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; ROC Curve; Sensitivity and Specificity; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden | 2014 |
Determinants of response to neoadjuvant chemotherapy for esophageal cancer using 18F-fluorodeoxiglucose positron emission tomography (18F-FDG-PET).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Survival Rate | 2014 |
Has integrated 18F FDG PET/CT improved staging, reduced early recurrence or increased survival in oesophageal cancer?
Topics: Adult; Aged; Aged, 80 and over; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Humans; Incidence; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Survival Rate; Tomography, X-Ray Computed; United Kingdom | 2015 |
18F-fluorodeoxyglucose PET/computed tomography and risk stratification after neoadjuvant treatment in esophageal cancer patients.
Topics: Disease-Free Survival; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Male; Middle Aged; Multimodal Imaging; Neoadjuvant Therapy; Positron-Emission Tomography; Retrospective Studies; Risk Assessment; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Pretreatment metabolic tumor volumes to predict the short-term outcome of unresectable locally advanced squamous cell carcinoma of the esophagus treated with definitive chemoradiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Chemoradiotherapy; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Retrospective Studies; Treatment Outcome; Tumor Burden | 2014 |
Role of surgical resection in complete responders on FDG-PET after chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Chemoradiotherapy; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Odds Ratio; Positron-Emission Tomography; Predictive Value of Tests; Prognosis; Radiopharmaceuticals; Remission Induction; Retrospective Studies; Treatment Failure; Treatment Outcome | 2014 |
[Determination of prognostic factors].
Topics: Adenocarcinoma; Carcinoma, Squamous Cell; Endosonography; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Multimodal Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2013 |
Detection of synchronous cancers by fluorodeoxyglucose positron emission tomography/computed tomography during primary staging workup for esophageal squamous cell carcinoma in Taiwan.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Retrospective Studies; Taiwan; Tomography, X-Ray Computed | 2013 |
Clinical utility of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the staging of patients with potentially resectable esophageal cancer.
Topics: Aged; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Male; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Prospective Studies; Radiopharmaceuticals; Survival Rate; Tomography, X-Ray Computed | 2013 |
[Utility and drawbacks of fludeoxyglucose-positron emission tomography in locally advanced esophageal cancer treated by neoadjuvant chemotherapy followed by esophagectomy].
Topics: Aged; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Positron-Emission Tomography | 2013 |
[Evaluation of tumor heterogeneity for esophageal squamous cell cancer by dynamic FDG-PET].
Topics: Carcinoma, Squamous Cell; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorodeoxyglucose F18; Humans; Neoadjuvant Therapy; Positron-Emission Tomography | 2013 |
[Evaluation of false-negative lymph nodes diagnosed by fludeoxy glucose-positron emission tomography in cases of metastatic esophageal squamous cell carcinoma].
Topics: Carcinoma, Squamous Cell; Combined Modality Therapy; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; False Negative Reactions; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Lymphatic Metastasis; Neoplasm Staging; Positron-Emission Tomography | 2013 |
Effectiveness of FDG-PET in screening of synchronous cancer of other organs in patients with esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms, Multiple Primary; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed | 2014 |
Diagnostic accuracy of ¹⁸F-FDG PET/CT for detection of suspected recurrence in patients with oesophageal carcinoma.
Topics: Adult; Aged; Carcinoma; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Male; Middle Aged; Multimodal Imaging; Neoplasm Recurrence, Local; Positron-Emission Tomography; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, X-Ray Computed | 2014 |
(18)F-FDG-PET/CT in assessing response to neoadjuvant chemoradiotherapy for potentially resectable locally advanced esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Imaging, Three-Dimensional; Kaplan-Meier Estimate; Liver; Male; Middle Aged; Multimodal Imaging; Neoadjuvant Therapy; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Maximum standardized uptake value on PET/CT in preoperative assessment of lymph node metastasis from thoracic esophageal squamous cell carcinoma.
Topics: Carcinoma, Squamous Cell; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Lymphatic Metastasis; Multimodal Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Sensitivity and Specificity | 2014 |
Isolated nasal tip metastasis from esophageal squamous cell carcinoma.
Topics: Aged; Carcinoma, Squamous Cell; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorodeoxyglucose F18; Humans; Multimodal Imaging; Nose Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Skin Neoplasms; Tomography, X-Ray Computed | 2015 |
Pre-treatment metabolic tumor volume and total lesion glycolysis are useful prognostic factors for esophageal squamous cell cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorodeoxyglucose F18; Glycolysis; Humans; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Prognosis; Prospective Studies; ROC Curve; Tumor Burden | 2014 |
Detection of early esophageal cancer and cervical lymph node metastases by (18)F-FDG PET/CT in a patient with Fanconi anemia.
Topics: Cervical Vertebrae; Child; Child, Preschool; Early Detection of Cancer; Esophageal Neoplasms; Fanconi Anemia; Female; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Multimodal Imaging; Positron-Emission Tomography; Tomography, X-Ray Computed; Young Adult | 2014 |
Prediction of occult lymph node metastasis by metabolic parameters in patients with clinically N0 esophageal squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Carcinoma, Squamous Cell; Endoscopy; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Glycolysis; Humans; Logistic Models; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Predictive Value of Tests; Radiographic Image Interpretation, Computer-Assisted; Radiopharmaceuticals; Retrospective Studies; Risk Factors; Tomography, X-Ray Computed; Ultrasonography | 2014 |
Incremental value of 18F-FDG PET/CT in therapeutic decision-making of potentially curable esophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Decision Making; Esophageal Neoplasms; False Negative Reactions; False Positive Reactions; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Retrospective Studies; Tomography, X-Ray Computed; Young Adult | 2014 |
Clinical significance of incidental findings on staging positron emission tomography for oesophagogastric malignancies.
Topics: Adult; Aged; Aged, 80 and over; Esophageal Neoplasms; False Positive Reactions; Female; Fluorodeoxyglucose F18; Humans; Incidental Findings; Male; Middle Aged; Neoplasm Staging; Neoplasms, Second Primary; Positron-Emission Tomography; Precancerous Conditions; Radiopharmaceuticals; Retrospective Studies; Stomach Neoplasms | 2014 |
Prognostic significance of novel ¹⁸F-FDG PET/CT defined tumour variables in patients with oesophageal cancer.
Topics: Adult; Aged; Carcinoma; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Reproducibility of Results; Risk Assessment; Sensitivity and Specificity; Survival Rate; Tomography, X-Ray Computed | 2014 |
False-positive 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) findings of bone metastasis from esophagogastric cancer: report of two cases.
Topics: Adenocarcinoma; Aged, 80 and over; Bone Neoplasms; Carcinoma, Signet Ring Cell; Carcinoma, Squamous Cell; Esophageal Neoplasms; Esophagectomy; False Positive Reactions; Fluorodeoxyglucose F18; Gastrectomy; Humans; Male; Middle Aged; Neoplasms, Multiple Primary; Positron-Emission Tomography; Radiopharmaceuticals; Stomach Neoplasms; Treatment Outcome | 2014 |
Prognostic impact of clinicopathological features and expression of biomarkers related to (18)F-FDG uptake in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Immunoenzyme Techniques; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Survival Rate | 2014 |
Advantages of FDG-PET/CT over CT alone in the preoperative assessment of lymph node metastasis in patients with esophageal cancer.
Topics: Adult; Aged; Esophageal Neoplasms; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Preoperative Period; Radiopharmaceuticals; Tomography, X-Ray Computed | 2015 |
Pretreatment metabolic tumour volume is predictive of disease-free survival and overall survival in patients with oesophageal squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Chemoradiotherapy; Disease-Free Survival; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Positron-Emission Tomography; Retrospective Studies; Tumor Burden | 2014 |
Imaging and clinicopathologic features of esophageal gastrointestinal stromal tumors.
Topics: Adult; Aged; Barium Sulfate; Biopsy; Diagnosis, Differential; Esophageal Neoplasms; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Leiomyoma; Leiomyosarcoma; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2014 |
Detecting interval metastases and response assessment using 18F-FDG PET/CT after neoadjuvant chemoradiotherapy for esophageal cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma; Chemoradiotherapy; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Multimodal Imaging; Neoadjuvant Therapy; Neoplasm Metastasis; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Clinical staging of patients with early esophageal adenocarcinoma: does FDG-PET/CT have a role?
Topics: Adenocarcinoma; Aged; Biopsy; Esophageal Neoplasms; False Positive Reactions; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed; Unnecessary Procedures | 2014 |
3'-deoxy-3'-[¹⁸F]-fluorothymidine PET/CT in early determination of prognosis in patients with esophageal squamous cell cancer: comparison with [¹⁸F]-FDG PET/CT.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Dideoxynucleosides; Disease-Free Survival; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Prognosis; ROC Curve; Tomography, X-Ray Computed; Young Adult | 2015 |
Impact of pretreatment imaging on survival of esophagectomy after induction therapy for esophageal cancer: who should be given the benefit of the doubt?: esophagectomy outcomes of patients with suspicious metastatic lesions.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Combined Modality Therapy; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Prospective Studies; Radiopharmaceuticals; Retrospective Studies; Survival Rate | 2015 |
Combination of FDG PET/CT and contrast-enhanced MSCT in detecting lymph node metastasis of esophageal cancer.
Topics: Adenocarcinoma; Aged; Carcinoma, Squamous Cell; Contrast Media; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Image Processing, Computer-Assisted; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Tomography, Spiral Computed; Tomography, X-Ray Computed | 2014 |
Value of CT-PET after neoadjuvant chemoradiation in the prediction of histological tumour regression, nodal status and survival in oesophageal adenocarcinoma.
Topics: Adenocarcinoma; Chemoradiotherapy; Disease-Free Survival; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Male; Neoadjuvant Therapy; Neoplasm Staging; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Remission Induction; Retreatment; Treatment Outcome | 2014 |
Clinical validation of FDG-PET/CT in the radiation treatment planning for patients with oesophageal cancer.
Topics: Adult; Aged; Aged, 80 and over; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Multimodal Imaging; Neoplasm Recurrence, Local; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal; Tomography, X-Ray Computed | 2014 |
Significance of 18F-Fluorodeoxyglucose Uptake at the Gastroesophageal Junction: Comparison of PET to Esophagogastroduodenoscopy.
Topics: Adult; Aged; Aged, 80 and over; Area Under Curve; Barrett Esophagus; Diagnosis, Differential; Endoscopy, Digestive System; Esophageal Diseases; Esophageal Neoplasms; Esophagitis; Esophagogastric Junction; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Retrospective Studies; ROC Curve; Tomography, X-Ray Computed; United States; United States Department of Veterans Affairs | 2015 |
Prognostic Significance of (18)F-fluorodeoxyglucose Positron Emission Tomography (FDG-PET)-Positive Lymph Nodes Following Neoadjuvant Chemotherapy and Surgery for Resectable Thoracic Esophageal Squamous Cell Carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Doxorubicin; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Positron-Emission Tomography; Proportional Hazards Models; Prospective Studies; Radiopharmaceuticals | 2015 |
Defining the target in cancer of the oesophagus: direct radiotherapy planning with fluorodeoxyglucose positron emission tomography-computed tomography.
Topics: Adult; Aged; Aged, 80 and over; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Incidence; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies | 2015 |
To evaluate the treatment response of locally advanced esophageal cancer after preoperative chemoradiotherapy by FDG-PET/CT scan.
Topics: Chemoradiotherapy; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Survival Rate; Treatment Outcome | 2015 |
18F-FDG PET/CT as a potential predictor of survival in patient with oesophageal cancer: a preliminary result.
Topics: Esophageal Neoplasms; Esophagus; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Predictive Value of Tests; Proportional Hazards Models; Radiopharmaceuticals; Reproducibility of Results; Survival Analysis; Tomography, X-Ray Computed | 2015 |
Pre-Radiation Therapy Fluorine 18 Fluorodeoxyglucose PET Helps Identify Patients with Esophageal Cancer at High Risk for Radiation Pneumonitis.
Topics: Adult; Aged; Aged, 80 and over; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Radiation Pneumonitis; Radiopharmaceuticals; Retrospective Studies; Risk Assessment; Tomography, X-Ray Computed | 2015 |
Potential values of metabolic tumor volume and heterogeneity measured with ¹⁸F-FDG PET/CT pretreatment to evaluate local control for esophageal squamous cell carcinoma treated with nonsurgical therapy.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Radiation Dosage; Retrospective Studies; Tomography, X-Ray Computed; Tumor Burden | 2015 |
Asymptomatic myocardial metastasis from cancers of upper aero-digestive tract detected on FDG PET/CT: a series of 4 cases.
Topics: Adult; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Heart Neoplasms; Humans; Male; Middle Aged; Mouth Neoplasms; Multimodal Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Tongue Neoplasms | 2014 |
Patterns of nodal metastases on 18F-FDG PET/CT in patients with esophageal squamous cell carcinoma are useful to guide treatment planning of radiotherapy.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2015 |
High FDG uptake areas on pre-radiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for locally advanced oesophageal cancer.
Topics: Aged; Chemoradiotherapy; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Multimodal Imaging; Neoplasm Recurrence, Local; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2015 |
Candida esophagitis mimicking esophageal malignancy on 18FDG PET/CT.
Topics: Candida; Candidiasis; Diagnosis, Differential; Esophageal Neoplasms; Esophagitis; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2015 |
Radiation-Induced Esophagitis Masquerading as Disease Progression in Case of Esophageal Carcinoma: A Diagnostic Dilemma Solved on Follow-up FDG PET/CT.
Topics: Carcinoma, Squamous Cell; Esophageal Neoplasms; Esophagitis; Female; Fluorodeoxyglucose F18; Humans; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy; Tomography, X-Ray Computed | 2015 |
Intra-tumour 18F-FDG uptake heterogeneity decreases the reliability on target volume definition with positron emission tomography/computed tomography imaging.
Topics: Adult; Aged; Artifacts; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tomography, X-Ray Computed; Tumor Burden | 2015 |
[Usefulness of FDG-PET for superficial esophageal squamous cell carcinoma].
Topics: Carcinoma, Squamous Cell; Endoscopy, Gastrointestinal; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorodeoxyglucose F18; Humans; Male; Positron-Emission Tomography; Radiopharmaceuticals | 2014 |
Discovery of the primary site of esophageal squamous cell carcinoma based on axillary lymph nodes metastasis detected with fluorodeoxyglucose positron-emission tomography: report of a case.
Topics: Axilla; Carcinoma, Squamous Cell; Endoscopy; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fatal Outcome; Fluorodeoxyglucose F18; Humans; Intraoperative Care; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Positron-Emission Tomography | 2014 |
A case of carcinosarcoma of the esophagus detected on fluorodeoxyglucose positron emission tomography.
Topics: Carcinosarcoma; Esophageal Neoplasms; Esophagoscopy; Female; Fluorodeoxyglucose F18; Humans; Middle Aged; Positron-Emission Tomography | 2014 |
Role of Repeat 18F-Fluorodeoxyglucose Positron Emission Tomography Examination in Predicting Pathologic Response Following Neoadjuvant Chemoradiotherapy for Esophageal Adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Chemoradiotherapy; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoadjuvant Therapy; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2015 |
Indications and Limitations in the Management Algorithm of Patients With Esophageal Adenocarcinoma: Positron Emission Tomography Computed Tomography.
Topics: Adenocarcinoma; Chemoradiotherapy; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Neoadjuvant Therapy; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2015 |
FDG Positron Emission Tomography and Computed Tomography Demonstration of Carcinoma Arising in an Epiphrenic Diverticulum.
Topics: Diverticulum, Esophageal; Endosonography; Esophageal Neoplasms; Esophagectomy; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Multimodal Imaging; Phrenic Nerve; Radionuclide Imaging; Radiopharmaceuticals; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
The precision of textural analysis in (18)F-FDG-PET scans of oesophageal cancer.
Topics: Esophageal Neoplasms; Esophagus; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Reproducibility of Results | 2015 |
Change in volume parameters induced by neoadjuvant chemotherapy provide accurate prediction of overall survival after resection in patients with oesophageal cancer.
Topics: Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Glycolysis; Humans; Male; Middle Aged; Multimodal Imaging; Neoadjuvant Therapy; Positron-Emission Tomography; Prognosis; Proportional Hazards Models; Retrospective Studies; Tomography, X-Ray Computed; Tumor Burden | 2016 |
Prognostic Value of Pretherapeutic Tumor-to-Blood Standardized Uptake Ratio in Patients with Esophageal Carcinoma.
Topics: Aged; Aorta; Carcinoma; Chemoradiotherapy; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Positron-Emission Tomography; Prognosis; Proportional Hazards Models; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
FDG-PET nodal staging does not correlate with histopathological nodal stage for oesophageal cancers.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Combined Modality Therapy; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Retrospective Studies; Tomography, X-Ray Computed | 2015 |
Evaluation of GMI and PMI diffeomorphic-based demons algorithms for aligning PET and CT Images.
Topics: Aged; Algorithms; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Male; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Radiotherapy Dosage; Tissue Distribution; Tomography, X-Ray Computed | 2015 |
Factors that affect PERCIST-defined test-retest comparability: an exploration of feasibility in routine clinical practice.
Topics: Adult; Aged; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, X-Ray Computed | 2015 |
Mapping of failures after radiochemotherapy in patients with non-metastatic esophageal cancer: A posteriori analysis of the dose distribution in the sites of loco-regional relapse.
Topics: Aged; Aged, 80 and over; Chemoradiotherapy; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Male; Middle Aged; Neoplasm Recurrence, Local; Radiotherapy Dosage; Tomography, X-Ray Computed; Treatment Failure | 2015 |
The correlation between the metabolic tumor volume and hematological parameters in patients with esophageal cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorodeoxyglucose F18; Hematologic Tests; Humans; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Tomography, X-Ray Computed; Tumor Burden | 2015 |
Relationship Between the Size of Metastatic Lymph Nodes and Positron Emission Tomographic/Computer Tomographic Findings in Patients with Esophageal Squamous Cell Carcinoma.
Topics: Blood Vessels; Carcinoma, Squamous Cell; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Female; Fluorodeoxyglucose F18; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Lymphatic Vessels; Male; Mediastinum; Middle Aged; Multimodal Imaging; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Risk Factors; Tomography, X-Ray Computed; Tumor Burden | 2015 |
Predicting Response to Neoadjuvant Chemotherapy with PET Imaging Using Convolutional Neural Networks.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neural Networks, Computer; Positron-Emission Tomography; Treatment Outcome | 2015 |
Tumour delineation in oesophageal cancer - A prospective study of delineation in PET and CT with and without endoscopically placed clip markers.
Topics: Aged; Aged, 80 and over; Algorithms; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Surgical Instruments; Tomography, X-Ray Computed; Tumor Burden | 2015 |
(18)F-FDG uptake of the spinal cord was decreased after conventional dose radiotherapy in esophageal cancer patients.
Topics: Aged; Aged, 80 and over; Biological Transport; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Positron-Emission Tomography; Radiation Dosage; Radiotherapy Dosage; Retrospective Studies; Spinal Cord; Time Factors | 2016 |
Squamous cell carcinoma arising from a Zenker's diverticulum: contribution of FDG-PET/CT to the diagnosis.
Topics: Aged; Carcinoma, Squamous Cell; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorodeoxyglucose F18; Humans; Male; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Zenker Diverticulum | 2016 |
Pragmatic staging of oesophageal cancer using decision theory involving selective endoscopic ultrasonography, PET and laparoscopy.
Topics: Adult; Aged; Aged, 80 and over; Decision Theory; Endosonography; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Laparoscopy; Male; Middle Aged; Multidetector Computed Tomography; Neoplasm Staging; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Reproducibility of Results | 2015 |
Dyspnoea in a 72-year-old woman.
Topics: Adenocarcinoma; Aged; Colonic Neoplasms; Dyspnea; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Liver Neoplasms; Lung Neoplasms; Positron-Emission Tomography | 2015 |
Use of FDG-PET to detect a chronic odontogenic infection as a possible source of the brain abscess.
Topics: Aged; Brain Abscess; Esophageal Neoplasms; Fluorides; Fluorodeoxyglucose F18; Humans; Male; Periodontal Diseases; Positron-Emission Tomography; Staphylococcal Infections; Staphylococcus | 2016 |
The prognostic value of total lesion glycolysis via 18F-fluorodeoxyglucose PET-CT in surgically treated esophageal squamous cell carcinoma.
Topics: Carcinoma, Squamous Cell; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorodeoxyglucose F18; Glycolysis; Humans; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Prognosis; Retrospective Studies; Tomography, X-Ray Computed | 2016 |
Impact of number of [(18)F]fluorodeoxyglucose-PET-positive lymph nodes on survival of patients receiving neoadjuvant chemotherapy and surgery for oesophageal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Multivariate Analysis; Positron-Emission Tomography; Radiopharmaceuticals; Treatment Outcome | 2016 |
Determination of regional lymph node status using (18)F-FDG PET/CT parameters in oesophageal cancer patients: comparison of SUV, volumetric parameters and intratumoral heterogeneity.
Topics: Aged; Aged, 80 and over; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed | 2016 |
Tumor/normal esophagus ratio in (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for response and prognosis stratification after neoadjuvant chemotherapy for esophageal squamous cell carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Esophagus; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Image Interpretation, Computer-Assisted; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Taxoids; Treatment Outcome | 2016 |
¹⁸F-Fluorodeoxyglucose Positron Emission Tomography for Evaluating the Response to Neoadjuvant Chemotherapy in Advanced Esophageal Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Treatment Outcome | 2016 |
[Prognostic value of the metabolically active tumour volume].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Chemoradiotherapy; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Male; Middle Aged; Multimodal Imaging; Multivariate Analysis; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed; Tumor Burden | 2016 |
Total Lesion Glycolysis Using ¹⁸F-FDG PET/CT as a Prognostic Factor for Locally Advanced Esophageal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Area Under Curve; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Glycolysis; Humans; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Proportional Hazards Models; Radiopharmaceuticals; Retrospective Studies; ROC Curve; Survival Rate; Tomography, X-Ray Computed | 2016 |
Changes in Total Lesion Glycolysis Evaluated by Repeated F-18 FDG PET/CT as Prognostic Factor in Locally Advanced Esophageal Cancer Patients Treated with Preoperative Chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Dose Fractionation, Radiation; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Fluorouracil; Glycolysis; Humans; Male; Middle Aged; Multimodal Imaging; Neoadjuvant Therapy; Positron-Emission Tomography; Predictive Value of Tests; Preoperative Care; Prognosis; Radiopharmaceuticals; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Survival Rate; Tomography, X-Ray Computed; Tumor Burden | 2016 |
The Comparison of Computed Tomography Perfusion, Contrast-Enhanced Computed Tomography and Positron-Emission Tomography/Computed Tomography for the Detection of Primary Esophageal Carcinoma.
Topics: Adult; Aged; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Retrospective Studies; Sensitivity and Specificity; Tomography, X-Ray Computed | 2016 |
The Incremental Value of Subjective and Quantitative Assessment of 18F-FDG PET for the Prediction of Pathologic Complete Response to Preoperative Chemoradiotherapy in Esophageal Cancer.
Topics: Adenocarcinoma; Chemoradiotherapy; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Multivariate Analysis; Positron-Emission Tomography; Preoperative Period; Retrospective Studies | 2016 |
A Mimic of Intra-abdominal Malignancy: Physiological Urinary Excretion of FDG in the Rare Adult Vesicourachal Diverticulum.
Topics: Abdominal Neoplasms; Diagnosis, Differential; Diverticulum; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Incidental Findings; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Urachus; Urinary Tract | 2016 |
Individualized Radiation Dose Escalation Based on the Decrease in Tumor FDG Uptake and Normal Tissue Constraints Improve Survival in Patients With Esophageal Carcinoma.
Topics: Aged; Aged, 80 and over; Combined Modality Therapy; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Precision Medicine; Prognosis; Radiotherapy Dosage; Radiotherapy, Image-Guided; Treatment Failure; Treatment Outcome | 2017 |
Prediction of Recurrence and Mortality of Locally Advanced Esophageal Cancer Patients Using Pretreatment F-18 FDG PET/CT Parameters: Intratumoral Heterogeneity, SUV, and Volumetric Parameters.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Survival Rate; Tissue Distribution; Tomography, X-Ray Computed; Tumor Burden | 2016 |
Restaging oesophageal cancer after neoadjuvant therapy with (18)F-FDG PET-CT: identifying interval metastases and predicting incurable disease at surgery.
Topics: Adult; Aged; Chemotherapy, Adjuvant; Decision Theory; Disease Progression; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Risk Assessment; Sensitivity and Specificity; Tomography, X-Ray Computed | 2016 |
Predictive value of repeated F-18 FDG PET/CT parameters changes during preoperative chemoradiotherapy to predict pathologic response and overall survival in locally advanced esophageal adenocarcinoma patients.
Topics: Adenocarcinoma; Aged; Chemoradiotherapy; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Middle Aged; Positron-Emission Tomography; Retrospective Studies; ROC Curve; Tomography, X-Ray Computed | 2016 |
Usefulness of 18f-Fluorodeoxyglucose Positron Emission Tomography for Predicting the Pathological Response of Neoadjuvant Chemoradiotherapy for T4 Esophageal Squamous Cell Carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cohort Studies; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Esophagus; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Lymph Node Excision; Lymph Nodes; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Taxoids; Treatment Outcome | 2015 |
Use of Positron Emission Tomography to Detect Recurrence and Associations With Survival in Patients With Lung and Esophageal Cancers.
Topics: Aged; Aged, 80 and over; Cohort Studies; Confounding Factors, Epidemiologic; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Medical Overuse; Medicare; Neoplasm Recurrence, Local; Positron-Emission Tomography; Radiopharmaceuticals; SEER Program; Sensitivity and Specificity; Survival Analysis; United States | 2016 |
Chronic Esophageal Perforation With Periesophageal Abscess Mimicking Malignancy on FDG PET/CT.
Topics: Abscess; Barium Sulfate; Chronic Disease; Contrast Media; Diagnosis, Differential; Endoscopy; Endoscopy, Digestive System; Esophageal Neoplasms; Esophageal Perforation; Fluorodeoxyglucose F18; Granulation Tissue; Humans; Image-Guided Biopsy; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Radiography; Radiopharmaceuticals; Ultrasonography | 2016 |
Prognostic Significance of 2-Deoxy-2-[18F]-Fluoro-D-Glucose PET/CT in Patients With Locally Advanced Esophageal Cancer Undergoing Neoadjuvant Chemoradiotherapy Before Surgery: A Nonparametric Approach.
Topics: Aged; Body Composition; Chemoradiotherapy, Adjuvant; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Statistics, Nonparametric; Tomography, X-Ray Computed | 2016 |
PET/CT in the evaluation of treatment response to neoadjuvant chemoradiotherapy and prognostication in patients with locally advanced esophageal squamous cell carcinoma.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Chemoradiotherapy; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Treatment Outcome; Young Adult | 2016 |
A Dirichlet process mixture model for automatic (18)F-FDG PET image segmentation: Validation study on phantoms and on lung and esophageal lesions.
Topics: Algorithms; Bayes Theorem; Calibration; Esophageal Neoplasms; Esophagus; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Lung; Lung Neoplasms; Models, Anatomic; Pattern Recognition, Automated; Phantoms, Imaging; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals | 2016 |
PET/CT imaging in diagnosing lymph node metastasis of esophageal carcinoma and its comparison with pathological findings.
Topics: Adult; Aged; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Tomography, X-Ray Computed | 2016 |
Distribution of lymph node metastases on FDG-PET/CT in inoperable or unresectable oesophageal cancer patients and the impact on target volume definition in radiation therapy.
Topics: Adult; Aged; Aged, 80 and over; Esophageal Neoplasms; Esophagus; Female; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Retrospective Studies | 2016 |
Molecular biological correlation of fluorine-18 fluorodeoxyglucose uptake in esophageal squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Biological Transport; Biomarkers, Tumor; Carcinoma, Squamous Cell; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorodeoxyglucose F18; Glucose Transporter Type 1; Humans; Male; Middle Aged; Neoplasm Staging; Retrospective Studies | 2016 |
Positive PET in a Patient With Esophageal Leiomyoma.
Topics: Adult; Diagnosis, Differential; Esophageal Neoplasms; Fluorodeoxyglucose F18; Hodgkin Disease; Humans; Leiomyoma; Male; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals | 2016 |
Ability of Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography to Predict Outcomes of Neoadjuvant Chemoradiotherapy Followed by Surgical Treatment for Esophageal Squamous Cell Carcinoma.
Topics: Aged; Carcinoma, Squamous Cell; Chemoradiotherapy; Cohort Studies; Combined Modality Therapy; Disease-Free Survival; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Positron-Emission Tomography; Predictive Value of Tests; Prognosis; Prospective Studies; ROC Curve; Survival Rate; Treatment Outcome | 2016 |
Clinical Significance of FDG-PET to Predict Pathologic Tumor Invasion and Lymph Node Metastasis of Superficial Esophageal Squamous Cell Carcinoma.
Topics: Aged; Area Under Curve; Carcinoma, Squamous Cell; Disease-Free Survival; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Humans; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Positron-Emission Tomography; Predictive Value of Tests; Preoperative Period; Radiopharmaceuticals; Retrospective Studies; ROC Curve; Survival Rate | 2016 |
FDG-PET/CT lymph node staging after neoadjuvant chemotherapy in patients with adenocarcinoma of the esophageal-gastric junction.
Topics: Adenocarcinoma; Adult; Aged; Chemotherapy, Adjuvant; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Prospective Studies; Radiopharmaceuticals; Sensitivity and Specificity | 2016 |
Development of a novel handheld intra-operative laparoscopic Compton camera for (18)F-Fluoro-2-deoxy-2-D-glucose-guided surgery.
Topics: Endoscopes; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Laparoscopy; Photons; Positron-Emission Tomography; Radiopharmaceuticals; Surgery, Computer-Assisted | 2016 |
The value of
Topics: Adenocarcinoma; Antineoplastic Agents; Chemoradiotherapy, Adjuvant; Disease-Free Survival; Early Detection of Cancer; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Induction Chemotherapy; Longitudinal Studies; Male; Middle Aged; Positron-Emission Tomography; Preoperative Care; Prognosis; Radiopharmaceuticals; Reproducibility of Results; Retrospective Studies; Sensitivity and Specificity; Survival Rate; Texas; Treatment Outcome | 2017 |
A Case of Focal Bone Marrow Reconversion Mimicking Bone Metastasis: The Value of 111Indium Chloride.
Topics: Aged; Bone Marrow; Bone Marrow Neoplasms; Carcinoma; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Indium; Male; Positron Emission Tomography Computed Tomography; Tomography, Emission-Computed, Single-Photon | 2016 |
Utility of
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Chemoradiotherapy; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Remission Induction; Retrospective Studies; Survival Rate | 2017 |
Prognostic value of preoperative total psoas muscle area on long-term outcome in surgically treated oesophageal cancer patients.
Topics: Adult; Aged; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Lymph Node Excision; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Prognosis; Proportional Hazards Models; Psoas Muscles; Retrospective Studies; Risk Factors; Survival Rate | 2017 |
68Ga-NODAGA-RGDyK PET/CT Imaging in Esophageal Cancer: First-in-Human Imaging.
Topics: Adult; Carcinoma; Coordination Complexes; Esophageal Neoplasms; Esophagogastric Junction; Fluorodeoxyglucose F18; Humans; Male; Neovascularization, Pathologic; Peptides, Cyclic; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals | 2016 |
Prognostic value of metabolic response measured by 18F-FDG-PET in oesophageal cancer patients treated with definitive chemoradiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Chemoradiotherapy; Disease-Free Survival; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prognosis; Radiopharmaceuticals; Retrospective Studies | 2016 |
Texture analysis of
Topics: Aged; Aged, 80 and over; Algorithms; Chemoradiotherapy; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Male; Middle Aged; Outcome Assessment, Health Care; Pattern Recognition, Automated; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Reproducibility of Results; Retrospective Studies; Sensitivity and Specificity; Treatment Outcome; Tumor Burden | 2017 |
Primary Maligant Melanoma of the Oesophagus.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Esophagectomy; Esophagoscopy; Female; Fluorodeoxyglucose F18; Humans; Interferons; Liver Neoplasms; Melanoma; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals | 2015 |
Topics: Adenocarcinoma; Contrast Media; Endosonography; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorodeoxyglucose F18; Humans; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Predictive Value of Tests; Preoperative Period; Radiopharmaceuticals; Sensitivity and Specificity; Stomach Neoplasms | 2017 |
PET-CT Post-Hepatic Radiation Changes in Gastroesophageal Adenocarcinoma.
Topics: Adenocarcinoma; Diagnosis, Differential; Esophageal Neoplasms; Esophagogastric Junction; Fluorodeoxyglucose F18; Hepatitis; Humans; Image-Guided Biopsy; Positron Emission Tomography Computed Tomography; Radiation Injuries; Radiopharmaceuticals; Radiotherapy, Conformal; Stomach Neoplasms; Tomography, X-Ray Computed; Ultrasonography | 2017 |
Hepatic radiation injury mimicking metastasis in distal esophageal cancer
Topics: Adenocarcinoma; Adult; Diagnosis, Differential; Esophageal Neoplasms; Fluorodeoxyglucose F18; Hepatitis; Humans; Liver Neoplasms; Male; Positron Emission Tomography Computed Tomography; Radiation Injuries; Radiopharmaceuticals | 2017 |
Metabolic tumor volume provides complementary prognostic information to EUS staging in esophageal and junctional cancer.
Topics: Adult; Aged; Aged, 80 and over; Endosonography; Esophageal Neoplasms; Esophagogastric Junction; Esophagoscopy; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Prognosis; Proportional Hazards Models; Prospective Studies; Radiopharmaceuticals; Regression Analysis; Statistics, Nonparametric; Tumor Burden; Young Adult | 2017 |
Distribution of FDG-avid nodes in esophageal cancer: implications for radiotherapy target delineation.
Topics: Adult; Aged; Aged, 80 and over; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Positron Emission Tomography Computed Tomography | 2016 |
Prognostic significance of venous invasion and maximum standardized uptake value of
Topics: Adult; Aged; Carcinoma, Squamous Cell; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Humans; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Risk Factors; Treatment Outcome; Vascular Neoplasms | 2017 |
Heterogeneity of Glucose Metabolism in Esophageal Cancer Measured by Fractal Analysis of Fluorodeoxyglucose Positron Emission Tomography Image: Correlation between Metabolic Heterogeneity and Survival.
Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Fractals; Glucose; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Positron-Emission Tomography; Proportional Hazards Models; Radiopharmaceuticals; Retrospective Studies; Survival Rate | 2017 |
Effectiveness of Repeat 18F-Fluorodeoxyglucose Positron Emission Tomography Computerized Tomography (PET-CT) Scan in Identifying Interval Metastases for Patients with Esophageal Cancer.
Topics: Adenocarcinoma; Carcinoma, Squamous Cell; Chemoradiotherapy; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Survival Rate | 2017 |
Comparative evaluation of target volumes defined by deformable and rigid registration of diagnostic PET/CT to planning CT in primary esophageal cancer.
Topics: Aged; Algorithms; Dimensional Measurement Accuracy; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Reproducibility of Results; Tomography, X-Ray Computed; Tumor Burden | 2017 |
Metabolic nodal response as a prognostic marker after neoadjuvant therapy for oesophageal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals | 2017 |
The impact of intratumoral metabolic heterogeneity on postoperative recurrence and survival in resectable esophageal squamous cell carcinoma.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Positron-Emission Tomography; Postoperative Complications; Prognosis; Radiopharmaceuticals; Retrospective Studies; Survival Rate; Tumor Burden | 2017 |
Answer to Photo Quiz: An old male with multiple hotspots on
Topics: Adipose Tissue, Brown; Carcinoma, Squamous Cell; Deglutition Disorders; Diagnosis, Differential; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagus; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals | 2017 |
Role of
Topics: Aged; Carcinoma, Squamous Cell; Chemoradiotherapy; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Outcome Assessment, Health Care; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies | 2017 |
Predictive value of initial FDG-PET features for treatment response and survival in esophageal cancer patients treated with chemo-radiation therapy using a random forest classifier.
Topics: Aged; Aged, 80 and over; Algorithms; Area Under Curve; Chemoradiotherapy; Disease-Free Survival; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Positron-Emission Tomography; Predictive Value of Tests; Prognosis; Radiopharmaceuticals; Retrospective Studies; ROC Curve; Treatment Outcome | 2017 |
Serial imaging using [18F]Fluorodeoxyglucose positron emission tomography and histopathologic assessment in predicting survival in a population of surgically resectable distal oesophageal and gastric adenocarcinoma following neoadjuvant therapy.
Topics: Adenocarcinoma; Adult; Aged; Disease-Free Survival; Esophageal Neoplasms; Esophagus; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Gastric Mucosa; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Stomach; Stomach Neoplasms | 2017 |
AEG I and II: is it one tumor entity?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Barrett Esophagus; Chemotherapy, Adjuvant; Disease-Free Survival; Esophageal Neoplasms; Esophagogastric Junction; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Positron-Emission Tomography; Postoperative Complications; Radiopharmaceuticals; Remission Induction; Risk Assessment; Survival Rate; Treatment Outcome | 2008 |
Prognostic value of initial fluorodeoxyglucose-PET in esophageal cancer: a prospective study.
Topics: Adult; Aged; Aged, 80 and over; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; France; Humans; Male; Middle Aged; Positron-Emission Tomography; Prevalence; Prognosis; Prospective Studies; Radiopharmaceuticals; Reproducibility of Results; Risk Assessment; Sensitivity and Specificity; Survival Analysis; Survival Rate | 2008 |
Using 18F-fluorodeoxyglucose positron emission tomography to estimate the length of gross tumor in patients with squamous cell carcinoma of the esophagus.
Topics: Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Male; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity | 2009 |
Importance of fluorodeoxyglucose-positron emission tomography (FDG-PET) and endoscopic ultrasonography parameters in predicting survival following surgery for esophageal cancer.
Topics: Adult; Aged; Biopsy, Needle; Cohort Studies; Disease-Free Survival; Endosonography; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Immunohistochemistry; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Patient Selection; Positron-Emission Tomography; Predictive Value of Tests; Preoperative Care; Probability; Proportional Hazards Models; Prospective Studies; Risk Assessment; Sensitivity and Specificity; Survival Analysis; Treatment Outcome | 2008 |
Impact of the introduction of integrated PET-CT into the preoperative staging pathway of patients with potentially operable oesophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Preoperative Care; Prognosis; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed | 2008 |
Dual-time-point FDG PET for the evaluation of locoregional lymph nodes in thoracic esophageal squamous cell cancer.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Thoracic Neoplasms | 2009 |
Visual PET/CT scoring for nonspecific 18F-FDG uptake in the differentiation of early malignant and benign esophageal lesions.
Topics: Aged; Area Under Curve; Chi-Square Distribution; Diagnosis, Differential; Esophageal Diseases; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Precancerous Conditions; Radiopharmaceuticals; Retrospective Studies; ROC Curve; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2008 |
Esophageal and laryngeal cancer incidentally found on [18F]fluorodeoxyglucose positron emission tomography/computed tomography during the staging workup for lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Incidental Findings; Laryngeal Neoplasms; Lung Neoplasms; Male; Neoplasms, Multiple Primary; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2008 |
Added value of PET and PET-computed tomography in oesophageal cancer: a review of current practice.
Topics: Cohort Studies; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Image Enhancement; Medical Oncology; Positron-Emission Tomography; Practice Guidelines as Topic; Practice Patterns, Physicians'; Tomography, X-Ray Computed | 2008 |
Adenocarcinomas of the esophagus: response to chemoradiotherapy is associated with decrease of metabolic tumor volume as measured on PET-CT. Comparison to histopathologic and clinical response evaluation.
Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Neoadjuvant Therapy; Positron-Emission Tomography; Tomography, X-Ray Computed; Tumor Burden | 2008 |
Intermittent FDG uptake in lipomatous hypertrophy of the interatrial septum on serial PET/CT scans.
Topics: Aged; Carcinoma; Cardiomegaly; Diagnosis, Differential; Esophageal Neoplasms; Fluorodeoxyglucose F18; Heart Septum; Humans; Lipoma; Male; Neoplasm Staging; Positron-Emission Tomography; Time Factors; Tomography, X-Ray Computed | 2008 |
Improving observer variability in target delineation for gastro-oesophageal cancer--the role of (18F)fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography.
Topics: Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Observer Variation; Positron-Emission Tomography; Stomach Neoplasms; Tomography, X-Ray Computed | 2008 |
Dose-related fluorodeoxyglucose uptake in acute radiation-induced hepatitis.
Topics: Acute Disease; Antineoplastic Agents; Combined Modality Therapy; Docetaxel; Dose-Response Relationship, Radiation; Esophageal Neoplasms; Fluorodeoxyglucose F18; Hepatitis; Humans; Liver; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Radiation Injuries; Radiopharmaceuticals; Taxoids | 2008 |
Positron emission tomography changes management and prognostic stratification in patients with oesophageal cancer: results of a multicentre prospective study.
Topics: Aged; Disease-Free Survival; Esophageal Neoplasms; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Male; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Prospective Studies; Radiopharmaceuticals; Tomography, X-Ray Computed | 2009 |
Routine positron emission tomography does not alter nodal staging in patients undergoing EUS-guided FNA for esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Biopsy, Fine-Needle; Carcinoma, Squamous Cell; Cross-Sectional Studies; Endosonography; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies | 2009 |
Limitations of FDG-PET and FDG-PET with computed tomography for detecting synchronous cancer in pharyngeal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Endoscopy, Digestive System; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Neoplasm Staging; Neoplasms, Multiple Primary; Pharyngeal Neoplasms; Positron-Emission Tomography; Retrospective Studies; Sensitivity and Specificity; Stomach Neoplasms; Tomography, X-Ray Computed | 2008 |
Use of (18)F-fluorodeoxyglucose-positron emission tomography to evaluate responses to neo-adjuvant chemotherapy for primary tumor and lymph node metastasis in esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cohort Studies; Disease-Free Survival; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoadjuvant Therapy; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Retrospective Studies; Tumor Burden | 2008 |
Mean and maximum standardized uptake values in [18F]FDG-PET for assessment of histopathological response in oesophageal squamous cell carcinoma or adenocarcinoma after radiochemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Combined Modality Therapy; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoadjuvant Therapy; Positron-Emission Tomography; ROC Curve; Treatment Outcome | 2009 |
The utility of FDG-PET in the preoperative staging of esophageal cancer.
Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Positron-Emission Tomography; Preoperative Care; Prospective Studies; Risk Assessment; Sensitivity and Specificity; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
Influence of the baseline 18F-fluoro-2-deoxy-D-glucose positron emission tomography results on survival and pathologic response in patients with gastroesophageal cancer undergoing chemoradiation.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Combined Modality Therapy; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Outcome Assessment, Health Care; Positron-Emission Tomography; Predictive Value of Tests; Prognosis; Survival Rate; Treatment Outcome | 2009 |
Correlations between selected tumor markers and fluorodeoxyglucose maximal standardized uptake values in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Combined Modality Therapy; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Glucose Transporter Type 1; Humans; Male; Middle Aged; Neoplasm Proteins; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Tissue Array Analysis | 2009 |
Integrated FDG-PET/CT compared with intravenous contrast-enhanced CT for evaluation of metastatic regional lymph nodes in patients with resectable early stage esophageal cancer.
Topics: Aged; Contrast Media; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Injections, Intravenous; Iopamidol; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Subtraction Technique; Systems Integration; Tomography, X-Ray Computed | 2009 |
Prognostic value of maximum standardized uptake values from preoperative positron emission tomography in resectable adenocarcinoma of the esophagus treated by surgery alone.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Disease-Free Survival; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Fluorodeoxyglucose F18; Humans; Middle Aged; Multivariate Analysis; Positron-Emission Tomography; Preoperative Period; Prognosis; Radiopharmaceuticals; Survival Analysis | 2009 |
Evaluation of response: is 18F-FDG PET the answer?
Topics: Carcinoma; Diagnostic Imaging; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Medical Oncology; Positron-Emission Tomography; Research Design | 2009 |
The influence of (18)flourodeoxyglucose positron emission tomography on the management of gastroesophageal junction carcinoma.
Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Stomach Neoplasms | 2009 |
The relationship between the glucose transporter type 1 expression and F-fluorodeoxyglucose uptake in esophageal squamous cell carcinoma.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Glucose Transporter Type 1; Humans; Immunohistochemistry; Lymphatic Metastasis; Male; Middle Aged; Positron-Emission Tomography | 2009 |
18F-FDG-PET imaging of a benign neurofibroma masquerading as metastatic oesophageal carcinoma.
Topics: Aged; Diagnosis, Differential; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Male; Neurofibroma; Positron-Emission Tomography | 2010 |
Dual-time F-18 FDG-PET/CT imaging for diagnosis of occult non-Hodgkin lymphoma in a patient with esophageal cancer.
Topics: Adenocarcinoma; Aged; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Lymphoma, Non-Hodgkin; Male; Positron-Emission Tomography; Time Factors; Tomography, X-Ray Computed | 2009 |
Clinical usefulness of 18F-FDG PET/CT in the restaging of esophageal cancer after surgical resection and radiotherapy.
Topics: Adult; Aged; Disease Progression; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Reproducibility of Results; Retrospective Studies; Tomography, Emission-Computed | 2009 |
Positron emission tomography-computed tomography in predicting locoregional invasion in esophageal squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Positron-Emission Tomography; Predictive Value of Tests; Radioisotopes; Tomography, X-Ray Computed; Video-Assisted Surgery | 2009 |
The clinical application of (18)F-fluorodeoxyglucose positron emission tomography to predict survival in patients with operable esophageal cancer.
Topics: Disease-Free Survival; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Positron-Emission Tomography; Preoperative Care; Prognosis; Retrospective Studies; Survival Analysis; Treatment Outcome | 2009 |
Schwannoma of the esophagus: a case exhibiting high 18F-fluorodeoxyglucose uptake in positron emission tomography imaging.
Topics: Aged; Anastomosis, Surgical; Biopsy, Needle; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Immunohistochemistry; Neoplasm Staging; Neurilemmoma; Positron-Emission Tomography; Risk Assessment; Sensitivity and Specificity; Thoracotomy; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
Predictive value of initial PET-SUVmax in patients with locally advanced esophageal and gastroesophageal junction adenocarcinoma.
Topics: Adenocarcinoma; Chi-Square Distribution; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Predictive Value of Tests; Prognosis; Radionuclide Imaging; Radiopharmaceuticals; Retrospective Studies; Survival Rate; Whole Body Imaging | 2009 |
Induction and concurrent taxanes enhance both the pulmonary metabolic radiation response and the radiation pneumonitis response in patients with esophagus cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Linear Models; Male; Middle Aged; Positron-Emission Tomography; Radiation Pneumonitis; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Remission Induction; Retrospective Studies; Taxoids; Tomography, X-Ray Computed | 2010 |
Expression of hexokinases and glucose transporters in treated and untreated oesophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Glucose Transport Proteins, Facilitative; Hexokinase; Humans; Immunohistochemistry; Male; Middle Aged; Positron-Emission Tomography; Protein Isoforms; Radiopharmaceuticals; Radiotherapy, Adjuvant | 2009 |
Intramural metastasis of esophageal carcinoma to the reconstructed gastric tube detected by FDG PET/CT.
Topics: Aged; Esophageal Neoplasms; Esophagectomy; Fluorodeoxyglucose F18; Humans; Male; Positron-Emission Tomography; Stomach Neoplasms; Tomography, X-Ray Computed | 2009 |
[18F-FDG PET/CT for the detection of primary tumors metastasizing to lymph nodes of the neck].
Topics: Adolescent; Adult; Aged; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Hypopharyngeal Neoplasms; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Mediastinal Neoplasms; Middle Aged; Nasopharyngeal Neoplasms; Neck; Positron-Emission Tomography; Pyriform Sinus; Radiopharmaceuticals; Tomography, X-Ray Computed; Young Adult | 2009 |
The utility of FDG-PET for detecting multiple primary cancers in hypopharyngeal cancer patients.
Topics: Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Hypopharyngeal Neoplasms; Laryngeal Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Oropharyngeal Neoplasms; Positron-Emission Tomography; Radiography; Radiopharmaceuticals | 2009 |
GTV spatial conformity between different delineation methods by 18FDG PET/CT and pathology in esophageal cancer.
Topics: Aged; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Tomography, X-Ray Computed | 2009 |
Consequences of additional use of PET information for target volume delineation and radiotherapy dose distribution for esophageal cancer.
Topics: Adenocarcinoma; Aged; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal; Tomography, X-Ray Computed | 2009 |
A suspected [18F]fluorodeoxyglucose positron emission tomography-negative metastatic lymph node successfully diagnosed by laparoscopic staging in esophageal cancer: report of two cases.
Topics: Aged; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Laparoscopy; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Tomography, X-Ray Computed | 2009 |
Prognostic value of metabolic tumor volume measured by 18F-fluorodeoxyglucose positron emission tomography in patients with esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Cohort Studies; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
Can hybrid FDG-PET/CT detect subclinical lymph node metastasis of esophageal cancer appropriately and contribute to radiation treatment planning? A comparison of image-based and pathological findings.
Topics: Aged; Carcinoma, Squamous Cell; Endosonography; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Patient Selection; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Sensitivity and Specificity; Tomography, X-Ray Computed | 2009 |
Abnormal fluorine-18-fluorodeoxyglucose uptake in benign esophageal leiomyoma.
Topics: Diagnosis, Differential; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Immunohistochemistry; Leiomyoma; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Thoracoscopy; Thoracotomy; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
Comparison of (18)F-fluorothymidine and (18)F-fluorodeoxyglucose PET/CT in delineating gross tumor volume by optimal threshold in patients with squamous cell carcinoma of thoracic esophagus.
Topics: Carcinoma, Squamous Cell; Dideoxynucleosides; Dose Fractionation, Radiation; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Heart; Humans; Lung; Lymph Node Excision; Male; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Spinal Cord; Tomography, X-Ray Computed; Tumor Burden | 2010 |
[Correlation between PET-CT 18FDG uptake in primary lesions and clinicopathological parameters in esophageal carcinoma patients].
Topics: Aged; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Tumor Burden | 2009 |
[18F]-Fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemoradiation in esophageal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Prospective Studies; Radiopharmaceuticals | 2009 |
Impact of 18-fluorodeoxyglucose positron emission tomography on computed tomography defined target volumes in radiation treatment planning of esophageal cancer: reduction in geographic misses with equal inter-observer variability: PET/CT improves esophage
Topics: Aged; Aged, 80 and over; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Observer Variation; Positron-Emission Tomography; Radiographic Image Interpretation, Computer-Assisted; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal; Retrospective Studies; Tomography, X-Ray Computed | 2010 |
Comparison of standardized uptake value-based positron emission tomography and computed tomography target volumes in esophageal cancer patients undergoing radiotherapy.
Topics: Analysis of Variance; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Liver; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Retrospective Studies; Tomography, X-Ray Computed; Tumor Burden; Ultrasonography, Interventional | 2010 |
(18)F-fluorodeoxyglucose positron emission tomography immediately after chemoradiotherapy predicts prognosis in patients with locoregional postoperative recurrent esophageal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Positron-Emission Tomography; Predictive Value of Tests; Prospective Studies; Radiopharmaceuticals; Radiotherapy, Adjuvant; Time Factors; Treatment Outcome | 2010 |
The diagnostic challenge of mediastinal sarcoidosis accompanying esophageal cancer.
Topics: Adenocarcinoma; Aged; Decision Making; Diagnosis, Differential; Endosonography; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Mediastinal Diseases; Middle Aged; Neoplasms, Squamous Cell; Palliative Care; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Sarcoidosis; Tomography, X-Ray Computed | 2010 |
Utility of response evaluation to neo-adjuvant chemotherapy by (18)F-fluorodeoxyglucose-positron emission tomography in locally advanced esophageal squamous cell carcinoma.
Topics: Aged; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Tomography, X-Ray Computed | 2010 |
Careful evaluation of CT findings of a cardiac viability F-18 FDG PET/CT study leading to detection of esophageal cancer.
Topics: Esophageal Neoplasms; Fluorodeoxyglucose F18; Heart; Humans; Male; Middle Aged; Positron-Emission Tomography; Tissue Survival; Tomography, X-Ray Computed | 2010 |
Association of the VEGF 936C>T polymorphism with FDG uptake, clinical, histopathological, and metabolic response in patients with adenocarcinomas of the esophagogastric junction.
Topics: Adenocarcinoma; Antineoplastic Agents; Base Sequence; DNA Primers; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Polymorphism, Genetic; Vascular Endothelial Growth Factor A | 2011 |
False positive diagnosis of metastatic esophageal carcinoma on positron emission tomography: a case report of cholecystitis simulating a hepatic lesion.
Topics: Aged; Cholecystitis; Diagnosis, Differential; Esophageal Neoplasms; False Positive Reactions; Fluorodeoxyglucose F18; Humans; Liver Neoplasms; Male; Neoplasm Staging; Positron-Emission Tomography; Tomography, X-Ray Computed | 2010 |
Glucose transporter expression of an esophageal gastrointestinal tumor detected by F-18 FDG PET/CT.
Topics: Aged; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Glucose Transport Proteins, Facilitative; Humans; Immunohistochemistry; Magnetic Resonance Imaging; Positron-Emission Tomography; Radiography; Tomography, Emission-Computed | 2010 |
18F-FAMT-PET is useful for the diagnosis of lymph node metastasis in operable esophageal squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; alpha-Methyltyrosine; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Tomography, X-Ray Computed | 2010 |
Critical role of surgery in patients with gastroesophageal carcinoma with a poor prognosis after chemoradiation as defined by positron emission tomography.
Topics: Adult; Aged; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Retrospective Studies; Stomach Neoplasms; Treatment Outcome | 2010 |
Two coincident squamous cell carcinomas of the esophagus in a patient with achalasia: evidence by F-18 FDG PET/CT.
Topics: Adult; Carcinoma, Squamous Cell; Esophageal Achalasia; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Male; Positron-Emission Tomography; Tomography, X-Ray Computed | 2010 |
F-18-fluorodeoxiglucose positron emission tomography for the evaluation of neoadjuvant therapy response in esophageal cancer.
Topics: Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Neoadjuvant Therapy; Positron-Emission Tomography; Radiopharmaceuticals; Treatment Outcome | 2010 |
The standardized uptake value of 18-fluorodeoxyglucose positron emission tomography after chemoradiation and clinical outcome in patients with localized gastroesophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Proportional Hazards Models; Regression Analysis; Retrospective Studies; Stomach Neoplasms | 2010 |
Reproducibility of 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET tumor volume measurements.
Topics: Algorithms; Breast Neoplasms; Dideoxynucleosides; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Positron-Emission Tomography; Reproducibility of Results; Tumor Burden | 2010 |
Additional benefit of ¹⁸F-fluorodeoxyglucose integrated positron emission tomography/computed tomography in the staging of oesophageal cancer.
Topics: Adult; Aged; Aged, 80 and over; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Image Enhancement; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Subtraction Technique; Tomography, X-Ray Computed | 2011 |
Outcomes of patients with esophageal cancer staged with [¹⁸F]fluorodeoxyglucose positron emission tomography (FDG-PET): can postchemoradiotherapy FDG-PET predict the utility of resection?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Contrast Media; Deoxycytidine; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Medical Records; Middle Aged; Multivariate Analysis; Neoplasm Staging; Paclitaxel; Platinum Compounds; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy, Adjuvant; Remission Induction; Retrospective Studies; Treatment Outcome | 2010 |
Early repeated 18F-FDG PET scans during neoadjuvant chemoradiation fail to predict histopathologic response or survival benefit in adenocarcinoma of the esophagus.
Topics: Adenocarcinoma; Adult; Aged; Combined Modality Therapy; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; ROC Curve; Survival Analysis; Whole Body Imaging | 2010 |
Mimicry of physiological urinary FDG excretion: squamous cell carcinoma of esophagus metastasizing to psoas muscle.
Topics: Carcinoma, Squamous Cell; Diagnosis, Differential; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Muscle Neoplasms; Positron-Emission Tomography; Psoas Muscles; Tomography, X-Ray Computed | 2011 |
Does pre-operative estimation of oesophageal tumour metabolic length using 18F-fluorodeoxyglucose PET/CT images compare with surgical pathology length?
Topics: Adult; Aged; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoadjuvant Therapy; Positron-Emission Tomography; Preoperative Period; Retrospective Studies; Tomography, X-Ray Computed; Tumor Burden | 2011 |
Was [¹⁸F]fluorodeoxyglucose positron emission tomography complete response after chemoradiotherapy defined as standardized uptake value(max-1 hour) ≤ 3 complete?
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Dosage; Survival Rate; Treatment Outcome | 2011 |
Hounsfield units upon PET/CT are useful in evaluating metastatic regional lymph nodes in patients with oesophageal squamous cell carcinoma.
Topics: Aged; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Sensitivity and Specificity; Tomography, X-Ray Computed | 2012 |
Intratumor heterogeneity characterized by textural features on baseline 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Radiotherapy, Conformal; Reproducibility of Results; Sensitivity and Specificity; Treatment Outcome | 2011 |
PET and PET-CT in esophageal and gastric cancer.
Topics: Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Neoplasm Recurrence, Local; Positron-Emission Tomography; Radiopharmaceuticals; Stomach Neoplasms; Tomography, Emission-Computed | 2011 |
Prognostic value of 18F-FDG PET image-based parameters in oesophageal cancer and impact of tumour delineation methodology.
Topics: Aged; Aged, 80 and over; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Retrospective Studies; Survival Analysis; Tumor Burden | 2011 |
Clinical usefulness of dual-time FDG PET-CT in assessment of esophageal squamous cell carcinoma.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Positron-Emission Tomography; Reproducibility of Results; Sensitivity and Specificity; Subtraction Technique; Tomography, X-Ray Computed | 2012 |
A prospective evaluation of staging and target volume definition of lymph nodes by 18FDG PET/CT in patients with squamous cell carcinoma of thoracic esophagus.
Topics: Aged; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; ROC Curve; Tomography, X-Ray Computed; Tumor Burden | 2011 |
Thoracoscopic enucleation of esophageal schwannoma exhibiting (18) F-fluorodeoxyglucose uptake on positron emission tomography.
Topics: Aged; Aortic Aneurysm, Abdominal; Biopsy, Fine-Needle; Endosonography; Esophageal Neoplasms; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Incidental Findings; Male; Neurilemmoma; Positron-Emission Tomography; Radiopharmaceuticals; Thoracoscopy; Tomography, X-Ray Computed; Ultrasonography, Interventional | 2013 |
Value of EUS in Determining Curative Resectability in Reference to CT and FDG-PET: The Optimal Sequence in Preoperative Staging of Esophageal Cancer?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Endoscopic Ultrasound-Guided Fine Needle Aspiration; Endosonography; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Humans; Likelihood Functions; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Multidetector Computed Tomography; Neoplasm Staging; Patient Selection; Positron-Emission Tomography; Preoperative Period; Prospective Studies; Radiopharmaceuticals | 2016 |
Baseline ¹⁸F-FDG PET image-derived parameters for therapy response prediction in oesophageal cancer.
Topics: Aged; Aged, 80 and over; Chemoradiotherapy; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Positron-Emission Tomography; Retrospective Studies; Treatment Outcome | 2011 |
PET imaging for prediction of response to therapy and outcome in oesophageal carcinoma.
Topics: Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Male; Positron-Emission Tomography | 2011 |
Sequential FDG-PET and induction chemotherapy in locally advanced adenocarcinoma of the Oesophago-gastric junction (AEG): the Heidelberg Imaging program in Cancer of the oesophago-gastric junction during Neoadjuvant treatment: HICON trial.
Topics: Adenocarcinoma; Antineoplastic Agents; Capecitabine; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Epirubicin; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Fluorouracil; Germany; Humans; Multicenter Studies as Topic; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Salvage Therapy; Taxoids; Treatment Outcome | 2011 |
Linear correlation between patient survival and decreased percentage of tumor [(18)F]fluorodeoxyglucose uptake for late-course accelerated hyperfractionated radiotherapy for esophageal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; China; Dose Fractionation, Radiation; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Linear Models; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Survival Rate; Tomography, X-Ray Computed | 2012 |
The value of post-neoadjuvant therapy PET-CT in the detection of interval metastases in esophageal carcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy, Conformal; Tomography, X-Ray Computed | 2011 |
Clinical significance of primary lesion FDG uptake for choice between oesophagectomy and endoscopic submucosal dissection for resectable oesophageal squamous cell carcinomas.
Topics: Aged; Endoscopy; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Humans; Male; Medical Oncology; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Retrospective Studies; Sensitivity and Specificity; Tomography, X-Ray Computed; Ultrasonography | 2011 |
The impact of ¹⁸F-fluorodeoxyglucose positron emission tomography positive lymph nodes on postoperative recurrence and survival in resectable thoracic esophageal squamous cell carcinoma.
Topics: Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Positron-Emission Tomography; Postoperative Period; Prognosis; Radiopharmaceuticals; Retrospective Studies; Sensitivity and Specificity; Survival Rate; Thoracic Neoplasms | 2012 |
Positron emission tomography scanning in oesophageal cancer - stuck at the first hurdle?
Topics: Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Positron-Emission Tomography; Radiopharmaceuticals | 2012 |
F-18 FDG PET/CT contributes to more accurate detection of lymph nodal metastasis from actively proliferating esophageal squamous cell carcinoma.
Topics: Carcinoma, Squamous Cell; Cell Proliferation; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Tomography, X-Ray Computed | 2011 |
Prediction of the outcome of definitive chemoradiation by decrease in F-18 FDG uptake in nonsurgical esophageal squamous cell cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Chemoradiotherapy; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Proportional Hazards Models; ROC Curve; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
The role of integrated F-18-FDG-PET scanning in the detection of M1 disease in oesophageal adenocarcinoma and impact on clinical management.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Colonic Neoplasms; Combined Modality Therapy; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms, Second Primary; Positron-Emission Tomography; Prostatic Neoplasms; Sensitivity and Specificity | 2011 |
External ultrasonography of the neck does not add diagnostic value to integrated positron emission tomography-computed tomography (PET-CT) scanning in the diagnosis of cervical lymph node metastases in patients with esophageal carcinoma.
Topics: Adenocarcinoma; Aged; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Neck; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Ultrasonography | 2012 |
Fluorine-18-fluorodeoxyglucose uptake in a benign oesophageal leiomyoma: a potential pitfall in diagnosis.
Topics: Adult; Esophageal Neoplasms; False Positive Reactions; Female; Fluorodeoxyglucose F18; Humans; Leiomyoma; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Thoracotomy; Tomography, X-Ray Computed; Unnecessary Procedures | 2012 |
Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Epirubicin; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Fluorodeoxyglucose F18; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Multimodal Imaging; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Positron-Emission Tomography; Prognosis; Prospective Studies; Radiopharmaceuticals; Survival Rate; Taxoids; Tomography, X-Ray Computed | 2012 |
Impact of partial-volume effect correction on the predictive and prognostic value of baseline 18F-FDG PET images in esophageal cancer.
Topics: Aged; Artifacts; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Male; Positron-Emission Tomography; Prognosis; Retrospective Studies; Tumor Burden | 2012 |
Prevalence of esophageal cancer during the pretreatment of hypopharyngeal cancer patients: routinely performed esophagogastroduodenoscopy and FDG-PET/CT findings.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Endoscopy, Digestive System; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Hypopharyngeal Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Prevalence; Prognosis; Prospective Studies; Radiopharmaceuticals; Tomography, X-Ray Computed | 2012 |
Metabolic-morphologic discordant solitary skeletal muscle metastasis on [(18)F]fluorodeoxyglucose positron emission tomography/computed tomography scan in synchronous lung and esophageal cancer: a lesson.
Topics: Aged; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Multimodal Imaging; Muscle Neoplasms; Neoplasm Staging; Neoplasms, Multiple Primary; Positron-Emission Tomography; Tomography, X-Ray Computed | 2012 |
Role of positron emission tomography-computed tomography in predicting survival after neoadjuvant chemotherapy and surgery for oesophageal adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Neoadjuvant Therapy; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Postchemoradiotherapy positron emission tomography predicts pathologic response and survival in patients with esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy, Intensity-Modulated; Retrospective Studies; Treatment Outcome; Tumor Burden | 2012 |
Giant asymptomatic primary esophageal schwannoma.
Topics: Aged; Esophageal Neoplasms; Esophagectomy; Fluorodeoxyglucose F18; Humans; Multimodal Imaging; Neurilemmoma; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2012 |
Reproducibility of tumor uptake heterogeneity characterization through textural feature analysis in 18F-FDG PET.
Topics: Biological Transport; Esophageal Neoplasms; Fluorodeoxyglucose F18; Image Processing, Computer-Assisted; Positron-Emission Tomography; Reproducibility of Results; Retrospective Studies; Treatment Outcome | 2012 |
Predictive value of metabolic tumor volume measured by 18F-FDG PET for regional lymph node status in patients with esophageal cancer.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Male; Middle Aged; Multivariate Analysis; Positron-Emission Tomography; Predictive Value of Tests; ROC Curve; Tumor Burden | 2012 |
The relationship between GLUT-1 and vascular endothelial growth factor expression and 18F-FDG uptake in esophageal squamous cell cancer patients.
Topics: Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Glucose Transporter Type 1; Humans; Male; Middle Aged; Neoplasm Staging; Radionuclide Imaging; Tumor Burden; Vascular Endothelial Growth Factor A | 2012 |
Esophageal gastrointestinal stromal tumor: report of 7 patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Combined Modality Therapy; Electronic Health Records; Esophageal Neoplasms; Esophagectomy; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Incidental Findings; Male; Middle Aged; Multimodal Imaging; Neoadjuvant Therapy; Neoplasms, Second Primary; Piperazines; Positron-Emission Tomography; Pyrimidines; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
A prospective evaluation of the utility of 2-deoxy-2-[(18) F]fluoro-D-glucose positron emission tomography and computed tomography in staging locally advanced gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Laparoscopy; Male; Middle Aged; Models, Economic; Multimodal Imaging; Neoplasm Micrometastasis; Neoplasm Staging; Patient Care; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Sensitivity and Specificity; Stomach Neoplasms; Tomography, X-Ray Computed | 2012 |
Successful enucleation of a fluorine-18-fluorodeoxyglucose positron emission tomography positive esophageal leiomyoma in the prone position using sponge spacer and intra-esophageal balloon compression.
Topics: Biomarkers, Tumor; Biopsy; Dilatation; Esophageal Neoplasms; Esophagectomy; Fluorodeoxyglucose F18; Humans; Leiomyoma; Male; Middle Aged; Multimodal Imaging; Patient Positioning; Positron-Emission Tomography; Predictive Value of Tests; Prone Position; Radiopharmaceuticals; Surgical Sponges; Thoracoscopy; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
18F-FDG PET/CT has a high impact on patient management and provides powerful prognostic stratification in the primary staging of esophageal cancer: a prospective study with mature survival data.
Topics: Adult; Aged; Aged, 80 and over; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Prospective Studies; Radiopharmaceuticals; Tomography, X-Ray Computed | 2012 |
The value of ¹⁸F-FDG PET/CT in assessment of metabolic response in esophageal cancer for prediction of histopathological response and survival after preoperative chemoradiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Multimodal Imaging; Neoadjuvant Therapy; Positron-Emission Tomography; Radiopharmaceuticals; Survival Rate; Tomography, X-Ray Computed | 2012 |
Symptomatic cardiac toxicity is predicted by dosimetric and patient factors rather than changes in 18F-FDG PET determination of myocardial activity after chemoradiotherapy for esophageal cancer.
Topics: Adult; Aged; Aged, 80 and over; Chemoradiotherapy; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Heart; Humans; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Dosage; Retrospective Studies | 2012 |
Hepatic radiation injury in distal esophageal carcinoma: a case report.
Topics: Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Liver; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Radiation Injuries; Tomography, X-Ray Computed | 2012 |
The role of qualitative and quantitative analysis of F18-FDG positron emission tomography in predicting pathologic response following chemoradiotherapy in patients with esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Treatment Outcome | 2012 |
Oesophageal squamous cell carcinoma: relationship between fluorine-18 fludeoxyglucose positron emission tomography CT maximum standardised uptake value, metabolic tumour volume, and tumour, node and metastasis classification.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Tumor Burden; Young Adult | 2012 |
The clinical application of 4D 18F-FDG PET/CT on gross tumor volume delineation for radiotherapy planning in esophageal squamous cell cancer.
Topics: Adult; Aged; Automation; Carcinoma, Squamous Cell; Esophageal Neoplasms; Fluorodeoxyglucose F18; Four-Dimensional Computed Tomography; Humans; Image Processing, Computer-Assisted; Male; Medical Oncology; Middle Aged; Positron-Emission Tomography; Radiotherapy; Respiration; Tumor Burden | 2012 |
18F-fluorodeoxyglucose positron emission tomography after definitive chemoradiotherapy in patients with oesophageal carcinoma.
Topics: Aged; Aged, 80 and over; Chemoradiotherapy; Esophageal Neoplasms; Esophagus; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Male; Middle Aged; Multivariate Analysis; Positron-Emission Tomography; Survival Analysis | 2012 |
Parotid gland metastasis from squamous cell carcinoma of esophagus detected by FDG PET/CT.
Topics: Carcinoma, Squamous Cell; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Multimodal Imaging; Parotid Neoplasms; Positron-Emission Tomography; Tomography, X-Ray Computed | 2012 |
Automated tumour boundary delineation on (18)F-FDG PET images using active contour coupled with shifted-optimal thresholding method.
Topics: Adult; Aged; Automation; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Male; Middle Aged; Phantoms, Imaging; Positron-Emission Tomography; Retrospective Studies; Whole Body Imaging | 2012 |
Prognostic significance of 18-FDG PET/CT and EUS-defined tumour characteristics in patients with oesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Disease-Free Survival; Endosonography; Esophageal Neoplasms; Esophagus; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Predictive Value of Tests; Prognosis; Radiopharmaceuticals; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden | 2013 |
Use of pretreatment metabolic tumor volumes on PET-CT to predict the survival of patients with squamous cell carcinoma of esophagus treated by curative surgery.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Marker selection based on only reproducibility can be questioned.
Topics: Esophageal Neoplasms; Fluorodeoxyglucose F18; Image Processing, Computer-Assisted; Positron-Emission Tomography | 2012 |
Three-dimensional positron emission tomography image texture analysis of esophageal squamous cell carcinoma: relationship between tumor 18F-fluorodeoxyglucose uptake heterogeneity, maximum standardized uptake value, and tumor stage.
Topics: Adult; Aged; Biological Transport; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Imaging, Three-Dimensional; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Retrospective Studies; Young Adult | 2013 |
Proton therapy radiation pneumonitis local dose-response in esophagus cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Radiation; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Proton Therapy; Protons; Radiation Pneumonitis; Retrospective Studies; Tomography, X-Ray Computed | 2013 |
Predictive and prognostic value of metabolic tumour volume and total lesion glycolysis in solid tumours.
Topics: Carcinoma, Squamous Cell; Disease-Free Survival; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Genital Neoplasms, Female; Glycolysis; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Medical Oncology; Neoplasm Staging; Neoplasms; Positron-Emission Tomography; Predictive Value of Tests; Prognosis; Treatment Outcome; Tumor Burden | 2013 |
(18)F-FDG PET-detected synchronous primary neoplasms in the staging of esophageal cancer: incidence, cost, and impact on management.
Topics: Adult; Aged; Aged, 80 and over; Decision Making; Disease-Free Survival; Esophageal Neoplasms; False Negative Reactions; Fluorodeoxyglucose F18; Humans; Incidence; Middle Aged; Multimodal Imaging; Neoplasm Staging; Neoplasms, Multiple Primary; Positron-Emission Tomography; Tomography, X-Ray Computed | 2012 |
Commentary on: Prognostic significance of 18-FDG PET/CT and EUS-defined tumour characteristics in patients with oesophageal cancer.
Topics: Adenocarcinoma; Carcinoma, Squamous Cell; Endosonography; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Multimodal Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2013 |
Oesophageal tumour progression between the diagnostic ¹⁸F-FDG-PET and the ¹⁸F-FDG-PET for radiotherapy treatment planning.
Topics: Adult; Aged; Aged, 80 and over; Disease Progression; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted | 2013 |
Spatial-temporal [¹⁸F]FDG-PET features for predicting pathologic response of esophageal cancer to neoadjuvant chemoradiation therapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Cisplatin; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Male; Middle Aged; Multimodal Imaging; Neoadjuvant Therapy; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Spatio-Temporal Analysis; Tomography, X-Ray Computed | 2013 |
Clinical significance of ¹⁸F-fluorodeoxyglucose positron emission tomography in superficial esophageal squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Esophageal Neoplasms; Esophagectomy; Esophagoscopy; Female; Fluorodeoxyglucose F18; Glucose Transporter Type 1; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Lymphatic Vessels; Male; Middle Aged; Neoplasm Invasiveness; Positron-Emission Tomography; Prognosis; Proportional Hazards Models; Radiopharmaceuticals | 2013 |
[Esophageal cancer: outcome according to therapeutic strategy].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Dose-Response Relationship, Radiation; Esophageal Neoplasms; Esophagectomy; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Fluorouracil; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy, Conformal; Retrospective Studies; Tomography, Emission-Computed, Single-Photon; Treatment Outcome | 2013 |
Registration of PET and CT images based on multiresolution gradient of mutual information demons algorithm for positioning esophageal cancer patients.
Topics: Algorithms; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Multimodal Imaging; Pattern Recognition, Automated; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy, Image-Guided; Reproducibility of Results; Sensitivity and Specificity; Subtraction Technique; Tomography, X-Ray Computed | 2013 |
Evaluation of 18F-FDG PET/CT and CT/MRI with histopathologic correlation in patients undergoing central compartment neck dissection for squamous cell carcinoma of the larynx, hypopharynx, and esophagus.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Cohort Studies; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Hypopharyngeal Neoplasms; Laryngeal Neoplasms; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Middle Aged; Multimodal Imaging; Neck Dissection; Neoplasm Staging; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Retrospective Studies; Sensitivity and Specificity; Tomography, X-Ray Computed | 2013 |
Increased FDG activity in a dermatofibroma in esophageal cancer patient.
Topics: Esophageal Neoplasms; False Positive Reactions; Fluorodeoxyglucose F18; Histiocytoma, Benign Fibrous; Humans; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Tomography, X-Ray Computed | 2013 |
Evaluation of early response to concomitant chemoradiotherapy by interim 18F-FDG PET/CT imaging in patients with locally advanced oesophageal carcinomas.
Topics: Adult; Aged; Carcinoma; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
Predicting tumour response to chemoradiotherapy in oesophageal cancer by early interim 18F-FDG PET: where do we stand and where should we go?
Topics: Carcinoma; Chemoradiotherapy; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Multimodal Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2013 |
[Positron emission tomography for the preoperative staging of esophageal carcinoma].
Topics: Carcinoma; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2002 |
"Straight line" sign of diffuse peritoneal carcinomatosis on sagittal FDG positron emission tomographic images.
Topics: Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorodeoxyglucose F18; Humans; Middle Aged; Neoplasms, Multiple Primary; Peritoneal Neoplasms; Radiography; Radiopharmaceuticals; Tomography, Emission-Computed | 2002 |
Usefulness of positron emission tomography for assessing the response of neoadjuvant chemoradiotherapy in patients with esophageal cancer.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoadjuvant Therapy; Predictive Value of Tests; Radiopharmaceuticals; Radiotherapy, Adjuvant; Retrospective Studies; Tomography, Emission-Computed; Treatment Outcome | 2002 |
Early changes in [18F]FLT uptake after chemotherapy: an experimental study.
Topics: Antineoplastic Agents; Artifacts; Carcinoma, Squamous Cell; Cell Survival; Cisplatin; Deoxycytidine; Dideoxynucleosides; Dose-Response Relationship, Drug; Esophageal Neoplasms; Fluorodeoxyglucose F18; Fluorouracil; Gemcitabine; Humans; Methotrexate; Radionuclide Imaging; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Statistics as Topic; Tumor Cells, Cultured | 2002 |
Evaluation of esophageal cancer by positron emission tomography.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Radiopharmaceuticals; Retrospective Studies; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2002 |
[Barrett-adenocarcinoma of the esophagus: false negative finding in a surgeon using FDG-PET].
Topics: Adenocarcinoma; Adult; Barrett Esophagus; Diagnosis, Differential; Esophageal Neoplasms; False Negative Reactions; Fluorodeoxyglucose F18; Humans; Male; Radiopharmaceuticals; Reproducibility of Results; Tomography, Emission-Computed | 2002 |
Detection of response to neoadjuvant therapy of esophageal squamous cell carcinoma by positron emission tomography (PET).
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Neoadjuvant Therapy; Radiopharmaceuticals; Remission Induction; Tomography, Emission-Computed; Treatment Outcome | 2003 |
Role of FDG-PET scan in staging of cancer of the esophagus and gastroesophageal junction.
Topics: Esophageal Neoplasms; Esophagogastric Junction; Fluorodeoxyglucose F18; Humans; Neoplasm Staging; Prospective Studies; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed | 2002 |
[Neoadjuvant therapeutic principles guided by response prediction and evaluation].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; Esophageal Neoplasms; Fluorodeoxyglucose F18; Gene Expression Regulation, Neoplastic; Humans; Neoadjuvant Therapy; Nucleoside-Phosphate Kinase; Stomach Neoplasms; Tomography, Emission-Computed; Treatment Outcome | 2002 |
Metastasis to regional lymph nodes in patients with esophageal squamous cell carcinoma: CT versus FDG PET for presurgical detection prospective study.
Topics: Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Male; Middle Aged; Prospective Studies; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2003 |
[18F-Deoxyglucose PET for the staging of oesophageal cancer: influence of histopathological subtype and tumour grading].
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Biopsy; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Middle Aged; Neoplasm Staging; Radiopharmaceuticals; Tomography, Emission-Computed | 2003 |
Fluorodeoxyglucose-positron emission tomography in adenocarcinomas of the distal esophagus and cardia.
Topics: Adenocarcinoma; Adult; Aged; Blood Glucose; Cardia; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Radiopharmaceuticals; Reproducibility of Results; Stomach Neoplasms; Survival Rate; Tomography, Emission-Computed | 2003 |
[Positron emission tomography for preoperative lymph node diagnosis in esophageal carcinoma].
Topics: Adenocarcinoma; Aged; Biopsy; Carcinoma, Squamous Cell; Esophageal Neoplasms; Esophagectomy; Esophagus; Female; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Patient Care Planning; Prospective Studies; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2003 |
FDG-PET uptake in occult acute pelvic fracture.
Topics: Bone Neoplasms; Diagnosis, Differential; Esophageal Neoplasms; Fluorodeoxyglucose F18; Fractures, Bone; Humans; Ilium; Male; Middle Aged; Neoplasm Metastasis; Radiography; Tomography, Emission-Computed | 2004 |
Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment.
Topics: Aged; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Staging; Preoperative Care; Prognosis; Prospective Studies; Radiotherapy, Adjuvant; Risk Assessment; Sensitivity and Specificity; Survival Analysis; Tomography, Emission-Computed; Treatment Outcome | 2004 |
Effects of neoadjuvant radio-chemotherapy on 18F-FDG-PET in esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Chemotherapy, Adjuvant; Esophageal Neoplasms; Esophagitis; Esophagus; Female; Fluorodeoxyglucose F18; Germany; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Radiopharmaceuticals; Radiotherapy, Adjuvant; Statistics as Topic; Tomography, Emission-Computed; Tomography, X-Ray Computed; Treatment Outcome | 2004 |
Impact of FDG-PET for staging of oesophageal cancer.
Topics: Adult; Aged; Aged, 80 and over; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed | 2004 |
Value of positron emission tomography in the diagnosis of recurrent oesophageal carcinoma.
Topics: Adult; Aged; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Radiopharmaceuticals; Retrospective Studies; Sensitivity and Specificity; Tomography, Emission-Computed | 2004 |
[A case of enhanced FDG uptake in esophageal GIST (gastrointestinal stromal tumor)].
Topics: Aged; Esophageal Neoplasms; Esophagus; Female; Fluorodeoxyglucose F18; Gastrointestinal Neoplasms; Humans; Image Enhancement; Stromal Cells; Tomography, Emission-Computed | 2004 |
2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Combined Modality Therapy; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Staging; Predictive Value of Tests; Preoperative Care; Prognosis; Radiopharmaceuticals; Remission Induction; Retrospective Studies; Risk Factors; Sensitivity and Specificity; Survival Rate; Tomography, Emission-Computed | 2004 |
Virchow's node on F-18 FDG PET/CT.
Topics: Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neck; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2004 |
The role of PET scan in the preoperative management of oesophageal cancer.
Topics: Adult; Aged; Aged, 80 and over; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2004 |
Primary melanoma of the oesophagus well palliated by radiotherapy.
Topics: Aged; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Male; Melanoma; Palliative Care; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2004 |
Adenocarcinoma of the esophagus and the esophagogastric junction: positron emission tomography improves staging and prediction of survival in distant but not in locoregional disease.
Topics: Adenocarcinoma; Endosonography; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Predictive Value of Tests; Prospective Studies; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, X-Ray Computed | 2004 |
Positron emission tomography with F-18-fluorodeoxyglucose in a combined staging strategy of esophageal cancer prevents unnecessary surgical explorations.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Endosonography; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals | 2005 |
A case of small cell carcinoma of the esophagus detected incidentally by FDG-PET.
Topics: Aged; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Incidental Findings; Lung Neoplasms; Male; Positron-Emission Tomography; Radiopharmaceuticals | 2004 |
Comment on the publication 'Impact of FDG-PET for staging of oesophageal cancer' by A. Imdahl et al.
Topics: Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Neoplasm Staging; Positron-Emission Tomography; Sensitivity and Specificity | 2005 |
Reflux esophagitis secondary to chemotherapy detected by serial FDG-PET.
Topics: Aged; Antineoplastic Agents; Colonic Neoplasms; Diagnosis, Differential; Diagnostic Errors; Esophageal Neoplasms; Esophagitis, Peptic; Esophagus; Fluorodeoxyglucose F18; Humans; Male; Positron-Emission Tomography; Radiopharmaceuticals | 2005 |
The integration of 18-fluoro-deoxy-glucose positron emission tomography and endoscopic ultrasound in the treatment-planning process for esophageal carcinoma.
Topics: Adenocarcinoma; Carcinoma, Squamous Cell; Esophageal Neoplasms; Esophagoscopy; Fluorodeoxyglucose F18; Humans; Positron-Emission Tomography; Radiotherapy Planning, Computer-Assisted; Tomography, X-Ray Computed; Ultrasonography | 2005 |
PET detection of solitary distant skeletal muscle metastasis of esophageal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Male; Muscle Neoplasms; Positron-Emission Tomography; Radiography; Radiopharmaceuticals; Rare Diseases | 2005 |
Role of PET scan in management of oesophageal cancer.
Topics: Esophageal Neoplasms; Esophagogastric Junction; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Neoplasm Metastasis; Neoplasm Staging; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2005 |
Value of PET-CT fusion imaging in avoiding potential pitfalls in the interpretation of 18F-FDG accumulation in the distal oesophagus.
Topics: Artifacts; Diagnostic Errors; Esophageal Neoplasms; Esophagus; False Positive Reactions; Fluorodeoxyglucose F18; Humans; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Retrospective Studies; Sensitivity and Specificity; Subtraction Technique; Tomography, X-Ray Computed | 2005 |
Prognostic value of the standardized uptake value in esophageal cancer.
Topics: Aged; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Survival Rate | 2005 |
Gastrointestinal stromal tumor (GIST) of the esophagus detected by positron emission tomography/computed tomography.
Topics: Adult; Antigens, CD34; Esophageal Neoplasms; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Immunohistochemistry; Male; Positron-Emission Tomography; Proto-Oncogene Proteins c-kit; Radiopharmaceuticals; Staining and Labeling; Tomography, X-Ray Computed | 2005 |
[A case of high FDG-uptake into the myocardium after radiotherapy for esophageal cancer].
Topics: Aged; Carcinoma, Squamous Cell; Cardiomyopathies; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Male; Myocardium; Positron-Emission Tomography; Radiation Injuries | 2005 |
[Diagnostic kit for febrile headache!...].
Topics: Aged; Clinical Chemistry Tests; Esophageal Neoplasms; Fever; Fluorodeoxyglucose F18; Headache; Humans; Male; Radionuclide Imaging; Radiopharmaceuticals; Thyroid Nodule | 2005 |
Intense esophageal FDG activity caused by Candida infection obscured the concurrent primary esophageal cancer on PET imaging.
Topics: Candidiasis; Diagnosis, Differential; Esophageal Neoplasms; Esophagitis; False Negative Reactions; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals | 2005 |
Impact of CT and 18F-deoxyglucose positron emission tomography image fusion for conformal radiotherapy in esophageal carcinoma.
Topics: Adult; Aged; Combined Modality Therapy; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal; Tomography, X-Ray Computed | 2005 |
Metastatic lymph node and osteolytic skeletal metastasis detected by FDG-PET in an endoscopy-diagnosed early-stage esophageal cancer.
Topics: Bone Neoplasms; Esophageal Neoplasms; Esophagoscopy; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Osteolysis; Radionuclide Imaging; Radiopharmaceuticals; Sternum | 2005 |
Comparison of changes in tumor metabolic activity and tumor size during chemotherapy of adenocarcinomas of the esophagogastric junction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Time Factors; Tomography, X-Ray Computed | 2005 |
Malignant lesions can mimic gastric uptake on FDG PET.
Topics: Adult; Diagnosis, Differential; Esophageal Neoplasms; False Positive Reactions; Female; Fluorodeoxyglucose F18; Gastric Mucosa; Humans; Melanoma; Neoplasm Recurrence, Local; Positron-Emission Tomography; Radiopharmaceuticals; Stomach; Stomach Neoplasms | 2006 |
FDG PET and CT in locally advanced adenocarcinomas of the distal oesophagus. Clinical relevance of a discordant PET finding.
Topics: Adenocarcinoma; Biopsy; Esophageal Neoplasms; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Image Processing, Computer-Assisted; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Survival Analysis; Time Factors; Tissue Distribution; Tomography, X-Ray Computed | 2005 |
Quantifying the effect of IV contrast media on integrated PET/CT: clinical evaluation.
Topics: Contrast Media; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Radiopharmaceuticals; Subclavian Vein; Tomography, Emission-Computed; Tomography, X-Ray Computed; Triiodobenzoic Acids | 2006 |
Medical Image. Combined FDG-PET/CT and CT-guided biopsy in diagnosing oesophageal cancer recurrence.
Topics: Aged; Biopsy, Fine-Needle; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Neoplasm Recurrence, Local; Positron-Emission Tomography; Radiopharmaceuticals | 2006 |
Invited commentary.
Topics: Adenocarcinoma; Esophageal Neoplasms; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Neoplasm Staging; Positron-Emission Tomography; Sensitivity and Specificity; Survival Analysis | 2006 |
Preoperative 18[F]-fluorodeoxyglucose positron emission tomography standardized uptake values predict survival after esophageal adenocarcinoma resection.
Topics: Adenocarcinoma; Biological Transport; Esophageal Neoplasms; Fluorodeoxyglucose F18; Follow-Up Studies; Gastrectomy; Humans; Neoplasm Staging; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Retrospective Studies; Sensitivity and Specificity; Survival Analysis; Tomography, X-Ray Computed | 2006 |
Esophageal leiomyoma: a rare cause of false-positive FDG scans.
Topics: Adult; Esophageal Neoplasms; False Positive Reactions; Fluorodeoxyglucose F18; Humans; Leiomyoma; Male; Mediastinal Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals | 2006 |
Influence of F-fluorodeoxyglucose-positron emission tomography on computed tomography-based radiation treatment planning for oesophageal cancer.
Topics: Aged; Carcinoma, Squamous Cell; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Male; Positron-Emission Tomography; Radiotherapy Planning, Computer-Assisted; Tomography, X-Ray Computed | 2006 |
Monitoring of response to pre-operative chemoradiation in combination with hyperthermia in oesophageal cancer by FDG-PET.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Combined Modality Therapy; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Hyperthermia, Induced; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Positron-Emission Tomography; Preoperative Care; Prognosis; Prospective Studies; Radiotherapy; Sensitivity and Specificity; Treatment Outcome | 2006 |
(18)F-FDG accumulations in primary malignant melanoma of the esophagus.
Topics: Aged; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Melanoma; Positron-Emission Tomography; Radiopharmaceuticals | 2006 |
Maximum standardized uptake values on positron emission tomography of esophageal cancer predicts stage, tumor biology, and survival.
Topics: Adult; Aged; Aged, 80 and over; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Retrospective Studies | 2006 |
The diagnosis of esophageal cancer by 2-deoxy-2-F-18 fluoro-D-glucose positron emission tomography (F-18 FDG PET).
Topics: Aged; Bone and Bones; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Male; Neoplasm Metastasis; Positron-Emission Tomography; Tomography, X-Ray Computed | 2006 |
Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction.
Topics: Adenocarcinoma; Aged; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Glucose; Humans; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Patient Selection; Positron-Emission Tomography; Predictive Value of Tests; Prognosis; Prospective Studies; Radiopharmaceuticals; Stomach Neoplasms; Survival Analysis | 2006 |
Actinomycosis mimicking anastomotic recurrent esophageal cancer on PET-CT.
Topics: Actinomycosis; Aged; Carcinoma, Squamous Cell; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Male; Neoplasm Recurrence, Local; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2006 |
The utility of 18F-fluorodeoxyglucose positron emission tomography for early diagnosis of radiation-induced myocardial damage.
Topics: Aged; Aged, 80 and over; Early Diagnosis; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Heart; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Myocardium; Positron-Emission Tomography; Radiation Injuries; Radiopharmaceuticals | 2006 |
(18)FDG uptake during induction chemoradiation for oesophageal cancer fails to predict histomorphological tumour response.
Topics: Adult; Aged; Esophageal Neoplasms; Esophagus; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Prognosis; Reproducibility of Results; Sensitivity and Specificity; Tomography, Emission-Computed | 2006 |
Incidental pheochromocytoma mimicking adrenal adenoma because of rapid contrast enhancement loss.
Topics: Adenocarcinoma; Adenoma; Adrenal Gland Neoplasms; Barrett Esophagus; Contrast Media; Diagnosis, Differential; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Incidental Findings; Magnetic Resonance Imaging; Male; Middle Aged; Pheochromocytoma; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2006 |
PET: other thoracic malignancies.
Topics: Carcinoma; Cost-Benefit Analysis; Diagnostic Imaging; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Mesothelioma; Neoplasm Staging; Patient Care Planning; Pleural Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Thoracic Neoplasms; Thymoma; Thymus Neoplasms | 2006 |
Multiple metastases to skeletal muscle from carcinoma of the esophagus detected by FDG PET-CT imaging.
Topics: Adenocarcinoma; Aged; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Muscle Neoplasms; Muscle, Skeletal; Radionuclide Imaging; Radiopharmaceuticals; Subtraction Technique; Tomography, X-Ray Computed | 2006 |
FDG-PET in the initial staging of squamous cell oesophageal carcinoma.
Topics: Aged; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Radiography; Radioisotopes | 2006 |
Should FDG-PET imaging be considered on a routine basis in clinical trials for carcinoma of esophagus to assure uniformity of protocols among sites?
Topics: Carcinoma; Clinical Trials as Topic; Esophageal Neoplasms; Fluorodeoxyglucose F18; Guidelines as Topic; Humans; Positron-Emission Tomography; Quality Assurance, Health Care; Radiography; Radiopharmaceuticals | 2007 |
Is FDG-PET indicated for superficial esophageal cancer?
Topics: Adenocarcinoma; Diagnosis, Differential; Esophageal Neoplasms; Esophagoscopy; Esophagus; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Neoplasm Metastasis; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals | 2007 |
Radiation pneumonitis: local dose versus [18F]-fluorodeoxyglucose uptake response in irradiated lung.
Topics: Adult; Aged; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Linear Models; Lung; Male; Middle Aged; Positron-Emission Tomography; Radiation Pneumonitis; Radiopharmaceuticals; Radiotherapy Dosage; Tomography, X-Ray Computed | 2007 |
Preoperative chemo-radiation-induced ulceration in patients with esophageal cancer: a confounding factor in tumor response assessment in integrated computed tomographic-positron emission tomographic imaging.
Topics: Adult; Aged; Combined Modality Therapy; Esophageal Diseases; Esophageal Neoplasms; Esophagectomy; Esophagoscopy; False Positive Reactions; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Positron-Emission Tomography; Retrospective Studies; Tomography, X-Ray Computed; Ulcer | 2006 |
3'-deoxy-3'-(18)F-fluorothymidine (FLT) positron emission tomography for early prediction of response to chemoradiotherapy--a clinical application model of esophageal cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dideoxynucleosides; Disease Models, Animal; Docetaxel; Esophageal Neoplasms; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Forecasting; Humans; Mice; Neoadjuvant Therapy; Neoplasm, Residual; Positron-Emission Tomography; Radiotherapy, Adjuvant; Remission Induction; Taxoids; Treatment Outcome | 2007 |
Correlation of molecular response as measured by 18-FDG positron emission tomography with outcome after chemoradiotherapy in patients with esophageal carcinoma.
Topics: Adenocarcinoma; Analysis of Variance; Carcinoma, Squamous Cell; Combined Modality Therapy; Disease-Free Survival; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Humans; Male; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Dosage; Retrospective Studies; Tomography, Emission-Computed | 2007 |
[Correlation between FDG PET /CT and the expression of glutl and ki-67 antigen in esophageal cancer].
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Cell Differentiation; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Glucose Transporter Type 1; Humans; Immunohistochemistry; Ki-67 Antigen; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Tissue Distribution; Tomography, X-Ray Computed | 2007 |
Predicting response to chemoradiotherapy in rectal and oesophageal cancer with 18F-FDG: prognostic value and possible role in patient management.
Topics: Antineoplastic Agents; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Radiotherapy; Rectal Neoplasms; Treatment Outcome | 2007 |
Fluorine-18 fluorodeoxyglucose positron emission tomography in the preoperative staging of thoracic oesophageal and gastro-oesophageal junction cancer: a prospective study.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Preoperative Care; Prospective Studies; Radiopharmaceuticals; Thoracic Cavity | 2007 |
Diagnostic and prognostic value of 18F-FDG PET/CT for patients with suspected recurrence from squamous cell carcinoma of the esophagus.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Positron-Emission Tomography; Prognosis; Sensitivity and Specificity; Tomography, X-Ray Computed | 2007 |
[Role of [18]-FDG PET/CT in the initial staging of head and neck cancers].
Topics: Adult; Aged; Carcinoma, Squamous Cell; Endoscopy; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed | 2007 |
[FDG PET/CT versus PET alone for pre-surgical detection of lymph node metastasis in esophageal carcinoma].
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neck Dissection; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tomography, X-Ray Computed | 2007 |
18FDG uptake in oesophageal adenocarcinoma: linking biology and outcome.
Topics: Adenocarcinoma; Aged; Biomarkers, Tumor; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Immunoenzyme Techniques; Male; Middle Aged; Neoplasm Recurrence, Local; Positron-Emission Tomography; Preoperative Care; Radiopharmaceuticals; Tissue Array Analysis; Tissue Distribution; Treatment Outcome | 2008 |
A case of three synchronous primary tumors demonstrated by F-18 FDG PET.
Topics: Adenocarcinoma; Carcinoma, Squamous Cell; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasms, Multiple Primary; Positron-Emission Tomography; Radiopharmaceuticals; Tonsillar Neoplasms | 2007 |
Prediction of tumor response by FDG-PET: comparison of the accuracy of single and sequential studies in patients with adenocarcinomas of the esophagogastric junction.
Topics: Adenocarcinoma; Aged; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Treatment Outcome | 2007 |
FDG-PET/CT tumor segmentation-derived indices of metabolic activity to assess response to neoadjuvant therapy and progression-free survival in esophageal cancer: correlation with histopathology results.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; Disease-Free Survival; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Positron-Emission Tomography; Radiography; Radiopharmaceuticals; Retrospective Studies; Tomography, Emission-Computed; Treatment Outcome | 2007 |
PET-guided induction chemotherapy.
Topics: Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Neoadjuvant Therapy; Positron-Emission Tomography; Withholding Treatment | 2007 |
Temporal change in brain natriuretic Peptide after radiotherapy for thoracic esophageal cancer.
Topics: Aged; Aged, 80 and over; Biomarkers; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Heart; Humans; Male; Matrix Metalloproteinase 3; Middle Aged; Mucin-1; Myocardium; Natriuretic Peptide, Brain; Radionuclide Imaging; Radiopharmaceuticals; Retrospective Studies; Statistics, Nonparametric | 2007 |
Induction chemotherapy in Barrett cancer: influence on surgical risk and outcome.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Barrett Esophagus; Chemotherapy, Adjuvant; Disease-Free Survival; Esophageal Neoplasms; Esophagogastric Junction; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Positron-Emission Tomography; Postoperative Complications; Prospective Studies; Radiopharmaceuticals; Remission Induction; Risk Assessment; Survival Rate; Treatment Outcome | 2007 |
Limited additional value of positron emission tomography in staging oesophageal cancer.
Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neoplasms, Multiple Primary; Positron-Emission Tomography; Preoperative Care; Prospective Studies; Radiopharmaceuticals | 2007 |
Does FDG-PET add information to EUS and CT in the initial management of esophageal cancer? A prospective single center study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Endosonography; Esophageal Neoplasms; Esophagoscopy; False Positive Reactions; Female; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Palliative Care; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2008 |
Comparison of uptake characteristics and prognostic value of 201Tl and 18F-FDG in esophageal cancer.
Topics: Aged; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Prognosis; Proportional Hazards Models; Radiopharmaceuticals; Risk Assessment; Survival Analysis; Thallium Radioisotopes; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon | 2008 |
PET/CT and hepatic radiation injury in esophageal cancer patients.
Topics: Adult; Aged; Combined Modality Therapy; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Liver Diseases; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy; Retrospective Studies; Tomography, Emission-Computed | 2007 |
Visualisation of metastatic oesophageal and gastric cancer and prediction of clinical response to palliative chemotherapy using 18FDG PET.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Predictive Value of Tests; Radionuclide Imaging; Radiopharmaceuticals; Stomach Neoplasms; Survival Analysis; Tomography, X-Ray Computed | 2007 |
Pre-operative estimation of esophageal tumor metabolic length in FDG-PET images with surgical pathology confirmation.
Topics: Aged; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Image Interpretation, Computer-Assisted; Male; Phantoms, Imaging; Positron-Emission Tomography; Preoperative Care; Radiopharmaceuticals; Reproducibility of Results; Retrospective Studies; Sensitivity and Specificity | 2007 |
Evaluation of clinical significance of 18F-fluorodeoxyglucose positron emission tomography in superficial squamous cell carcinomas of the thoracic esophagus.
Topics: Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals | 2008 |
Positron emission tomography and pathological evidence of response to neoadjuvant therapy in adenocarcinoma of the esophagus.
Topics: Adenocarcinoma; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Neoadjuvant Therapy; Positron-Emission Tomography; Radiopharmaceuticals | 2008 |
Follicular thyroid carcinoma metastasis to the esophagus detected by 18FDG PET/CT.
Topics: Adenocarcinoma, Follicular; Esophageal Neoplasms; Esophagoscopy; Fluorodeoxyglucose F18; Humans; Iodine Radioisotopes; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Thyroid Neoplasms; Tomography, X-Ray Computed | 2008 |
FDG PET for esophageal cancer complicated by sarcoidosis mimicking mediastinal and hilar lymph node metastases: two case reports.
Topics: Aged; Diagnosis, Differential; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Mediastinum; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Sarcoidosis | 2008 |
Influence of cell proportions and proliferation rates on FDG uptake in squamous-cell esophageal carcinoma: a PET study.
Topics: Aged; Carcinoma, Squamous Cell; Cell Proliferation; Cell Size; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Immunohistochemistry; Male; Middle Aged; Positron-Emission Tomography | 2008 |
Application of whole-body positron emission tomography in the imaging of esophageal cancer: report of a case.
Topics: Aged; Carcinoma, Squamous Cell; Deoxyglucose; Esophageal Neoplasms; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Neoplasm Staging; Tomography, Emission-Computed; Tomography, X-Ray Computed | 1995 |
[Analysis of glucose metabolism in patients with esophageal cancer by PET: estimation of hexokinase activity in the tumor and usefulness for clinical assessment using 18F-fluorodeoxyglucose].
Topics: Aged; Deoxyglucose; Esophageal Neoplasms; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Glucose; Hexokinase; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Predictive Value of Tests; Prognosis; Retrospective Studies; Tomography, Emission-Computed | 1994 |
Staging of esophageal cancer with 18F-fluorodeoxyglucose positron emission tomography.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Deoxyglucose; Esophageal Neoplasms; Esophagus; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, X-Ray Computed | 1997 |
Development of oncology protocol using fluorine-18-FDG: one center's experience.
Topics: Blood Glucose; Colonic Neoplasms; Deoxyglucose; Esophageal Neoplasms; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Gamma Cameras; Head and Neck Neoplasms; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Lymphoma; Neoplasm Staging; Neoplasms; Patient Education as Topic; Practice Guidelines as Topic; Problem Solving; Quality Control; Quality of Health Care; Radiation Oncology; Radiology Information Systems; Radiopharmaceuticals; Rectal Neoplasms; Stomach Neoplasms; Tomography, Emission-Computed | 1997 |
Role of positron emission tomography in staging esophageal cancer.
Topics: Adenocarcinoma; Bone Neoplasms; Carcinoma, Squamous Cell; Deoxyglucose; Esophageal Neoplasms; False Negative Reactions; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Laparoscopy; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Neoplasm Staging; Patient Care Planning; Radiopharmaceuticals; Retrospective Studies; Sensitivity and Specificity; Thoracoscopy; Tomography, Emission-Computed; Tomography, X-Ray Computed; Video Recording | 1997 |
Improvement in staging of esophageal cancer with the addition of positron emission tomography.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Biopsy; Carcinoma, Squamous Cell; Contrast Media; Deoxyglucose; Esophageal Neoplasms; Esophagectomy; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Patient Selection; Radiographic Image Enhancement; Radiopharmaceuticals; Tomography, Emission-Computed; Tomography, X-Ray Computed | 1997 |
Minimally invasive surgical biopsy confirms PET findings in esophageal cancer.
Topics: Adenocarcinoma; Aged; Biopsy; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Laparoscopy; Liver Neoplasms; Lumbar Vertebrae; Lymphatic Metastasis; Male; Middle Aged; Minimally Invasive Surgical Procedures; Neoplasm Staging; Radiopharmaceuticals; Sacroiliac Joint; Spinal Neoplasms; Tomography, Emission-Computed | 1997 |
Evaluation of esophageal cancers using fluorine-18-fluorodeoxyglucose PET.
Topics: Adult; Aged; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Glucose; Hexokinase; Humans; Male; Middle Aged; Prognosis; Radiopharmaceuticals; Tomography, Emission-Computed | 1998 |
Computed tomography and positron emission tomography in the pre-operative staging of oesophageal carcinoma.
Topics: Esophageal Neoplasms; Esophagectomy; Esophagus; Fluorodeoxyglucose F18; Humans; Liver Neoplasms; Lymphatic Metastasis; Neoplasm Staging; Patient Selection; Prospective Studies; Radiopharmaceuticals; Stomach; Tomography, Emission-Computed; Tomography, X-Ray Computed | 1998 |
Detection of response to chemotherapy using positron emission tomography in patients with oesophageal and gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Esophageal Neoplasms; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Liver Neoplasms; Middle Aged; Radiopharmaceuticals; Stomach Neoplasms; Tomography, Emission-Computed; Treatment Outcome | 1998 |
Evaluation of distant metastases in esophageal cancer: 100 consecutive positron emission tomography scans.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Minimally Invasive Surgical Procedures; Neoplasm Metastasis; Neoplasm Staging; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, X-Ray Computed | 1999 |
Positron emission tomography of esophageal carcinoma using (11)C-choline and (18)F-fluorodeoxyglucose: a novel method of preoperative lymph node staging.
Topics: Aged; Aged, 80 and over; Carbon Radioisotopes; Choline; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Male; Middle Aged; Neoplasm Staging; Sensitivity and Specificity; Time Factors; Tomography, Emission-Computed | 1999 |
F-18 FDG uptake in benign esophageal disease.
Topics: Adult; Aged; Barrett Esophagus; Diagnosis, Differential; Esophageal Diseases; Esophageal Neoplasms; Esophageal Spasm, Diffuse; Esophageal Stenosis; Esophagitis; Female; Fluorodeoxyglucose F18; Gastroesophageal Reflux; Humans; Lymphatic Metastasis; Male; Middle Aged; Radiopharmaceuticals; Tomography, Emission-Computed | 1999 |
Staging an esophageal carcinoma by F-18 fluorodeoxyglucose whole-body positron emission tomography.
Topics: Carcinoma; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Staging; Radiopharmaceuticals; Spinal Neoplasms; Thoracic Vertebrae; Tomography, Emission-Computed | 2000 |
Improved detection of individual nodal involvement in squamous cell carcinoma of the esophagus by FDG PET.
Topics: Aged; Carcinoma, Squamous Cell; Endosonography; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Prospective Studies; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2000 |
Positron emission tomography: another useful test for staging esophageal cancer.
Topics: Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Neoplasm Staging; Radiopharmaceuticals; Tomography, Emission-Computed | 2000 |
Whole-body FDG positron emission tomographic imaging for staging esophageal cancer comparison with computed tomography.
Topics: Adenocarcinoma; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Male; Middle Aged; Minimally Invasive Surgical Procedures; Neoplasm Staging; Radiopharmaceuticals; Retrospective Studies; Sensitivity and Specificity; Thoracic Neoplasms; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2000 |
The utility of positron emission tomography for the diagnosis and staging of recurrent esophageal cancer.
Topics: Adenocarcinoma; Aged; Carcinoma, Squamous Cell; Endosonography; Esophageal Neoplasms; Esophagectomy; Esophagostomy; False Negative Reactions; False Positive Reactions; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Gastrectomy; Gastrostomy; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Sensitivity and Specificity; Survival Analysis; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2000 |
Histopathologic validation of lymph node staging with FDG-PET scan in cancer of the esophagus and gastroesophageal junction: A prospective study based on primary surgery with extensive lymphadenectomy.
Topics: Adult; Aged; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Radiopharmaceuticals; Sensitivity and Specificity; Stomach Neoplasms; Tomography, Emission-Computed | 2000 |
Evaluation of lymph node metastases in squamous cell carcinoma of the esophagus with positron emission tomography.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2001 |
Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography.
Topics: Adult; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoadjuvant Therapy; Predictive Value of Tests; Prospective Studies; Radiopharmaceuticals; Radiotherapy, Adjuvant; Survival Analysis; Tomography, Emission-Computed; Treatment Outcome | 2001 |
Metastatic peritoneal seeding patterns demonstrated by FDG positron emission tomographic imaging.
Topics: Adenocarcinoma; Aged; Ascitic Fluid; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Male; Neoplasm Seeding; Peritoneal Neoplasms; Radiopharmaceuticals; Tomography, Emission-Computed | 2001 |
Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Drug Monitoring; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorodeoxyglucose F18; Humans; Leucovorin; Male; Middle Aged; Patient Selection; Preoperative Care; Prognosis; Prospective Studies; Radiopharmaceuticals; Sensitivity and Specificity; Statistics, Nonparametric; Survival Rate; Tomography, Emission-Computed | 2001 |
Detection of Barrett's esophagus superimposed by esophageal cancer by FDG positron emission tomography.
Topics: Adenocarcinoma; Barrett Esophagus; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Radiopharmaceuticals; Tomography, Emission-Computed | 2001 |
Carbon-11 choline or FDG-PET for staging of oesophageal cancer?
Topics: Carbon Radioisotopes; Choline; Esophageal Neoplasms; Feasibility Studies; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Staging; Radiopharmaceuticals; Sensitivity and Specificity; Time Factors; Tomography, Emission-Computed | 2001 |
Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma.
Topics: Adult; Aged; Carcinoma; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Prognosis; Radiopharmaceuticals; Reproducibility of Results; Retrospective Studies; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2002 |
[Diagnosis of esophageal cancer using positron emission tomography].
Topics: Endosonography; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Sensitivity and Specificity; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2002 |
FDG-PET for response assessment: answers in search of questions.
Topics: Chemotherapy, Adjuvant; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Radiopharmaceuticals; Radiotherapy, Adjuvant; Remission Induction; Tomography, Emission-Computed; Treatment Outcome | 2002 |
Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer.
Topics: Adenocarcinoma; Carcinoma, Squamous Cell; Combined Modality Therapy; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Preoperative Care; Prospective Studies; Radiopharmaceuticals; Remission Induction; Risk Factors; Sensitivity and Specificity; Survival Rate; Tomography, Emission-Computed | 2002 |
[Current status of nuclear medicine. Clinical application of FDG-PET for cancer diagnosis. Esophageal cancer].
Topics: Aged; Aged, 80 and over; Esophageal Neoplasms; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Male; Middle Aged; Radiopharmaceuticals; Tomography, Emission-Computed; Tomography, X-Ray Computed | 2002 |
Assessment of response to cancer therapy using fluorine-18-fluorodeoxyglucose and positron emission tomography.
Topics: Adult; Aged; Carcinoma, Bronchogenic; Combined Modality Therapy; Deoxyglucose; Esophageal Neoplasms; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphoma; Male; Mediastinal Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Neoplasms; Rectal Neoplasms; Thyroid Neoplasms; Tomography, Emission-Computed | 1991 |